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Preface
Our hearty welcome to you all to this 2nd Asian Preventive Cardiology and Cardiac Rehabilitation Conference cum
7th Certificate Course in Cardiac Rehabilitation. Once again, we are able to have collaboration and support of overseas
organizations such as Preventive Cardiovascular Nurses Association (PCNA) of the USA and many local organizations
including Government, non-government, academic, service organizations as well as patient group to hold this event.
Control of risk factors is the target of intervention in prevention and cardiac rehabilitation. Despite of evidence and
availability of effective therapy, there is always a gap in reaching these treatment targets well documented in guidelines.
We try to bridge the gap by involving every stack holder who has a role to play in heart disease prevention. In depth
psychological and behavioral management was also emphasized since knowledge alone will need further action to
bring it into practice.
Overseas and local healthcare personnel will present their research and special findings in the free paper and poster
sessions. Two best paper awards will be given to the two best oral presentations.
The symposiums will commence with the Heart Foundation Lecture and included topics ranging from primary
prevention in schools to rehabilitating patients with coronary heart disease and heart failure; from epidemiology,
exercise, control of risk factors to contemporary cardiac care.
Concurrently, there will be the Rotary Heart Health Public Conference consisting of a whole day conference and
workshop to enhance the knowledge and skills in self-management of patients and their carers. In collaboration with
International Chinese Heart Health Network (ICHHN) and supported by the Jump Rope for Heart, a workshop for
teachers and parents on Successful Marketing of Heart-Smart Eating Program in Schools will be held.
Secondary prevention having proven benefits is worth doing despite the difficulties. The 7th Cardiac Rehabilitation
Workshop emphasizing on practical and behavioral issues will be conducted to enhance the skill of healthcare workers
in organization and running of the programs.
Prevention is better than cure. To achieve management to target in the whole population, we have to educate the
public, the healthcare personnel and most important of all, the policy makers to help create an healthy environment
and facilitate building up of healthy lifestyle. Let us all join hands to make prevention, the dream of this medical era
come true by collaborating to combat the threat of the cardiovascular diseases.

Prof. Chu-pak LAU
Co-Chairman
Executive Committee
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Co-Chairman
Executive Committee

November 2008

xiii

2nd Asian Preventive Cardiology and Cardiac Rehabilitation Conference cum
7th Certificate Course in Cardiac Rehabilitation

Executive Committee
Co-Chairmen :

Prof. Chu-pak LAU
Dr. Suet-ting LAU

Members

Dr. Ngai-yin CHAN
Dr. Shu-keung KWONG
Mr. Kam-tao LEUNG
Dr. Kei-pui LEUNG
Dr. Albert Wai-suen LEUNG
Dr. Leonard Sheung-wai LI
Prof. Cheuk-man YU

:

Organizing Committee
Co-Chairmen :

Prof. Chu-pak LAU
Dr. Suet-ting LAU

Members

Dr. Kam-tim CHAN
Prof. Cecilia Lai-wan CHAN
Dr. Ngai-yin CHAN
Dr. Andy Wai-kwong CHAN
Dr. Adolphus Kai-tung CHAU
Ms. Mabel CHAU
Dr. Chun-ho CHENG
Ms. Stella CHENG
Dr. Chung-seung CHIANG
Dr. Regina Cheuk-tuen CHING
Ms. Sandra CHOW
Dr. Charles Kau-chung HO
Dr. Patrick Tak-him KO
Dr. Shu-keung KWONG
Dr. Polly LAU

:

J HK Coll Cardiol, Vol 16 (Suppl 1)

Dr. Yuk-kong LAU
Dr. Kathy Lai-fun LEE
Prof. Stephen Wai-luen LEE
Mr. Kam-tao LEUNG
Dr. Kei-pui LEUNG
Dr. Albert Wai-suen LEUNG
Dr. Leonard Sheung-wai LI
Dr. Shu-kin LI
Dr. Chiu-on PUN
Dr. Tak-fu TSE
Dr. Chris Kwok-yiu WONG
Prof. Kam-sang WOO
Prof. Cheuk-man YU
Prof. Doris Sau-fung YU

November 2008

xi

Faculty
International
Ms. Kathy BERRA

Prof. Chul KIM

Clinical Director, Stanford Prevention Research Center,
Stanford University School of Medicine, USA

Head of Department of Rehabilitation Medicine, Director
of Cardiac Rehabilitation Clinic, Sanggye Paik Hospital,
Inje University Medical College, Seoul, Korea

Dr. Falvio BURGARELLA
Director of Heart Friends Around the World, Bergamo,
Italy

Prof. Bernard Man-yung CHEUNG
Chair of Clinical Pharmacology and Therapeutics,
Department of Clinical Pharmacology, University of
Birmingham, United Kingdom

Prof. Masahiro KOHZUKI
Professor and Chairman, Department of Internal Medicine
and Rehabilitation Science, Tohoku University Graduate
School of Medicine, Sendai, Japan

Dr. Lydia Abdul LATIF
Department of Allied Health Sciences, Faculty of
Medicine, University of Malaya, Kuala Lumpur, Malaysia

Dr. Johan DENOLLET
Professor of Medical Psychology, Tilburg University,
The Netherlands

Dr. Lan GUO
Guangdong Provincial Cardiovascular Institute,
Guangzhou, PR China

Prof. Jianan LI
Professor in Rehabilitation Medicine, Chairman of
Department of Rehabilitation Medicine, First Affiliated
Hospital of Nanjing Medical University, Nanjing, PR
China

Ms. Nancy Houston MILLER

Dr. Sandeep GUPTA
Consultant Cardiologist, Whipps Cross and St. Bartholomews
Hospitals, London, UK

Associate Director, Stanford Cardiac Rehabilitation
Program and Clinical Assistant Professor, University of
California San Francisco, School of Nursing, USA

Prof. Visal KANTARATANAKUL

Dr. Farzaneh TORKAN

Head of Department of Rehabilitation Medicine, Faculty
of Medicine of Ramathibodi Hospital, Mahidol University,
Bangkok, Thailand

Chairman of Department of Physical Medicine and
Rehabilitation, Mild Subspecialty Hospital, Iran

Prof. Terence KAVANAGH
Associate Professor, Faculty of Medicine and Professor,
Graduate Program in Exercise Science, Faculty of Physical
Education and Health, University of Toronto, Canada

Local
Ms. Eva AU
Ms. Jocelyn AU
Ms. Vanessa Lai-fan AU
Prof. Sek-ying CHAIR
Ms. Celia Hoi-yan CHAN
Dr. Kam-tim CHAN
Dr. Kin-wing CHAN
Prof. Cecilia Lai-wan CHAN
Dr. Ngai-yin CHAN
Dr. Andy Wai-kwong CHAN
Dr. Adolphus Kai-tung CHAU
Miss Mabel CHAU
Dr. Chun-ho CHENG
Miss Stella CHENG
Dr. Chung-seung CHIANG
Dr. Regina Cheuk-tuen CHING
Ms. Sandra CHOW
Mr. Andy Hau-yan HO
Dr. Charles Kau-chung HO
Dr. Yu-tak HUNG
xii

Miss Snowball IP
Ms. Selina KHOR
Dr. Patrick Tak-him KO
Dr. Shu-keung KWONG
Dr. Douglas Tat-chau LAI
Dr. Steve Wai-keung LAI
Dr. Ronald LAM
Dr. Yat-yin LAM
Prof. Chu-Pak LAU
Dr. Polly Mo-yee LAU
Dr. Suet-ting LAU
Dr. Yuk-kong LAU
Dr. Michael Kang-yin LEE
Dr. Kathy Lai-fun LEE
Prof. Stephen Wai-luen LEE
Mr. Kam-tao LEUNG
Dr. Kei-Pui LEUNG
Ms. Mandy Shun-yan LEUNG
Dr. Sum-kin LEUNG
Dr. Albert Wai-suen LEUNG
November 2008

Mr. Frederick Kin-wa LI
Dr. Leonard Sheung-wai LI
Dr. Shu-kin Li
Dr. Christina Kit-chee MAW
Mr. Peter POON
Dr. Chiu-on PUN
Dr. Kin-ming TAM
Prof. Brian TOMLINSON
Dr. Kai-fat TSE
Dr. Tak-fu TSE
Dr. Tak-sun TSE
Dr. Chi-ming WONG
Mr. Tony Ka-keung WONG
Dr. Chris Kwok-yiu WONG
Prof. Kam-sang WOO
Dr. Thomas Wai-cheong YIP
Prof. Cheuk-man YU
Prof. Doris Sau-fung YU
Dr. Chiu-sun YUE

J HK Coll Cardiol, Vol 16 (Suppl 1)

Congratulatory Message for
2nd Asian Preventive Cardiology and Cardiac Rehabilitation Conference cum
7th Certificate Course in Cardiac Rehabilitation

It is my great honor to attend the 2nd Asian Preventive Cardiology and Cardiac Rehabilitation Conference
cum 7th Certificate Course in Cardiac Rehabilitation. I would like to express my heartiest gratitude to
Hong Kong College of Cardiology for her invitation.

In last two decades, Hong Kong College of Cardiology made a noticeable contribution to the substantial
development of Cardiology in Hong Kong, promoting the care of patients in cardiovascular medicine.
The conference today is promisingly an excellent opportunity for the medical and paramedical profession
to share their experience. I would like to extend my appreciation to all who have participated in and
generously supported this conference.

Dr. Ka-lau LEUNG
Legislative Council Member
(Medical Constituency)
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4. Outpatient Cardiac Rehabilitation for Cardiac Surgery Patients
in National University Hospital − Report on Retrospective Data
5. Detection of Coronary Artery Disease in Asymptomatic High
Risk Individuals with Coroary CT Angiography
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10. CHF-HOME (Congestive Heart Failure − Home cOmmunity
Monitoring and Exercise) Program: A Multidisciplinary
Program to Improve the Outcome of Patients with Congestive
Heart Failure
11. Perioperative Negative Emotions and Quality of Life Six Months
after Cardiac Surgery
12. Community Cardiac Rehabilitation Program − Local Experience
in a Regional Rehabilitation Centre

(Venue: Room 601)
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xvii
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Dr. Sandeep GUPTA
Dr. Johan DENOLLET
Ms. Kathy BERRA

12:30-14:00 LUNCH BREAK
14:00-15:30 SYMPOSIUM 5 − Essential Component: Exercise
Moderators:
Dr. Chung-seung CHIANG
Dr. Kathy Lai-fun LEE
Dr. Ngai-yin CHAN
Dr. Chiu-sun YUE
Effect and Molecular Mechanism of Physiological Ischemia
Training of Skeletal Muscle on Angiogenesis at Remote Sites
with Pathological Ischemia in Rabbit Models of Coronary and
Peripheral Artery Stenosis
Exercise Prescription in Cardiac Patients
Electrical Stimulation of Skeletal Muscles in Patients with
Heart Failure: An Alternative to Aerobic Training?
Exercise and Hypertension

(Venue: Room 601)

Prof. Jianan LI

Dr. Farzaneh TORKAN
Prof. Masahiro KOHZUKI
Prof. Chul KIM

15:30-16:00 TEA BREAK
POSTER EXHIBIT

(Venue: Room 603-604)

16:00-17:30 SYMPOSIUM 6 − Control the Risks
Moderators:
Dr. Chun-ho CHENG
Dr. Kam-tim CHAN
Prof. Kam-sang WOO

(Venue: Room 601)

Is Cardiovascular Disease Preventable?
The Malignant Threat of Hypertension
How to Achieve Regression of Atherosclerosis

Prof. Bernard Man-yung CHEUNG
Ms. Nancy Houston MILLER
Prof. Brian TOMLINSON

♦♦♦♦♦♦
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(B) ICHHN Workshop on Successful Marketing of Heart-Smart Eating Program in Schools
SATURDAY, 22 NOVEMBER 2008
14:30-14:45 REGISTRATION

(Venue: Room 606-607)

14:45-14:55 Opening Remarks & Souvenir Presentation

Dr. Regina Cheuk-tuen CHING
Mrs. Chu-eng TAN

14:55-15:15 How to be Heart Healthy

Dr. Patrick Tak-him KO

15:15-15:35 Facts & Traps

Dr. Nanley CHENG

15:35-16:05 Be a Smart Customer − read the labels

Ms. Shanna WU

16:05-16:35 TEA BREAK
16:35-17:05 Promotion of Healthy Eating in Schools

Ms. Fanny CHAN

17:05-17:30 EatSmart at School − From Survey to Practice

Dr. Christina Kit-chee MAW

17:30-17:45 Closing Remarks

Dr. Kenneth NG

(C) Rotary Heart Health Public Conference
Update in Cardiac Treatment and Rehabilitation

SUNDAY, 23 NOVEMBER 2008

09:00-16:00 REGISTRATION

(Venue: Room 606-607)

09:30-10:00 Opening Remark

Dr. Suet-ting LAU
Mrs. Chelsia TO

10:00-11:00 LECTURES
Moderator:

Dr. Kin-ming TAM

Update in Medical Treatment
Update in Intervention Treatment and Rehabilitation

Dr. Yat-yin LAM
Dr. Albert Wai-suen LEUNG

11:00-11:25 Q&A
11:25-11:40 BREAK
11:40-12:10 LECTURES
Moderator:

Dr.Yu-tak HUNG

Update in Exercise and Cardiac Rehabilitation
Update in the Rehabilitation of Heart Failure
xx
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Dr. Leonard Sheung-wai LI
Dr. Kei-pui LEUNG
J HK Coll Cardiol, Vol 16 (Suppl 1)

12:40-13:00 Q&A
13:00:14:30 LUNCH BREAK
14:30-17:00 WORKSHOP 1
Healthful Eating for a Healthy Heart

(Venue: Room 605-607)
Ms. Selina KHOR

WORKSHOP 2
Nourish Your Heart: Say Goodbye to Stress

WORKSHOP 3
Exercise for Cardiac Patients

Prof. Cecilia Lai-wan CHAN
Ms. Celia Hoi-yan CHAN
Mr. Andy Hau-yan HO

Mr. Frederick Kin-wa LI
Ms. Eva AU
♦♦♦♦♦♦

(D) 7th Certificate Course in Cardiac Rehabilitation
MONDAY, 24 NOVEMBER 2008

(Venue: Room 601)

09:00-10:30 WORKSHOP 1 − Conducting Cardiac Rehabilitation Program
Moderator:
Dr. Ngai-yin CHAN
Inpatient Cardiac Rehabilitation

Dr. Farzaneh TORKAN
(Assistant: Dr. Laleh HAKEMI)
Dr. Farzaneh TORKAN
(Assistant: Dr. Laleh HAKEMI)

Outpatient Cardiac Rehabilitation

10:30-11:00 TEA BREAK
11:00-12:30 WORKSHOP 2 − Behavior Modification
Moderators:
Prof. Sek-ying CHAIR
Dr. Michael Kang-yin LEE
Behavioral Skills Training
Updates on Smoking Cessation
Motivational Interviewing and Smoking Cessation: What Is It and
Is It Effective?

Ms. Nancy Houston MILLER
Dr. Ronald LAM
Dr. Douglas Tat-chau LAI

12:30-14:00 LUNCH BREAK
14:00-15:30 WORKSHOP 3 − Patient Education
Moderator:
Dr. Thomas Wai-cheong YIP
Type II Diabetes − A 6-week Patient Education Program for Cardiac
Rehabilitation Professionals

Ms. Kathy BERRA

15:30-16:00 TEA BREAK

J HK Coll Cardiol, Vol 16 (Suppl 1)

November 2008

xxi

16:00-17:30 WORKSHOP 4 − Exercise
Moderator:
Dr. Polly Mo-yee LAU
How to Make People Exercise

Prof. Visal KANTARATANAKUL
(Assistant: Ms. Metta JARUKITJAROON)
♦♦♦♦♦♦

TUESDAY, 25 NOVEMBER 2008

(Venue: Room 601)

09:00-10:30 WORKSHOP 5 − Diet
Moderator:
Dr. Shu-keung KWONG
The Influence of Nutrition on Cardiovascular Health

Ms. Vanessa Lai-fan AU

10:30-11:00 TEA BREAK
11:00-12:30 WORKSHOP 6 − Self Management
Moderator:
Miss Mabel CHAU
Facilitating Self-management Behaviors in Cardiac Patients

Mr. Peter POON

12:30-14:00 LUNCH BREAK
14:00-15:30 WORKSHOP 7 − Exercise
Moderator:
Dr. Steve Wai-keung LAI
Exercise in Practice for Cardiac Patients

Miss Snowball IP
Ms. Mandy Shun-yan LEUNG

15:30-16:00 TEA BREAK
16:00-17:10 WORKSHOP 8 − Vocation and Driving
Moderators:
Miss Stella CHENG
Dr. Leonard Sheung-wai LI
Return to Work after Acute Myocardial Infarction
Driver Assessment for Cardiac Patients

Mr. Tony Ka-keung WONG
Ms. Jocelyn AU

17:10-17:30 CLOSING REMARK AND CERTIFCATE PRESENTATION

xxii
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1.
Improving Quality of Life of Patients with Cardiac Problems
Through Health Qigong Program
A POON, 1 CS YUE, 2 M WAN, 1 L MA, 1 P HUI, 1 E PO, 1 B CHEUNG, 3
WY CHU 3
1
Occupational Therapy Department; 2Medical & Geriatric Department, Cardiac
Division; 3Health Resource Center, United Christian Hospital, Hong Kong
Objectives: Health qigong practice had been incorporated in our cardiac
rehabilitation program phase II since 2000 with proven effects. However, the
maintenance effects after the program is still doubtful. Last year, occupational
therapy department, medical and geriatric department and health resource
center collaborated to develop a health qigong group program with patients
attending weekly qigong practice led by trained lay leaders by occupational
therapist and performing daily practice at home. The present study aimed at
evaluating the physiological and psychosocial effect of this 12-week health
qigong (Badunjin) program on cardiac patients. The maintenance effect of
the program was also evaluated at post-discharge 12-week from the program.
Methods: A pre-test and post-test control design was adopted. A sample of 57
(39 male and 18 female) subjects was recruited from those patients who had
just completed the cardiac rehabilitation program phase II. Thirty-one were
allocated to the experimental group with 12-week health qigong program
(employing lay leaders and emphasis on self-management principles) and 26
to the control group with no active treatment provided. Patients in the
experimental group would attend the program on weekly basis for 12 weeks
with home practice not less than five times per week. Outcome measures of
blood pressure (SBP & DBP), heart rate (HR), psychosocial functioning, quality
of life (C-SF36), readmission and mortality rate were adopted. Outcome data
were collected at the point of initial assessment, at the completion of the 12-

week program and at 12-week interval after discharged from the program.
Results: Repeated measure of ANOVA revealed that there was reduced HR of
patients in the experimental group (p=0.001) with overt improvement in DBP
and SBP while patients in the control group showed increase in HR, DBP and
SBP. C-SF36 results also indicated that there was general improvement in
psychosocial functioning and quality of life in the experimental group. Besides,
three patients were readmitted due to cardiac problems in the control group
but none in the experimental group. Positive feedback from participants showed
that they were more active in daily life with enhanced confidence and selfefficacy in coping with their cardiac problems and dealing with their daily
lives. Other factors like the cultural relevant Traditional Chinese Medical
components of health qigong, sense of empowerment as in the lay leaders,
changes in lifestyle, peer group sharing, learning and support were also
identified which had contributed to the positive outcome of the program.
Conclusion: The 12-week health qigong (Badunjin) program was effective
not only in improving the quality of life of patients with cardiac problems but
their self-efficacy, coping strategies and lifestyle as well. Through the use of
culturally relevant health qigong treatment modality, recruitment and training
of lay leaders, impacts of group effects and multi-disciplinary collaboration,
the program can be considered as a cost-effective intervention to facilitate
active lifestyle engagement and long-term community reintegration with
possible reduction in the avoidable re-admissions due to cardiac problems.

2.
Cardiovascular Risk Profile in Individuals with or without History
of Cardiovascular Disease
ST LAU, A LAI, YH CHOW, M CHAN, PT TSUI
Kwai Tsing Safe Community & Healthy City Association, Hong Kong
Background: Cardiovascular risks are very common amongst the general
population. Patients may already had manifestation of diseases such as
ischaemic heart disease (IHD) or cerebral vascular disease (CVA) while others
has no known disease. Though the methods of detection, monitoring and
treatment of the modifiable risks are available, it is not unusual that they not
well controlled. This study compares the control of these risk factors in the
two categories of patients.
Methods: Community health promotion and screening programs were
conducted in 16 housing estates in collaboration with the local District Council
in 2006-2007. A self-administered questionnaire with demographics, known
history and treatment of hypertension, hypercholesteramia, diabetes mellitus,
exercise and smoking history were recorded. Body mass index, blood pressure,
spot sugar and total cholesterol were taken. Counseling, health talk and
distribution of educational pamphlets were given by healthcare personnel
supported by volunteers.
Results: A total of 2463 participants with 492(20%) male and 1589(65%)
over 60 years of age were recruited.
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BMI >25

IHD or CVA
42.4% (42/99)

No history of IHD or CVA
32.5 (353/1087)

Smoker or quit <1 year

9.5% (9/95)

6.3 (66/1047)

Exercise 3 times per week

67.0% (65/97)

64.4 (676/1050)

BP >140/90 mmHg

45.8% (103/225)

42.7 (956/2240)

TC >5.2 mmol/l

21.3 % (48/225)

32.6 (730/2240)

BS >7 mmol/l

37.3% (84/225)

27.5 (615/2240)

BP >140/90 mmHg
Known HT on Rx

55.7% (73/131)

58.8% (378/643)

TC >5.2 mmol/l
Known high TC on Rx

16% (8/50)

34.5% (40/116)

BP >140/90 mmHg
No/Unknown Hx of HT

27.5% (22/80)

34.2% (488/1425)

TC >5.2 mmol/l
21.2% (28/132)
No/unknown Hx of high TC

30.3% (536/1771)

Conclusion: The prevalence of cardiovascular risks is high especially in those
with history of IHD or CVA. Hypertension is notoriously poorly controlled
even in those with known history of cardiovascular diseases. Additional effort
and resources should be put in the control of these modifiable cardiovascular
risks in our population for prevention of cardiovascular diseases.
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Prevent Rehospitalisation Program for High Risk Heart Failure
Patients
KC LEUNG, KP LEUNG, KM CHAN, SW TANG
Cardiac Rehabilitation & Resources Center, Tung Wah Eastern Hospital, Hong Kong
Background:
1. Heart failure (HF) has become a worldwide health and economic burden
with high mortality rate and rehospitalisation rate. Around 25-50% of
hospitalized patients will be readmitted within 6 months after discharge.
2. In 2006, there were about 16,000 HF admissions to HA hospitals (~2000 in
HKEC), accounting for 1.4% of total hospital admissions. In HKEC, each
HF patient had an average of 1.4 admissions per year. Around 100 high risk
HF patients (~10% of all HF patients) had ≥4 cardiac hospitalizations in
one year.
3. Meta-analysis revealed that specialized multidisciplinary team disease
management could decrease mortality and hospitalization.
Objective:
To utilize a case-managed HF program in reduction of rehospitalization, length
of stay (LOS) in these high risk HF patients
Program Outline:
A. Eligible participants
- HF patients who had >2 or 4 HF hospitalizations in past 6 and 12 months
respectively (high risk group)
B. Format
1. Case managed approach
2. Medical follow up started 1 week after discharge and then every 1-2 weeks
till stable.
3. Subsequent follow up interval will be extended and thereafter, nurse led
follow up will provide continuation of care
C. Components of the program include
1. Aggressive titration of anti-HF medications by physician
2. Surveillance and management of salt and fluid status
3. Multidisciplinary input (nurse- as case manager, dietitian, physiotherapist

and occupational therapist) for education and skills on self management
strategies
4. Supervised exercise training to improve functional capacity and other
vascular benefits
Results:
In 2007, 20 patients were recruited. Mean age was 73.2 (range 48 to 90).
Fifteen (75%) were male. Mean Ejection fraction was 30.9%. Over 70% was
belonged to New York Heart Association Functional Class II. Fifteen (75%)
patients had participated in exercise training.
A. Exercise capacity
Mean 6-minute walking test improved from 349 to 463m (p=0.02) or 32.3%
increment.
B. Mortality rate (6 month)
2 (10%) died within 6 month after recruitment. Both were at extreme age (86 and
90) with many co-morbidities and accounted for all 4 admissions in this study.
C. Admission rate and LOC (6 month)
Total 6-month cardiac
related admissions
Mean 6-month cardiac
related admission rate
Total 6-month LOS (days)
Mean 6-month LOS

Pre-program

Post-program

77

4

p value

3.85 times/person

0.2 times/person

(p <0.0001)

909
45.5 days/person

51
2.5 days/person

(p <0.0001)

1. 6-month cardiac related admission rate showed an average reduction of 3.65
times
2. 6-month mean LOS reduced by 42.9 days
D. Drug utilization
At the end of the program, around 95% patients was receiving optimized anti
CHF medications (i.e. ACEI or Angiotension II blocker and beta-blocker)
Conclusion:
A case managed model for high risk CHF patients was clinically beneficial
and highly effective to reduce hospitalisations and LOS.

4.
Outpatient Cardiac Rehabilitation for Cardiac Surgery Patients
in National University Hospital − Report on Retrospective Data
K GEETHA, PF LEE, YH CHAN, Y LIANG
National University Hospital, Department of Rehabilitation, Physiotherapy
National University of Singapore, School of Medicine, Singapore
Background: The 6 minute walk test (6MWT) is a simple test administered
in cardiac surgery patients to assess exercise tolerance and the effects of
cardiac rehabilitation programs (CRPs). However, the number of patients
referred to such CRP continues to be low and the fallout rate of these patients
is common due to complications. In this study, the 6MWT is used as an
assessment tool to observe the exercise tolerance and the effectiveness of a
CRP for a group of cardiac surgery patients.
Materials and Method: One hundred patients who had undergone coronary
artery bypass graft surgery (CABG) were enrolled into the National
University Hospital Outpatient CRP (NUHCRP). Patients were selected based
on inclusion criteria of completion of at least one phase of the NUHCRP
and the 6MWT pre and post rehabilitation. Thirty-four patients [91% males,
mean age (59±9); 9% females, mean age (61±5)] were selected from this
group for the 6MWT analysis. Twenty-seven percent of the patients had a
valve surgery with a CABG (CABG + valve) and 73% had a pure CABG.
The patients underwent a short length of inpatient rehabilitation and enrolled
into the NUHCRP. Rehabilitation comprised of 1.5 hrs of intensive aerobic
and strengthening exercises conducted by a physiotherapist, for 12 to 24
sessions over two and a half months. A regression equation derived in a
6MWT study was used to determine the predicted total distance walked.

A2

Results: One way ANOVA and Spearman's correlation were used to
determine differences in the 6MWD (Diff6MWD) and selected variables.
Based on the regression equation, 30% of patients exceeded the predicted
distance in post 6MWT. Ninety-seven percent of the patients walked an
absolute distance more than 300m post 6MWT. Mean distance walked pretest was (463±87m) and post-test (485±85m). Patients ≥70 years old walked
a mean Diff6MWD of (60±58m) with the largest increase in distance against
all the age groups ranging from 50 to ≥70 compared < 50 years old (44±76m).
Mean ejection fraction of the patients was (52±13%). Diff6MWD walked in
the diabetic group compared to the non-diabetic group was not found to be
different; however patients with a smoking history walked a mean difference
of (25±67m) as compared to the non-smokers (20±94m). CABG patients
had increased Diff6MWD (36±63m) compared to CABG + valve patients.
Seventy-one percent of patients who did not have ECG changes after cardiac
surgery had a Diff6MWD of (31±89m) as compared to those with ECG
changes. Sixty-eight percent of the patients showed ≥10% increase in distance
walked between the two tests. The pre 6MWD was found to be positively
correlated to post 6MWD (r= 0.612, p<0.01) and negatively correlated to
the difference in the distance walked (r= -0.558, p<0.01).
Conclusion: Our data suggests that 6MWD is feasible and tolerated in older
patients after cardiac surgery. Following NUHCRP, cardiac surgery patients
showed significant improvement in the 6MWD, which is a true improvement
in functional capacity as a true consequence of therapeutic intervention.
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Detection of Coronary Artery Disease in Asymptomatic High Risk
Individuals with Coronary CT Angiography
RHM CHAN, S JAVALI, T SHETH
McMaster University, Hamilton, Ontario, Canada
Background: Few studies have looked at the prevalence of obstructive
coronary artery disease (CAD) in asymptomatic patients with multiple CAD
risk factors.
Methods: We performed a retrospective pilot study of asymptomatic high
risk patients who were referred to a single computed tomography coronary
angiography (CTA) center for evaluation of CAD from January 2007 to July
2008. Patients with previously documented CAD were excluded.
Results: Of the 26 patients identified, 79% were male. Average age was 58.4.
34% were of advanced age (male >60, female >70), 54% had hypertension,
15% were diabetic, 19% were current smokers, 65% had hyperlipidemia, 42%
had a positive family history. Average number of risk factors was 2.4. Fiftyfour percent had ≥3 CAD risk factors. Atherosclerotic plaques were identified
in 81% of the asymptomatic patients. 35% had CAD with stenosis of <70%
diameter, while 42% had CAD with severe (>70% diameter) stenosis in one
or more vessels. Furthermore, 20% had severe (>70% diameter) plaques
identified in either their left main or proximal left anterior descending (LAD)
artery.
Conclusion: Prevalence of obstructive CAD is very high in asymptomatic
patients with multiple coronary risk factors, with a significant proportion with
severe stenosis detected, some of which were in either left main or proximal
LAD lesions. CTA has the potential to be used as a tool to identify occult high
risk lesions in this population. Further research is needed to determine the
optimal management strategy for these patients.

6.
Cardiovascular Risk Factors, Echocardiographic Parameters and
2 Years Outcome in End Stage Renal Disease Patient
YK LO, CL LAU, CC CHOY, ST LAU
Department of Medicine and Geriatric, Princess Margaret Hospital, Hong Kong
Background: Cardiovascular disease is common amongst end stage renal
failure patients. The combination of cardiovascular disease and renal disease
amplifies the progression of disease in the individual system. Their presence
and association await further investigation in our local setting.
Objective: To assess the cardiovascular risk factors, echocardiographic
parameters and their 2 years cardiovascular morbidity and mortality in
patients on renal replacement therapy.
Methods: 101 end stage renal failure (ESRF) patients receiving renal dialysis
for more than 6 months were followed up since 6/2006. Baseline
epidemiological data, cardiovascular risk factors, echocardiographic
parameters were assessed. Cardiovascular morbidity and mortality were
recorded till 31/7/2008.
Results: 101 dialysis patients were studied. 87.1% and 42.6% of the patients
were hypertensive and diabetic respectively. 18.8% had ischaemic heart
disease. 4% had a previous cerebrovascular event. 22.8% had been
hospitalized because of heart failure symptoms. 27% had blood pressure
equal or lower than 130/80 mmHg. 38.6% were taking angiotensin converting
enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and 55.4%
were taking beta-blocker. 21.8% were on lipid-lowering agents. 67% had
left ventricular hypertrophy while 81.2% had diastolic dysfunction. 31.7%,
13.9% and 5% patients had mildly impaired ejection fraction (50-59.9%),
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moderately impaired ejection fraction (35-49.9%) and poor LV contraction
(EF less than 35%) respectively. During the two years follow up, 12% patients
had an episode of cerebrovascular event requiring hospitalization. Twentyfour percent had been hospitalized because of acute coronary syndrome.
23% had succumbed during the 2 years follow up (11 patients died of
infection, 7 patients died of acute coronary syndrome, 4 patients died of
cerebrovascular event, 1 patient died of hepatocellular carcinoma and
1 patient died of unknown cause).
Conclusion: End stage renal failure patients have very high prevalence of
cardiovascular risk factors, related morbidity and mortality. More attention
and better preventive measures should be carried out to improve their disease
outcome.
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To Investigate the Effectiveness of Cardiac Rehabilitation Program
for Patients Utilising the Exercise Prescription Program Based on
American College of Sports Medicine Exercise Prescription
Guidelines in Changi General Hospital

Review of Cardiac Rehabilitation Outcome Achievements

MX LIM, CC TEO, PP GOH, SC CHAI, VH TAN, CK LIM
Department of Rehabilitative Services and Cardiology, Changi General
Hospital, Singapore
Aim: To investigate the effectiveness of cardiac rehabilitation program (CRP)
for patients utilising the exercise prescription program based on American
College of Sports Medicine (ACSM) exercise prescription guidelines.
Method: A randomised control study of patients with cardiac abnormalities
attending the CRP program in Changi Sports Medicine Centre. A total of 16
CRP patients who fulfilled the inclusion and exclusion criteria were recruited
from mid August 2008 till end September 2008. These patients were divided
into two groups; the control group undergo the CRP without using the exercise
prescription program based on the previous protocol while the second group
went through the program using the exercise prescription program. The assessor
will be blinded to the two groups of CRP patients. Both groups of CRP patients
will attend 12 sessions. Outcome measures used included 6 Minute Walk Test
and SF 36.
Results: The result shows that there is a significant difference in the change
in 6 Minute Walk Test i.e. median 148m versus 62.5 m for the exercise program
prescription versus non program group. (p=0.05 by Mann Whitney U test).
However there is no significant difference in the change in SF36 for the 2
groups respectively i.e. median 13.60 versus 17.41. ( p =1.00 by Mann Whitney
U test).
Conclusion: We propose that the discrepancy in the primary end-point may
be due to patients' perception that they are fitter after the cardiac rehabilitation
program without any awareness of the extent of improvement till they complete
the 6 min walk test which is more objective.

YM FONG, YY HO, KB LAM, CP LAU, HF TSE, LSW LI
Cardiac Rehabilitation and Prevention Center, Tung Wah Hospital, Hong Kong
Objective: To review the sustainability of cardiac rehabilitation outcome
achievement among patients underwent four phases in two years of cardiac
rehabilitation program.
Methodology: Patients recruited for cardiac rehabilitation program and have
completed all four phases of program are included in the data collection.
Patients with cardiac diseases but failed to complete all four phases are not
included in this survey. Outcomes includes body mass index, exercise
capacity, blood sugar level (HbA1c) and lipid profile were monitored and
recorded at the phase I (in patient phase), phase II (8 weeks supervised
hospital based training), phase III (3 months after active training ) and phase
IV (12 months after phase III).
Results: A total of 556 ( Male : Female, 436 : 120) patients have completed
all four phases of cardiac rehabilitation program between November 1998
and November 2007. The mean age was 63±12. Data were analyzed with
multivariate test and comparisons were adjusted with Bonferroni test.
A quadriatric trend with exercise capacity was reported F(1, 377.5) =228.4
p =0.000. Significant improvement was reflected between phase II and phase
I. A linear trend in body mass index F (1, 139.9 ) = 98.3 p=0.000 was
observed from phase II, III and IV. Significant cubic trend with blood sugar
HbA1c level F(1, 5.07) = 10.3 p=0.002 was recorded with significant change
between phase I & II and phase III & II. Significant linear trend with
triglyceride F(1,7.7) = 13.4 p =0.000 , and HDL F(1,6.4) = 135.7 p=0.000
whilst a quadriatric trend with LDL was observed F(1, 52.8) = 110 p=0.000.
Conclusion: Blood results in sugar level and lipid were better controlled
while the exercise capacity and body mass index were inversely recorded
over the two year monitoring. The findings postulate professional input after
phase II would be necessary for a better mastering of risk factors.

9.
Comparison of Treatment Outcome and Health-related Quality
of Life in Acute Coronary Syndrome Patients of Three Age
Groups: <60, 60 to 80, and >80 Years
RJ LI, M ZHANG, Q ZHANG, QH ZHANG, CP CHAN, GWK YIP; M DONG, D
DING, BRYAN P YAN, EB WU, CM YU
Institute of Vascular Medicine and Division of Cardiology, Prince of Wales
Hospital, The Chinese University of Hong Kong, Hong Kong
Objective: Prevalence of octogenarians presenting with acute coronary
syndrome (ACS) is increasing as the population ages. This study evaluated
the effect of age on health-related quality of life (HRQOL) in 3 age groups
presenting with ACS.
Methods: We prospectively analysed 429 patients presenting with ACS
admitted to our institution with ACS from Feb 2006 to March 2008. SF-36
was used to assess HRQOL at baseline and 6-month. Baseline characteristics,
treatment & HRQOL were compared across 3 age groups (<60, 60-80 &
>80 yrs). Multivariate linear regression was performed to identify predictors
of improvement in SF-36 and its physical & mental component scores.

HRQOL
<60 yrs
60-80 yrs
>80 yrs
p value

A4

Baseline
54.1±17.8
44.4±18.7
39.4±17.1
<0.01

SF-36
6 Month
58.9±15.9
56.6±18.6
51.5±17.2
0.07

p
0.01
<0.001
<0.001

Baseline
61.4±27.3
45.2±29.0
35.7±20.1
<0.01

Results: 108 Patients (25.2%) were <60 yrs, 236 pts (55.0%) between 6080 yrs and 85 pts (19.8%) >80 yrs. Elderly pts were more likely to be
female (19 vs. 36 vs. 50%, p<0.01), less likely to present with
ST-elevation myocardial infarction (44 vs. 31 vs. 25%, p<0.01) & to undergo
coronary revascularization (62 vs. 48 vs. 23%, p<0.01). Six-month mortality
increased incrementally by age group (2 vs. 6 vs. 19%, p<0.01). SF-36 and
its physical component score (PCS) improved significantly at 6 month in
all the 3 groups (Table). Increasing age was associated with lower baseline
HRQOL but more improvement of SF-36 score (+5.4±7.5 vs. +11.9±18.9
vs. +12.9±19.7, p=0.03). Age (β=2/10 yrs; 95%CI 1.2-5.1) and PCI
(β=0.12; 95%CI 0.01-9.0) were independent predictors of improvement in
SF-36 at 6 months.
Conclusions: Increasing age was associated with worse HRQOL &
mortality in ACS pts at 6 months. However, octogenarians experienced
more improvement in HRQOL than the youngest age group despite lowest
rate of revascularization. Thorough clinical evaluation is mandatory in
the management of the elderly to balance benefits in mortality vs.
HRQOL.

PCS
6 Month
73.4±25.0
67.6±26.7
59.8±26.2
0.02
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p
<0.001
<0.001
<0.001

Baseline
55.1±24.0
51.4±22.5
52.2±21.5
0.44

MCS
6 Month
52.9±19.7
57.2±19.4
60.9±18.8
0.07

p
0.47
0.005
0.12
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CHF-HOME (Congestive Heart Failure - Home. cOmmunity,
Monitoring and Exercise) Program: A Multidisciplinary Program
to Improve the Outcome of Patients with Congetive Heart Failure
TS TSE,1 YFT LEE,1 HL CHAN,1 SF YEUNG,1 R WONG,2 KW WONG,3
WK CHEUNG,1 CHB CHAU,1 KL WU,1 SHG CHEUNG,1 CY CHEUNG,1
YNA NG, 3 D WONG, 2 A LI, 4 HY CHO, 1 SW WONG, 1 KL TSUI, 1
KK CHAN,1 SK LI1
1
Department of Medicine; 2Community and Patient Resource Centre;
3
Department of Physiotherapy; 4Department of Dietetics, Pamela Youde
Nethersole Eastern Hospital, Hong Kong
Introduction: Congestive Heart Failure (CHF) is a growing public health
problem in Hong Kong. In Pamela Youde Nethersole Eastern Hospital,
numbers of admissions for CHF continued to increase, with 1.5 fold increase
from 2001 to 2005. It is one of the leading causes of hospitalization in
individuals older than 65 years of age. Readmission rate for CHF is very
high, with 33% of patients readmitted or died within 60 days.
Objective: To improve the clinical outcome of patients with CHF, and reduce
hospital admissions and resources utilizations.
Methodology: A multidisciplinary heart failure management team was
established in October 2007 to identify, assess, intervene and monitor selected
patients admitted with CHF, i.e., in-patient clinical assessment, predischarge
education and counseling, post-discharge management plan, telephone
follow-up and enquiry service, early clinic follow-up.
Clinical outcome of those patients with history of recurrent CHF, i.e., 60
days readmission with CHF before and after enrollment into this program
were analyzed.

Results: A total of 173 patients were enrolled between 3rd October and
30th June 2008. Ninety-eight patients had history of recurrent admission
for CHF. Their mean age was 74.75 yrs. The numbers of 60 days readmissions
for CHF amongst these 98 patients were 29 before enrolling into this program,
and were reduced to 16 after enrolling into this program (P=0.04).
A total of 264 telephone follow-up and 49 telephone enquiry service were
provided. Thirty-five episodes of early evidence of CHF were recognized,
which were settled without hospital admissions. Drug and dietary advice,
awareness of CHF disease and symptoms, importance of home care and
self-assessment were reinforced through these services.
Conclusions: CHF-HOME Program improves the clinical outcome of
patients with CHF, and reduce hospital admissions and resources utilizations.

11.
Perioperative Negative Emotions and Quality of Life Six Months
after Cardiac Surgery
PJ TULLY,1,2 RA BAKER,1 DA TURNBULL,2 HR WINEFIELD2
Cardiac Surgery Research Unit, Flinders Medical Centre; 2School of
Psychology, The University of Adelaide, South Australia
1

Objective: Specific syndromal aspects of depression and anxiety have not
been explored in relation to changes in health related quality of life (HRQOL)
after cardiac surgery. The purpose of this study was to examine the impact
of depression, anxiety and general stress on quality of life (QOL) after
coronary artery bypass graft (CABG) surgery. Utilizing a tripartite conceptual
model of depression and anxiety as a theoretical framework, we hypothesized
that general stress symptoms, rather than unique depressive or anxiogenic
symptoms, will predict lower improvement in QOL after CABG surgery.
Methods: Elective CABG patients (n=226) completed baseline self-report
measures of negative emotions and HRQOL and 193 patients completed
these measures at six-month follow-up. Multi-level modeling analyses were
performed to test the hypothesis.
Results: Depression and anxiety symptoms simultaneously tempered gains
in HRQOL domains tapping into vitality, social functioning, general health,
bodily pain and physical role functioning (all p<0.05). General stress, in
combination with depressive symptoms, mediated HRQOL in the areas of
general mental health and emotional role functioning (all p<0.05).
Conclusion: This study adds to previous research by outlining discrete
associations between specific HRQOL domains, and is perhaps the first to
test a theoretical model of depression and anxiety in relation to CABG
patients' perceptions of HRQOL. These findings encourage further research
on negative emotions and HRQOL in cardiac surgery patients.
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Community Cardiac Rehabilitation Program − Local Experience
in a Regional Rehabilitation Centre
KC LEUNG,1 KP LEUNG,1 SW TANG,1 KM CHAN1
1
Cardiac Rehabilitation Team, Tung Wah Eastern Hospital; 2Tung Wah Group
of Hospitals Ko Wong Mo Ching Memorial Holistic Health Care Centre;
3
Haven of Hope Community Rehabilitation Day Centre, Hong Kong
Introduction: Comprehensive Cardiac Rehabilitation Program (CRP) has been
shown to have positive health benefits in particularly cardiopulmonary fitness.
In 2006, only 15.2% of HKEC in-patients discharged with coronary heart
disease had participated in the exercise-based CRP. To cope with the increasing
demand of CR and widen the service provision in terms of more flexible time
and convenient place, a community based CRP through partnership with NGOs
was set up to enhance patient's early community reintegration with positive
health-related outcomes while decreasing the service demand of HA.
Purpose of the Project: To study the feasibility of a community based, high
quality CRP in utilization of community resources and to evaluate the
improvement of health parameters.
Methods / Program Outline:
1. Eligible participants
- patients with coronary heart disease (CHD) or with multiple
cardiovascular risk factors (referred from acute hospital without prior
rehabilitation training and belonged to low risk group)
2. Format
- An initial multidisciplinary assessment in Tung Wah Eastern Hospital
(TWEH)
- In addition to individualized home exercise program, six exercise sessions
(once per week) were conducted in 2 community centers with
physiotherapy guidance ± TWEH nurse or physiotherapist support as
necessary
3. Outcome Measures (initial assessment and one week after the sixth training
session)
- maximum aerobic capacity and Heart rate parameters (measured by
exercise stress testing)
- lipid profile
- quality of life

C. Mean resting and submaximal workload HR (Bruce Protocol)
All were significantly reduced, reflecting an improvement in cardiac reserve
(N.B. 7 were excluded due to change of betablocker dosage)
Resting
stage 1
stage 2
stage 3
stage 4

HR (beats/min)
↓8.6±11.0
↓12.2±10.9
↓14.1±11.3
↓16.3±13.6
↓14.8±10.3

(p<0.0001)
(p<0.0001)
(p<0.0001)
(p<0.0001)
(p=0.03)

D. Quality of Life (measured by WHOQOL)
Improvement in scores of all domains was noted:
Physical Health
Psychological Health
Social
Environmental

↑0.5±1.0
↑0.2±1.4
↑0.4±1.5
↑0.4±1.3

(p=0.009)
(p=NS)
(p=NS)
(p=NS)

E. Admission
No mortality and post 6 month CVS related re-admissions and events was
noted for these patients.
Conclusion: Community CRP is a feasible model in enhancing service link
between hospital and community centres. It was shown to improve health
outcomes (comparable to hospital − based model).

Results:
- From May 2007 to May 2008, 36 patients were recruited. 30 (83%) were
male and the mean age was 58.1 (Range 43 to 79).
- Thirty patients had CHD and 6 had multiple cardiovascular risk factors.
Twenty-one patients (58%) had percutaneous angioplasty done.
- All of them completed the program uneventfully. No exercise related
complications occurred.
A. Aerobic capacity
There was significant improvement in mean aerobic capacity from 10.4 to
12.9 METS, i.e. 2.5±1.3 METS (p <0.0001) or 24% increment which was
comparable to hospital based model.
B. Mean lipid profile
Improvement in mean lipid profile was noted.
Total Cholesterol (TC)
Total Triglyceride (TG)

↓0.8±0.95
↓0.35±0.76

(p <0.001)
(p =0.013)

HDL-Cholesterol
LDL-Cholesterol

↑0.01±0.12
↓0.66±0.85

(p = NS)
(p <0.001)

Around 72% of patients achieved target LDL-C <2.6 mmol/L after the program.
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Affective Disorders as Risk Factors for Delirium after Cardiac
Surgery
PJ TULLY,1,2 RA BAKER,1 DA TURNBULL,2 HR WINEFIELD2
Cardiac Surgery Research Unit, Flinders Medical Centre; 2School of
Psychology, The University of Adelaide, South Australia
1

Objectives: Delirium is a known adverse outcome of cardiac surgery and
research has supported an association with depressive symptoms. The
objective of this study was to determine the association between incident
delirium after cardiac surgery and preoperative affective disorders, and also
Type-D personality.
Methods: Ninety nine cardiac surgery patients were assessed preoperatively
for mood and anxiety disorders using structured diagnostic interview, and
patients completed a Type-D scale. Patients were re-examined for
postoperative delirium and results were analysed using Fisher's exact tests.
Results: Postoperative assessment showed that 22 (22.2%) patients met
criteria for delirium. The prevalence of affective disorders at baseline was
12.1% for current major depression, 8.1% for panic disorder and 4% for
generalized anxiety disorder (GAD). Delirium was associated with major
depression (5.2% vs. 36.4%), p<0.001, panic disorder (2.6% vs. 27.3%),
p<0.001, GAD (1.3% vs. 18.2%), p<0.01 and current alcohol abuse (0%
vs. 9.1%), p=0.05. Social phobia was not associated with incident delirium
(1.3% vs. 9.1%), p=0.12. Delirium was associated with high negative affect
without social inhibition (23.4% vs. 45.5%), p=0.06, but not in combination
with social inhibition (i.e. Type-D personality) where a trend was observed
(11.7% vs. 27.3%), p=0.10.

Conclusions: This preliminary study highlights an association between
affective disorders and incident delirium following cardiac surgery, while
support was also shown for negative affect in isolation without social
inhibition. This suggests that current distress rather than distressed
personality style is associated with incident delirium. Future research should
consider the utility of differential diagnosis for postoperative delirium among
cardiac surgery candidates who have a high prevalence of affective disorders
and explore rehabilitation options for this precarious population.

14.
Hypertension in Pregnacy is an Independent Risk Factor for
Hypertension Later in Life
VD GAROVIC, 1 KR BAILEY, 1 E BOERWINKLE, 2 SC HUNT, 3
AB WEDER,4 D CURB,5 TH MOSLEY, JR.,6 HJ WISTE,1 ST TURNER1
1
Mayo Clinic, Rochester, MN; 2 University of Texas, Houston, TX;
3
University of Utah, Salt Lake City, UT; 4University of Michigan, Ann Arbor,
MI; 5Pacific Health Research Institute, Honolulu; 6University of Mississippi
Medical Center, Jackson, MS, USA
Objective: The association between hypertension in pregnancy and
hypertension later in life increasingly is being reported. We aimed to assess
the role of hypertension in pregnancy as an independent risk factor for future
hypertension.
Materials and Methods: Women who participated in the Family Blood
Pressure Program study (n=4782) were categorized into women with no
history of pregnancy lasting more than 6 months (n=718), women with no
history of hypertension in pregnancy (n=3421), and women with a history
of hypertension in at least one pregnancy (n=643). We used Kaplan-Meier
and Cox proportional hazard models to estimate and contrast the risks of
subsequent diagnoses of hypertension among the groups.
Results: Women with a history of hypertension in pregnancy, compared to
those without such a history, were at significantly increased risks for the
subsequent diagnoses of hypertension (p<0.001). The increased risk for
subsequent hypertension remained significant after controlling for race,
family history of CVD, smoking, dyslipidemia and diabetes mellitus, with
an adjusted hazard ratio (HR) of 1.88, p<0.001.
Conclusions: Our results suggest that hypertension in pregnancy may be an
independent risk factor for hypertension later in life.
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Clinical Outcomes of Cardiac Rehabilitation Program on
Functional Capacity, Biochemistry and Physiolofical Changes
S KANCHANAPORN, R CHUANCHAIYAKUL, D RIANNUKOOL
Cardiac Rehabilitation Clinic, Bangkok Heart Hospital, Thailand
Objective: To evaluate the effectiveness of cardiac rehabilitation program
impact on functional capacity, biochemistry and physiological changes.
Design: Retrospective study, 2-tailed test.
Method: Patient who enrolled to phase 2 cardiac rehabilitation program
and attended more than 2 sessions from the period of January 2006 - June
2008. Outcome variables were measured pre and post program including
three categories; functional capacity was measured by distance covered in a
6 minute-walk distance (6MWD) and metabolic equivalent (METs)
comparison. Biochemistry was measured by fasting plasma glucose (FBS)
hemoglobin A1c (HbA1c), lipid profile including LDL, HDL, triglyceride
and the last categories were physiological changes that measured by resting
heart rate and blood pressure adaptation and body composition.
Result: 420 patients were male 77.1%, female 22.9%, mean aged 59.5 years
old. Patients were attended cardiac rehabilitation that was implemented
supervised exercise program, counseling of risk factor modification and
smoking cessation. Mean duration of cardiac rehabilitation program was
184.6 days and frequency of attention in cardiac rehabilitation program was
1.83 sessions per week. Functional capacity outcome showed significantly
improvement. Pre-post program 6MWD was 363.1±141.3 vs 414.5±132
(p=0.001), METs related physical activity was 2.27±0.09 vs 3.34±1.7
(p=0.000). Biochemistry showed significantly reduction in FBS 125±49.3
vs 111.86±30.4 (p=0.003) LDL 112.25±40.4 vs 94.8±29.99 (p=0.000) and
triglyceride 135.14±68.3 vs120.31± 49.69 (p=0.048), significant higher in

A8

HDL 45.49±14.48 vs 47.65±11.75 (p=0.043) but no significant change in
HbA1c 10.27±17.8 vs 7.14±1.14 (p=0.263). Physiological adaptation showed
significantly reduction in resting heart 81.17±55.33 vs 74.3±13.7 (p=0.002)
no significantly reduction in systolic and diastolic blood pressure 126.12±
56.25 vs 121.86±15.01 (p=0.187), 75.09±9.4 vs 74.9±8.7 (p=0.72)
respectively. Body composition showed significantly reduction only
percentage of body fat 29.31±10.37 vs 26.4±8.4 (p=0.009). No significant
changes in waist circumference , body weight and body mass index (BMI)
were 36.18±3.9 vs 37.01±9.3 (p=0.429), 72.73±18.73 vs72.02±18.16
(p=0.561) and 26.25±5.9 vs 26.83±13 (p=0.831) respectively.
Conclusion: Cardiac rehabilitation program significantly improves clinical
outcome at the end of rehab measure on functional capacity, fasting blood
sugar, lipid profile, resting heart rate and percentage of body fat.
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Chronic Kidney Disease, Especially Proteinuria, is a Powerful
Predictor for Cardiovascular Events in High-Risk Hypertensive
Patient
K UESHIMA,1 S YASUNO,1 K OBA,1 A FUJIMOTO,1 T OGIHARA,2 T SARUTA,3
K NAKAO1,4
1
EBM Research Center, Kyoto University Graduate School of Medicine,
Kyoto; 2Osaka General Medical Center, Osaka; 3Keio University Graduate
School of Medicine, Tokyo; 4Department of Medicine and Clinical Science,
Kyoto University Graduate School of Medicine, Kyoto, Japan
Objective: Chronic kidney disease (CKD) is associated with cardiovascular
(CV) morbidity and mortality as well as loss of renal function. In this context,
we aimed to evaluate the effect of proteinuria and the level of estimated
glomerular filtration rate (eGFR) on CV events rate in high-risk hypertensive
patients as a subanalysis of CASE-J (Candesartan Antihypertensive Survival
Evaluation) trial.
Method: The CASE-J trial enrolled 4,728 high-risk Japanese hypertensive
patients, who were randomly assigned to candesartan- or amlodipine-based
treatment regimens. This trial disclosed that both two treatment regimens
equally suppressed the incidence rates of CV events. Thus, we analyzed the
data as an observational study irrespective of allocated drugs. CKD was
defined as proteinuria (PU) and/or decreased eGFR (<60 ml/min/1.73 m2) at
enrollment. We divided CASE-J patients into two groups (without CKD:
n=1983, with CKD: n=2720), and also evaluated the effect of proteinuria
and the level of eGFR (cut-off point: 60 ml/min/1.73 m2) on CV events rate
(Group A: PU(-) and eGFR≥60, n=1983, B: PU(-) and eGFR<60, n=1815,
C: PU(+) and eGFR≥60, n=330, D: PU(+) and eGFR<60, n=575). Hazard
ratio (HR) was calculated with multivariable Cox regression analysis adjusted
for difference of baseline characteristics.

Results: During 3.2 ± 0.9 years of follow-up, 201 (7.4%) patients with CKD
experienced CV events and 67 (3.4%) patients without CKD did (HR: 2.08,
95%CI: 1.57-2.76). In a subgroup analysis, 67 (3.4%) patients in Group A,
95 (5.2%) in Group B, 31 (9.4%) in Group C and 75 (13.0%) in Group D
experienced CV events (Group B; HR: 1.38, 95%CI: 1.00-1.90, Group C;
HR: 3.07, 95%CI: 2.00-4.70, Group D: 4.00, 95%CI: 2.85-5.59 vs. Group
A). These results indicated that proteinuria has an adverse impact on CV
events rate independent of the level of eGFR.
Conclusion: The present study shows that CKD, especially proteinuria, is a
powerful predictor for CV events. Accordingly, we should pay more attention
to presence or absence of proteinuria in risk stratification in high-risk
hypertensive patients.

2.
Predictive Values of Blood Pressure Indexes for Cardiovascular
Events in High-Risk Hypertensive Patients: A Subanalysis of CaseJ Trial
S YASUNO, 1 K UESHIMA, 1 K OBA, 1 A FUJIMOTO, 1 T OGIHARA, 2
T SARUTA,3 K NAKAO1,4
1
EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto;
2
Osaka General Medical Center, Osaka; 3Keio University Graduate School of
Medicine, Tokyo; 4Department of Medicine and Clinical Science, Kyoto
University Graduate School of Medicine, Kyoto, Japan

3.2±0.9 years of follow-up. HR for CV events per 1SD increase of SBP, DBP,
and PP were 1.19 (95%CI; 1.04-1.36), 0.79 (95%CI; 0.69-0.90), and 1.35
(95%CI; 1.19-1.53). Improvement of likelihood ratios were 6.1, 11.7, and
20.7, respectively. Pairwise comparison revealed that SBP and DBP were not
positively associated with CV events in models with PP, whereas a positive
relationship with PP was still observed.
Conclusion: The present study showed that PP has a stronger predictive utility
for CV events than SBP and DBP in high-risk hypertensive patients. These
findings supported the concept that increased PP was associated with advanced
atherosclerosis and target organ damage.

Objective: Hypertension is the most common risk factor for cardiovascular
(CV) events. Systolic blood pressure (SBP), diastolic blood pressure (DBP)
and pulse pressure (PP) have been reported to be the predictors of CV events.
However, there is no consensus as to which is best. Thus, we aimed to compare
the associations of SBP, DBP, and PP levels at enrollment with the incidence
of CV events in high-risk hypertensive patients as a subanalysis of Candesartan
Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Methods: We analyzed data of 4,703 patients from CASE-J trial who were
randomly assigned to either candesartan - or amlodipine-based regimens. We
used the multiple Cox regression analysis to estimate the hazard ratio (HR)
for CV events adjusted for baseline characteristics. Improvement of likelihood
ratio was calculated to compare the predictive utility for CV events among
three BP indexes. To perform pairwise comparison, two of three BP indexes
were subsequently included in the multiple Cox regression analyses.
Results: The exceptional BP control (less than 140/80 mmHg) was achieved
in the present study. Of 4,703 patients (mean age: 63.8 years), 268 (5.7%)
patients experienced CV events for a rate of 17.7 per 1000 person-years during
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The Role of the Health Fitness Programmer for Cardiac
Rehabilitation in a General Hospital
T SAKAGUCHI, M CHIBA, R SAKAE, S YANAGIMOTO, Y SAKAMOTO,
S TAKAOKA, T HAYASE, K UESHIMA, Y NOGI
Nogi Hospital, EBM Research Center at Kyoto University, Japan
Background: Since 2006, our general hospital, which has 95 beds, has been
insurance-approved for Cardiovascular Rehabilitation (CR). In our hospital,
2 Health Fitness Programmers (HFP) are engaged in CR. Although HFP were
originally working at sports facilities and fitness clubs, up to 40% of HFP
have now begun to work for medical institutions. We will consider the ideal
future for HFP in general through examining the operation of our HFP.
Current state: Our HFP are engaged in providing CR and exercise training
for patients with diabetes mellitus while in hospital. Also, they work as exercise
instructors in our facility in accordance with Article 42 of the Medical Care
Law and in a nursing-care facility as exercise trainers. The actual numbers of
exercise training given for CR, patients with DM, patients in a facility in
accordance with Article 42 of the Medical Care Law, and patients in a nursingcare facility per week were 32, 18, 21, and 4 cases, respectively. Our HFP
give questionnaires to their patients periodically, both to improve their exercise
instruction, and to revise their exercise programs. Accordingly, patients have
not become bored with their physical training, because their requests about
exercise programs changes have been accepted.
Perspective: Since other medical staff members are unfamiliar with giving
instructions for special physical training and resistance training, HFP should

take a major role in these fields. In addition, we are ready to forge a medical
partnership with fitness clubs or health promotion facilities. When the
partnership is achieved, HFP will mainly concentrate on developing and
maintaining good working relationships.
Conclusion: HFP are expected to be important leaders in the fight against
lifestyle-related disease and in preventing ischemic heart disease. As the
number of HFP who are hired into positions as medical staff leaps upward,
HFP should begin to combine both advanced skills in exercise training and
comprehensive medical knowledge.

4.
The Accuracy of the New Portable ECG Monitor, HCG-901 and
Its Usefulness in Cardiac Rehabilitation
M IMAI, 1 I MASUDA, 1 K UENISHI, 1 M MISHINA, 1 K UESHIMA, 2
H KUZUYA1
1
Higashiyama Takeda Hospital, Kyoto; 2EBM Research Center, Kyoto
University Graduate School of Medicine, Kyoto, Japan

Discussion: The comparison suggests that ECG recorded with HCG-901 is
quite accurate and the analysis result was credible. With the simplicity in
use, HCG-901 is expected to be a useful monitoring tool for cardiac
rehabilitation.

Purpose: As portable ECG monitors are more commonly used nowadays,
we evaluated the accuracy of the non-transmission portable ECG monitor,
HCG-901 (Omron Healthcare Co., Ltd.) for clinical use and the usefulness
of the monitor on non-supervised cardiac rehabilitation.
Method: Ten subjects with the convalescent phase of cardiac diseases
(7 males aged 60±8) were enrolled. 1) ECG was recorded simultaneously
with HCG-901 and ECG monitoring device during supervised exercise
training. Those records were compared with the ones from the other ECG
monitoring device. 2) ECG was recorded with internal or external electrodes
during exercise training at home, on awakening, after dinner, before bedtime
or on the occurrence of subjective symptoms.
Results: 1) The records from both devices were very much concordant
regarding R-R interval (r=0.98), QRS complex (r=0.98), T-wave amplitude
(r=0.95) and R-wave amplitude (r=0.81), including the ones recorded during
exercise. Thirteen cases (26%) of VPC, SVPC as well as ST segment
depression recorded during exercise were detected. 2) Patients recorded ECG
as followings: Duration: 9.2±2.9 days, Number of records: 53±23, Total
number of records: 527. Eight cases of VPC, paroxysmal atrial fibrillation,
SVPC, sinus bradycardia or ST segment depression during exercise training
were detected. ECG was recorded during exercise training at home while
keeping the heart rate between 99.0±11.3.

A10

November 2008

J HK Coll Cardiol, Vol 16 (Suppl 1)

2ND ASIAN PREVENTIVE CARDIOLOGY AND CARDIAC REHABILITATION CONFERENCE
CUM 7TH CERTIFICATE COURSE IN CARDIAC REHABILITATION
ABSTRACTS
Abstracts Presentation (Poster):
5.
Profitability of the Japanese Cardiovascular Rehabilitation System
for a Small General Hospital
S YANAGIMOTO, M CHIBA, Y SAKAMOTO, T HAYASE, K UESHIMA,
Y NOGI
Nogi Hospital, EBM Research Center at Kyoto University, Japan

Conclusion: When the CR system is established in a small hospital, it is
important to consider profitability as well as necessity. Using our original
equipment and manpower, we were able to demonstrate highly persistent and
profitable CR. This shows that even in small hospitals, highly profitable CR
can operate.

Background: Since 2006, our small general hospital, which has only 95 beds,
has been insurance-approved for Cardiovascular Rehabilitation (CR). In these
small hospitals, maintaining the profitability of medical practice is very
important. We calculated the balance of payments of CR performed in our
hospital in order to evaluate the profitability of Japanese CR system for small
general hospitals.
Method: After establishing the CR system in our hospital, we assessed the
total income and expenditure for CR. Total income consisted of all fees charged
for CR, CR planning, exercise testing, exercise prescription, drug
administration guidance, nutritional guidance, and discharge guidance. Total
expenses consisted of equipment purchase expenses, depreciation expenses,
supply expenses, and personnel expenses.
Results: Persistent CR (more than 70% of persistence rate) was performed for
55 patients. Settlements of balance per month including 1) the number of CR
cases, 2) total revenue, 3) total expenditure, and 4) profit rate were as following:
($1.00 = ¥107)
In fiscal 2006,
1) 86.7 cases,
2) $6,075,
3) $3,147, 4) 48.2%.
In fiscal 2007,
1) 142.8 cases,
2) $8,203,
3) $3,132, 4) 61.8%.
And for 2008,
1) 137.0 cases,
2) $7,867,
3) $3,127, 4) 59.9%.
We could carry out highly profitable CR in a small hospital because of
insurance-approval of our facility for criterion I (high grade), using existing
medical instruments and existing manpower, and by maintaining a highly
persistent rate of CR.

6.
Disclosure of Information on the Internet about Cardiac
Rehabilitation in Insurance-Approved Institues in Japan
S YAMADA, M CHIBA, S YANAGIMOTO, Y SAKAMOTO, T HAYASE,
A KONDO, K UESHIMA, Y NOGI
Nogi Hospital, EBM Research Center at Kyoto University, Japan

Conclusion: In conclusion, even for the insurance-approved institutes of CR
which are registered on the website of the JACR, their description rates about
CR on their websites are not very high. Disclosure of information about CR
on the Internet should be strengthened in order to promote improved CR in
Japan.

Background: Recently, many kinds of information have become available
through the internet about the various medical fields. We evaluated the quality
and quantity of information available on the Internet about cardiac
rehabilitation (CR) in Japanese insurance-approved institutes.
Methods: There are 143 Japanese insurance-approved institutes of CR which
are registered on the website of the Japanese Association of Cardiac
Rehabilitation (JACR). We evaluated the following data through the web-sites
of each institute: 1) the numbers of cardiologists and cardiovascular surgeons,
2) the numbers of registered cardiac rehabilitation masters, 3) the annual
numbers of patients with percutaneous coronary intervention (PCI) and patients
with cardiac surgery, 4) the annual numbers of patients receiving CR,
5) contents of the CR. We assessed the description rates for each of these
information items.
Results: Although the mean description rates of the numbers of cardiologists
and cardiovascular surgeons were 79% and 67% respectively, the mean
description rate of the numbers of registered cardiac rehabilitation masters
was only 11% (p < 0.0001). Moreover, while the mean description rates of the
annual numbers of patients with PCI and cardiac surgery were 63% and 52%
respectively, but the mean description rate of the annual numbers of patients
receiving CR was only 13% (p < 0.0001). Only 46% of the institutes introduced
their CR system at all.
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The Relationshop Between the Intensity of Systemic Hypoxia and
Cardiac Autonomic Activity Induced by Physical Stimulation
SC HUANG,1 MK WONG,1,2 JS WANG2
1
Department of Physical Medicine and Rehabilitation, Chang Gung Memorial
Hospital; 2Graduate Institute of Rehabilitation Science and Center for Healthy
Aging Research, Chang Gung University, Tao-Yuan, Taiwan
Objective: This study investigates how various hypoxic interventions affect
cardiovascular autonomic activities during posture change and the Valsalva
maneuver.
Materials and Methods: Ten healthy sedentary men exposed to 12%, 15%
and 21% O2 for 1 hour in a normobaric hypoxia chamber in a random order.
Before and 3o min after various O2 concentrations were administered, subjects
performed the sit-up test and the Valsalva maneuver. A spectral analysis of
heart rate variability and cardioacceleration response to posture change as well
as Valsalva ratio were performed to determine the cardiac autonomic activity.
Result: While the patient rested in a supine position, exposure to 12% O2
reduced total power and high frequency (HF) and increased low frequency
(LF) and the ratio of LF to HF. Furthermore, this hypoxic exposure
simultaneously(i) lowered the changes of time and frequency domains in
HRV and cardioacceleration response induced by the sit-up test. (ii) attenuates
the HR responses to the Valsalva maneuver. However, resting and posture
change-induced HRV and heart rate response values were not influenced by
both 15% and 21% O2 exposures.
Conclusion: Acute hypoxic exposure affects cardiac autonomic activities,
with reactions determined by the intervening O2 concentrations. Exposure
to 12% O2, but not 15% O2, down-regulates cardiac autonomic responses to
posture change and the Valsalva manever.

8.
Does the Dialysis Arteriovenous Fistula Possess Homogeneous
Mechanical Properties?
PJ KO,1 WC TSAI,2 SH PAO,3 CH WANG,4 TC FU,5 CC HSU5
Division of Thoracic and Cardiovascular Surgery, Chang Gung Memorial
Hospital, Linkou; 2Department of Physical Medicine and Rehabilitation,
Chang Gung Memorial Hospital, Linkou; 3 Industrial Technology and
Research Institute, Hsinchu; 4Department of Cardiology, Chang Gung
Memorial Hospital, Keelung; 5 Department of Physical Medicine and
Rehabilitation, Chang Gung Memorial Hospital, Keelung, Taiwan

1

Results: The peak systolic and end diastolic velocities increased after entry
into the fistula and the greatest values were 236 cm/s and 128 cm/s
respectively at Segment c. They decreased after leaving this area. The
maximum strain had the similar trend as the flow velocity. The greatest
value was 4.22% at Segment c and the least value was 1.11% at Segment e.
Conclusion: Ultrasonography can successfully evaluate regional
hemodynamic characteristics and mechanical properties in the dialysis
access. The AVF behaves heterogeneously at different segments.

Objectives: To prove that different local hemodynamic characteristics and
physical factors cause different clinical manifestations at different segments
in the arteriovenous fistula (AVF).
Materials and methods: Six stage 5 chronic renal failure patients, aged
about 57 years old, were recruited in a tertiary care hospital. Four of them
had patent radiocephalic anastomosis and the remaining had patent
brachiocephalic anastomosis. Another four similar aged patients underwent
percutaneous transluminal angioplasty owing to radiocephalic shunt stenosis
were also enrolled. Peak systolic and end diastolic velocities, diameter at
end diastolic phase, intima-media wall thickness, and the maximum strain
at the arterial inflow (Segment a), venous anastomosis (Segment b), 1 cm
downstream from the anastomosis (Segment c), midway between the
anastomosis and the needlepuncture site (Segment d) and needle access region
(Segment e) were measured with ultrasonography. Pressure recording at the
above five locations in the other four patients was done after successful
treatment of AVF stenosis. A mathematical model was derived to approximate
the intra-access pressure from the brachial artery pressure of uninvolved
limbs. Elastic modulus in each segment can then be calculated.
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Effects of Long-Term Exercise with Medium Intensity on Heart
Function of Mice and Possible Mechanisms Approach
S LIU, Y CAI, Y XU
Cardiac Rehabilitation Center, Xiangya Hospital of Central South University,
Changsha, Hunan, 410008 China
Study Objective: Epidemiology data demonstrate that regular exercise can
reduce the morbidity and mortality of cardiovascular diseases by 40-50%.
One of the mechanisms known is exercise induced myocardial protection.
However, the exact mechanisms of myocardial protection are not clear yet.
In this study, the effects of long-term exercise with medium intensity on
cardiac function, as well as the effects on heat shock proteins (HSPs) and
hypoxia-inducible factor-1α (HIF-1α) expression in mouse myocardium were
explored. Possible mechanisms of exercise induced myocardial protection
were discussed.
Materials and Methods: Sixteen wild-type mice were randomly divided
into two groups: control group (n=8) and exercise group (n=8). The mice in
exercise group were forced to run with medium intensity on a treadmill for
one hour per day, five days per week. All the treatments in control group are
the same as in the exercise group except no running exercise involved. After
10 weeks of intervention, (1) mice cardiac function and heart weight were
analyzed by echocardiography; (2) left ventricle weight and tibia length
were measured after the mice were sacrificed; (3) the medium part of the
left ventricle were used for morphology analysis by hematoxylin & eosin
(HE) staining and light microscope imaging; (4) the upper part of left ventricle
were used for HSPs and HIF-1α gene expression analysis by RT-PCR or
quantitative PCR.

Results: (1) Compared to control group, interventricular septum (IVS)
(1.22±0.13 vs 0.80±0.09 P<0.01), posterior wall of left ventricle (LVPW)
(1.28±0.30 vs 0.79±0.09 P<0.01) of exercise group were significantly thicker;
ejection fraction (EF) (90.0±3.16 vs 81.6±7.26 P<0.01) and left ventricular
shortening fraction (FS) (53.4±3.28 vs 47.2±5.71 P<0.05) were dramatically
elevated. (2) Both left ventricle weight to body weight ratio (6.3±0.74 vs
5.0±0.61 P<0.01) and left ventricle weight to tibia length ratio (12.7±1.35
vs 10.2±2.22 P<0.05) were significantly higher of exercise group than those
of control group. (3) Light microscope observation showed that cardiac
muscle fibers of exercise mice were thickened and cardiomyocytes were
augmented than those of control mice. (4) HSP70 (0.59±0.24 vs 2.36±0.32
P<0.01), HSP90 (0.65±0.31 vs 2.29±0.47 P<0.01), HSP 27 (0.98±0.54 vs
2.15±1.22 P<0.05), αβ-lensprotein (0.84±0.39 vs 2.16±1.45 P<0.05) mRNA
expression in exercise group were significantly higher than those of control
group; HIF-1α expression in exercise group was increased by 1.78-fold
compared to control group(P<0.01).
Conclusion: Long-term exercise with medium intensity caused myocardial
hypertrophy and better heart function in mice. Inducing HSPs and HIF-1α
expression in myocardium by exercise might be one of the possible
mechanisms.
(This study is supported by National Natural Scientific Fund. No: 30672213.)

10.
Measuring Self-Care of Chronic Heart Failure
DSF YU,1 DTF LEE,1 J WOO,2 EMF LEUNG3
1
The Nethersole School of Nursing, The Chinese University of Hong Kong;
2
Department of Medicine and Therapeutics, The Chinese University of Hong
Kong; 3Department of Medicine and Geriatrics, United Christian Hospital,
Hong Kong
Objective: There is more evidence to indicate that self-care is the cornerstone
of therapy in managing chronic heart failure (CHF). Self-care refers to the
beahviors that the patient engages in and the decision they make about activities
that promote health and limit illness. A reliable and valid measure for CHFrelated self-care is crucial for assessing patients' ability in managing the disease
and evaluating the adequacy of health services. The purpose of this study was
to conduct psychometric evaluation on the Self-Care Heart Failure Index
(SCHFI) and the European Heart Failure Self-care Behavioral Scale (EHFScBS)
in the Chinese CHF patients.
Methods: A purposive sample of 19 CHF patients were recruited from a
hospital and a community settings for focus group interviews. Their views on
CHF-related self-care were used to conduct cross-cultural adaptation of the
two tested instruments. Another 143 community-dwelling CHF patients were
recruited for conducting the psychometric evaluation. The main outcome
measures involved the Chinese versions of SCHFI and EHFScBS. The Medical
Outcomes Study Social Support Survey (MOS-SSS-C) and the Hospital
Anxiety and Depression Scale (HADS) were used for construct validation.

J HK Coll Cardiol, Vol 16 (Suppl 1)

Results: A few SCHFI and EHFScBS items were modified to optimize their
cultural relevancy. The Chinese versions of SCHFI and EHFScBS had content
validity indices as 0.89 and 0.93, and Cronbach's alphas as 0.82 and 0.73,
respectively. Construct validity was supported by their respective significantly
correlations with the MOS-SSS but not with the HADS. The low level of
psychological distress among the sample may mask such theoretically
porpurted relationships. Confirmatory factor analysis supported the 3-factor
structure of the SCHFI in measuring self-care maintenance, self-care
management and self-care self-confidence.
Conclusion: The Chinese version of SCHFI and EHFScBS are culturally
relevant, reliable and valid tools for use in CHF patients. Whereas the SCHFI
can be used to gather precise information about how to enhance self-care of
CHF patients, the EHFScBS provides a brief measure for service evaluation.
These two instruments are complementary to each other and allow a better
understanding of the self-care of CHF patients.
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Type D Personality in Chinese Patients with Coronary Artery
Disease
DSF YU,1 DR THOMPSON,2 CM YU,3 S PEDERSEN,4 J DENOLLET4
1
The Nethersole School of Nursing, The Chinese University of Hong Kong,
Hong Kong; 2Department of Health Sciences, University of Leicester, Leicester,
the UK; 3Department of Medicine and Therapeutics, The Chinese University
of Hong Kong, Hong Kong; 4CoRPS-Center of Research on Psychology in
Somatic diseases, Department of Medical Psychology, Tilburg University, The
Netherlands
Objective: Increasing evidence supports the prognostic impact of Type D
personality (i.e., increased negative emotions paired with emotional nonexpression) in patients with coronary artery disease (CAD). This study aimed
at estimating the prevalence of Type D in Chinese patients with CAD and
performing cross-cultural validation of the DS14 in the Chinese culture.
Method: Patients with CAD (N=326) were recruited from a regional universityaffiliated hospital and invited to complete the Chinese version of the DS14.
The NEO Five Factor Inventory (n1=120), the Hospital Anxiety and Depression
Scale (HADS) and the Stress Symptom Checklist (SSC) (n 2=66) were
administered to sub-samples to establish construct and discriminant validity,
respectively. Administration of the DS14, HADS and SSC was repeated at
one month after hospital discharge (n2=66). Stability of the DS14 was examined
by repeating data collection with another sub-sample (n3=100).
Results: The prevalence of Type D personality was 31% in Chinese patients
with CAD. Confirmatory factor analysis indicated that there was no crosscultural variation in the theoretical structure of Type D personality [χ2/df=
2.89, RMSEA=0.08, Normal fit index = 0.91, Non-normal fit index=0.91,

Comparative fit index = 0.93]. The Negative Affectivity and Social Inhibition
subscales of the DS14 were internally consistent (α=0.89/0.81), measured
stable traits (3-month test retest ICC=0.76/0.74), and demonstrated
significant correlations with the NEO-FFI neuroticism (r=0.78) and
extraversion (r=-0.64) subscales, respectively. They also discriminated
themselves from the more transient emotional states, as the Negative
Affectivity and Social Inhibition scores remained unchanged in patients who
reported significant improvement in depressed mood and stress level over
the first month of hospital discharge.
Conclusion: Type D personality is a prevalent personality trait in Chinese
people with CAD. This study suggests that the DS14 is a valid, reliable, and
internally consistent measure when used in the Chinese population. Studies
are now warranted examining the prognostic risk of Type D personality in
Chinese people with CAD.

12.
Return to Work after Coronary Disease − A Retrospective Review
TKK WONG ,1 KB LAM,2 LSW LI,2 RSM WONG,1 CP LAU,2,3 HF TSE,2,3
CSF YAU1
1
Occupational Therapy Department; 2Cardiac Rehabilitation and Prevention
Centre, Tung Wah Hospital; 3Department of Medicine, University of Hong
Kong, Hong Kong
Objectives: To review the rate of "return to work" of patients after completion
of cardiac rehabilitation program.
Method: It was a retrospective study covering the period from 01/01/2006 to
31/12/2007. Patients engaged in remunerative jobs prior to the onset of
coronary disease were recruited for work status and job nature analysis. Data
were collected at 1) Program entry; 2) End of the 8 weeks program; and 3)
One year post training.
Results: In the review period, a total of 160 patients had completed the cardiac
program in Tung Wah Hospital. Age ranged from 33 to 87 (mean 62±11.7);
gender distribution was 127 male and 33 female. Among the 160 patients,
only 47% (n=75) was working prior to admission. Age ranged from 33 to 81
(mean 55±9.9); gender distribution was 70 male and 5 female. By the end of
8 weeks' program, 86.7% (n=65) were able to return to previous or other work;
only 9 patients changed the job nature due to cardiac related reasons.

Amongst the 60 subjects still maintained their work after one year, 11 were
over 65 years old and still working for their life expenses.
Conclusion: According to Mital (2004), return to work is one of the important
markers of the success of cardiac rehabilitation. The work simulation training
and work counseling of our program helped to assist clients to face their
limitation of physical ability and psychological stress; eventually resumed
their work. This was reflected by the relatively high rate of return to work
(80%). Our result also showed that age above 65 was still able to sustain their
job.
This review indicated our sample tended to skew towards older population
(62±11.7) as the tren for aging population. The younger clients who would
benefit from such program might be missed because of some other reasons
such as lack of time to participate in a cardiac rehabilitation program. Modified
rehabilitation program tailored for this group of client could be our future
direction.

The job natures of the subjects are illustrated in following table:
Job nature
Manual laborer Technical Clerical Management Professional
Before onset of CHD
14
15
8
24
14
After 8-weeks program
10
11
8
22
14
After 1 year
7
11
7
22
13
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CVD Prevention: How Low to Go in 2009?
SANDEEP GUPTA
From Whipps Cross and St Bartholomews Hospitals, London, United Kingdom

In a world population of around 6 billion,
some 17 million deaths occur from CVD each year...
and around 80% of them occur in Emerging/
Developing economies. In addition, some 20 million
people survive a heart attack or stroke each year, and
their risk for further CV events remain 5-8 times
greater.
We acknowledge the concept of 'lower is better'
for management of key cardiovascular risk factors −
such as LDL-Cholesterol, blood pressure, salt intake
and BMI. The INTERHEART study emphasizes the
impact of established risk factors in all populations, and
various International guidelines have set suggested
goals/targets for such factors. Compounding this is the

debate of 'genes versus environment' in causation of
CVD.
Concerted efforts need to be maintained to
encourage healthier lifestyles, a focus on primary
prevention and addressing the particular needs of
individual populations − taking into account cultural
variations, metabolism issues and socio-economic
factors. In parallel the importance of aggressive
secondary prevention − whether CV intervention,
pharmaco-therapy or cardiac rehabilitation − for
those suffering a first or recurrent CV event, remains.
How stringent we address the CV prevention
targets, as we approach year 2009, will be discussed
and reflected upon.

Address for reprints: Dr. Sandeep Gupta
Consultant Cardiologist, Whipps Cross and St Bartholomews
Hospitals, London, United Kingdom
Received October 27, 2008; accepted October 29, 2008
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The Role of Fitness and Physical Activity in Heart Disease
TERENCE KAVANAGH
From Faculties of Medicine and Physical Education and Health, University of Toronto, Canada

There is compelling evidence that regular
physical activity whether expended at work or during
leisure activities, is associated with a reduction in the
incidence of heart disease.
As a corollary, since the mid-19th century
exercise has also played a role in the rehabilitation of
patients with established disease. Initially the approach
was pragmatic, with the goal being alleviation of angina
and improvement in functional capacity. Subsequently
exercise therapy fell out of favour for an extended period
and it was not until the 1950's that it re-emerged as a
component of cardiac rehabilitation programs. Ensuing
research has established its worth.
Physical fitness, considered a surrogate for
physical activity, has now been shown to be a significant
predictor of cardiac and all-cause mortality. As such, it
should be incorporated into a risk stratification
procedure for individuals with suspected or established
vascular disease. Questions remain as to:

1. The mechanisms by which physical exercise benefits
the cardiovascular system,
2. The degree to which one's genotype contributes to
exercise capacity, and
3. Whether the improvement in survival in patients
attending a cardiac rehabilitation program is
associated with an increase in physical fitness or
physical activity,
4. These and related subjects will be addressed.

Objectives of the Session
1. Outline the historical background of exercise therapy
in ischaemic heart disease
2. Explain the scientific rational for its place in a
comprehensive cardiac rehabilitation program
3. Evaluate the role of physical fitness as a prognostic
indicator in cardiac rehab patients

Address for reprints: Prof. Terence Kavanagh
Room 306, 901 Lawrence Ave. W., Toronto, ON M6A 1C3,
Canada
Received October 8, 2008; accepted October 29, 2008
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EatSmart at School: From Survey to Practice
CHRISTINA KIT-CHEE MAW, KIT-CHING TO, CATHERINE SHUK-YEE HO, REGINA CHEUK-TUEN
CHING
From Central Health Education Unit, Department of Health, Hong Kong

Background & Objectives

Results

With an increasing trend of obesity among
primary school students, promoting healthy eating
habits has become one of the important initiatives of
the Department of Health (DH). In this light, a territorywide EatSmart@school.hk Campaign was launched in
2006. Following the baseline survey in schools in 2006,
another survey was commissioned in 2008 to deepen
our understanding on the knowledge, attitudes and
practices among students, parents and schools towards
healthy eating during this period.

Fifty-one primary schools were recruited with
9152 (81.9%) students and 8265 (73.9%) parents
responding. Most students had good knowledge of
healthy eating principles though half of them would still
choose less healthy food. Girls were more likely than
boys to have adequate intakes of fruit and vegetables,
and to participate in healthy eating promotional
activities. Majority (78.6%) of responding parents
considered nutritional value an important factor
influencing food selection and they were generally
capable of selecting healthier food items. Over half
(61.3% to 92.1%) of the parents supported some form
of regulation on school lunch and snack provision. Less
educated and lower income parents showed lower levels
of understanding and support for healthy eating. About
half (52.9%) of the schools developed healthy eating
policies whereas one-fifth did not participate in any
healthy eating promotional activities. Overall, schools
that participated in DH healthy eating promotion
programmes showed more encouraging results.
Compared with 2006, improvements were seen in
students' attitudes and practices as well as parents'
support for healthy eating and their tighter regulation.

Methods
The 2008 survey was a cross-sectional study
conducted in primary schools in Hong Kong in January.
Standardised questionnaires were used to collect
information from the school management, Primary 4
and 5 students and their parents.

Address for reprints: Dr. Christina Kit-Chee Maw
Central Health Education Unit, 7/F, Southorn Centre, 130 Hennessy
Road, Wan Chai, Hong Kong.
Tel: (852) 2835 1827 Fax: (852) 2591 6127
Received September 26, 2008; accepted October 29, 2008
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Conclusion
Compared with 2006, this survey showed that
parents and children were more supportive towards
healthy eating. Gaps were identified for further
programme and research planning.
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Metabolic Syndrome Identification and Treatment
KATHY BERRA
From Stanford Prevention Research Center, Standfore University School of Medicine, California, USA

Metabolic syndrome (MS) [also known as
Syndrome X − Insulin Resistance Syndrome −
Dysmetabolic Syndrome − Multiple Metabolic
Syndrome − The Deadly Quartet − and Cardiometabolic
Risk] defines a clustering of cardiovascular risk factors
associated with an increased risk of developing Type 2
Diabetes and cardiovascular disease (CVD). These risk
factors include: glucose intolerance, dyslipidemia
(especially high triglycerides and low HDL cholesterol,
small dense LDL, postprandial lipemia and remnant
lipoproteins), hypertension, obesity, and increased waist
circumference. Other abnormal pathophysiologic
processes often accompany MS such as endothelial
dysfunction, a prothrombotic state, and increased and
levels of inflammatory markers.
Although the term MS is commonly used, the
underlying pathophysiology is a condition called
"Insulin Resistance" (IR). Not everyone with MS is
insulin resistant. However, IR is significantly more
common in persons with MS. One's susceptibility to
become insulin resistant is influenced by genetics and
lifestyle. Two major lifestyle risk factors for the
development of IR are increased weight and decreased
physical activity levels.
Researchers are looking for ways to more easily
identify those persons with the MS risk factors who
are insulin resistant. An important finding by
McLaughlin and colleagues was the association
between TG/HDL-C ratio and the presence of IR. Their
studies indicate that a ratio of >3 TG/HDL-C (in persons
with a BMI >25 and TG >130 mg/dL) is predictive of
insulin resistance. In pre-menopausal women this ration
is >1.5.
Address for reprints: Ms. Kathy Berra
Stanford Prevention Research Center, Stanford University
School of Medicine, 211 Quarry Road, Stanford, California
94305, USA
Received October 19, 2008; accepted October 29, 2008
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Treatment for MS and IR is multifactorial and is
based on key therapeutic lifestyle changes. Improving
and maximizing regular aerobic exercise, reaching ideal
body weight, and smoking cessation will significantly
improve insulin sensitivity thus reducing IR and it's
associated negative metabolic processes. A heart healthy
diet designed to lower calories, triglycerides, and
saturated fat is an additional key component of treating
persons with MS and IR. Making these lifestyle changes
is critical in preventing the onset of Type 2 Diabetes
and cardiovascular diseases. In addition to therapeutic
lifestyle changes, medical therapies such as statins,
fibrates, niacin, aspirin, hypoglycemics, antihypertensives (including Angiotensin Converting
Enzyme Inhibitors for persons with renal disease) are
recommended for the treatment of associated
cardiovascular risk factors. It is important to remember
that persons with insulin resistance but without CVD
who develop Type 2 Diabetes are considered to be at an
equivalent risk for a cardiac event when compared to
persons with CVD.
Our challenge is to prevent the development of
this constellation of well know risk factors for the
Metabolic Syndrome and Insulin Resistance through
early therapeutic lifestyle change and cardiovascular risk
factor management.

Furture Readings
1. Reaven G. The metabolic syndrome or the insulin resistance
syndrome? Different names, different concepts, and different
goals. Endocrinol Metab Clin N Am 2004;33:283-303.
2. Grundy SM, Cleeman JI, Daniels SR, et. al. Diagnosis and
management of the metabolic syndrome: an American Heart
Association/National Heart, Lung, and Blood Institute Scientific
Statement. Circulation 2005;112:2735-52.
3. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic
markers to identify overweight individuals who are insulin
resistant. Ann Intern Med 2003;139:802-9.
4. ACE Task Force on the Insulin Resistance Syndrome.
Endocrine Practice 2003;9(suppl 2):9-21.
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Recent Advances in Heart Failure Treatment
CHEUK-MAN YU
From Department of Medicine & Therapeutics, Prince of Wales Hospital; and Institute of Vascular Medicine, The
Chinese University of Hong Kong, Hong Kong

Heart failure (HF) is a disease with high
morbidity and mortality. It is also the commonest cause
of medical ward admission in developed countries. The
incidence of HF has been increasing world-wide in the
past two decades. With the current state-of-the-art
therapy, 3-year mortality remain >30% in NYHA class
III HF, and close to 40% in NYHA class IV HF.
Nowadays HF is classified according to its stages
into A to D. Stage A: High risk for developing HF, Stage
B: Asymptomatic HF, Stage C: Symptomatic HF, and
Stage D: Refractory end-stage HF. Most of the clinical
trials targeting on Stage C, though some of them also
focused on stage B and D. In the diagnosis, the use of
natriuretic peptide has shown to be a both sensitive and
in particular specific marker, i.e. good as a rule-out test
if BNP or NT-proBNP levels are normal. Medical
therapy has not been significantly changed in the last
few years, but consolidated on the use of neurohormonal
blockers, such as ACE inhibitors, beta-blockers, and
consider the third drug by either aldosterone receptor
blocker or angiotensin receptor in selected patients.
These agents are important as survival benefit
and reduction of hospitalization rate are clearly
demonstrated.
Despite medical therapy which has been rather
steady in the past few years, device therapy for HF
has been blooming. Studies observed that at least a
quarter of patients with heart failure had evidence of

Address for reprints: Prof. Cheuk-Man Yu
Professor of Medicine, Head of Division of Cardiology, Department
of Medicine & Therapeutics, Prince of Wales Hospital, Shatin,
New Territories, Hong Kong
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electromechanical delay, commonly in the form of
left bundle branch block or intraventricular
conduction delay on surface electrocardiogram. This
condition results in asynchronous contraction, mitral
regurgitation and was associated with a poor
prognosis. Cardiac resynchronization therapy (CRT)
has a potential role in these patients. Initial nonrandomized, and subsequently multicenter clinical
trials, consistently found the following benefits after
CRT: improvement of symptoms and exercise
capacity (6-minute hall walk distance), gain in
ejection fraction as well as improvement of quality
of life. In addition, we have demonstrated that
biventricular pacing increases diastolic filling time,
reduces pre-systolic time, reduces mitral
regurgitation, and decreases left ventricular volume
(reverse remodeling). Reduction of all-cause
mortality, heart failure event and sudden cardiac
death by CRT has also been confirmed by mutlicentre
trials (COMPANISON and CARE-HF studies).
Although not every patient response to CRT, the use
of echocardiographic imaging has been found highly
useful in assessment pre-pacing intraventricular
asynchrony and therefore predicting responders of
CRT. Another potentially useful device is cardiac
contractility modulation (CCM), which is an
implantable which boost the intrinsic contractility of
the left ventricular by delivering a current to the heart
in late systole. Initial results of the device appears
p r o m i s i n g i n E u r o p e , w i t h i m p r ove m e n t o f
symptoms, exercise capacity and ejection fraction.
We are currently conducting the only clinical trial
outside US and Europe for further evaluation of this
new device. Lastly, the use of monitoring device for
heart failure is becoming increasingly important in
patients receiving HF therapy.
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Models for Cardiac Rehabilitation
VISAL KANTARATANAKUL
From Cardiac Rehabilitation Unit, Samitivej Hospital; and Cardiac Rehabilitation Unit, Ramathibodi Hospital, Mahidol
University, Thailand

Cardiac rehabilitation is already recognized as
the multidisciplinary interventions that assist the patient
to learn, to get along and to modify their lifestyle after
any type of heart disease. In spite of that cardiac
rehabilitation service is still underutilized around the
world. There are many models of cardiac rehabilitation:
home-based, hospital based and corporate-based and
including primary prevention program.
The useful indexes to measure the effectiveness
of the model are compliance, cost-effectiveness and
reduction of morbidity.
The data from our unit had shown the factors that
influence attendance to our program are transportation,
working situation, no companion and unrecognized
benefits.
Our model combines home-based program with
4-6 visits with our physician during 4-8 months. The
patient will be discharge if he/she could reach our goals:
- Exercise at least 20-30 minutes/time for 3 times per
week.
- Control weight
- Good control of physiological outcomes: blood
pressure, glucose and cholesterol level.

After discharge, all of them will join the
STRONG HEART self-help group.
The CARES-THAI already implement
CARES-THAI ACTION which adapted concepts
from EUROACTION program to set the cardiac
rehabilitation after discharge from the hospital by
one-week interval visit with our cardiac rehabilitation
therapist for one month. The data showed that both
models had very high attendance and low dropout
with favorable outcome in exercise habit but no
significant change in blood chemistry levels.

Further Readings
1. Dafoe WA. Program models for cardiac rehabilitation. In
Pashkow FJ, Dafoe WA (eds): Clinical cardiac rehabilitation:
A cardiologist's guide, 2 nd Ed. Baltimore MD, Williams &
Wilkins, 1999, pp 446-78.
2. Numpichitre N, Ua-Aree P. Exercise Maintenance of Cardiac
Patients After Participation in Cardiac Rehabilitation Phase II
and Influential Factors in Ramathibodi Hospital. Ramathibodi
Nurs J 2000;6:142-53.
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Coronary Artery Disease Club − One of the Experience of Cardiac
Rehabilitation in Guangdong
LAN GUO, PING WANG, GUO-LIN ZHANG, ZHI LIU, GUI-LAN WU
From Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Guangdong General Hospital,
Guangdong, China

Introduction
Cardiac rehabilitation (CR) programs are
designed to limit the physiologic and psychological
effects of cardiac illness, reduce the risk for sudden
death or re-infarction, control cardiac symptoms,
stabilize or reverse the atherosclerotic process and
enhance the psychosocial and vocational status of the
patients. Very few Chinese patients attend the
programs because of various reasons. How to
motivate patients to participate in the programs is a
real problem. Coronary artery disease (CAD) Club
is a way to recruit patients and attract them to keep
participating in the CR programs. We evaluated the
effects of cardiac rehabilitation exercise therapy on
quality of life (QOL) in the CAD patients. The
psychological and physiological status, the social
adaptation ability and knowledge and practices in
CHD prevention/control were also studied.

Methods
A CAD Club was set up to recruit patients. A
staff performed initial and follow-up patient
assessment. Cardiac rehabilitation sessions include
a combination of telemetry-monitored exercise,
individual counseling, and small and large group
education classes. Letters and telephone were used
to improve the CR compliance. During follow up of
patients in clinics, patients were encouraged to

comply with comprehensive second prevention and
lifestyle changes (such as stop smoking, regular
exercise and dieting). Typical program involves
prescribed exercise sessions using THR and RPE.
Exercise time is 30 minutes, 3-5 times a week. The
follow-up post-CR included 1, 3, 6 months and 1 year
post program assessment. 109 CAD patients after
percutaneous transluminal coronary angioplasty
(PTCA) were randomized. 78 of them were set in the
rehabilitation exercise group and 31 in the control
group. All patients were tested with the CAD QOL
questionnaire. The questionnaire was filled by the
patients or assisted by the staffs without any guidance.
SPSS 10.0 was use to analyze the data.

Results
125 questionnaires were distributed and 109 were
returned, the participating rate was 87%. There was no
significant difference between the two groups in sex,
age, education, marriage status and occupation. The
results showed significant difference in total score
(t=2.63, p=0.01) and sub-score of knowledge/practices
in CHD prevention/control (t=4.74, p<0.001). The
rehabilitation exercise group had higher score than the
control. No difference was observed in the scores of
psychological and physiological status, of social
adaptation ability and social supports.

Conclusion
Address for reprints: Dr. Lan Guo
Guangdong General Hospital, Guangdong Cardiovascular Institute,
Guangdong Academy of Medical Sciences, 106 zhongshan Er Road,
Guangzhou, 510080, Guangdong, China
Received October 5, 2008; revision accepted October 29, 2008

J HK Coll Cardiol, Vol 16 (Suppl 1)

The total QOL score in CAD patients after
PTCA in the CAD Club could be improved by
cardiac rehabilitation exercise therapy particularly
in knowledge and practices in CHD prevention/
control. CAD Club is a useful way to improve the
secondary prevention of CAD in China.
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Health Experience of Chronic Ischemic Heart Disease in Malaysia
LYDIA ABDUL LATIF and SHAARI MOHD YATIM
From Department of Rehabilitation Medicine, Faculty of Medicine, University of Malaya, Malaysia

Introduction

Subject

To assess the health experience using the ICF
Core Sets for Ischemic heart diseases (IHD) in
patients after myocardial infarction , coronary artery
by-pass grafting surgery (CABG) and percutaneous
transluminal coronary angioplasty (PTCA) were
recruited for cardiac rehabilitation. This is the pilot
study in initiating the use of ICF Core Sets for IHD.

Total of 50 patients after myocardial infarction,
coronary artery by-pass grafting surgery (CABG) and
percutaneous transluminal coronary angioplasty
(PTCA) were recruited for cardiac rehabilitation
program and for the trial (25 patients from each
hospital).

Main Outcome Measures
Bodily functions and structure impairment,
activity limitation, level of functioning and
participation were investigated.

Methodology
Design
Patient were interviewed using ICF Core Sets
for IHD by health professional by a dedicated Cardiac
Rehabilitation team of both hospital.

Conclusion
The presentation will describe the findings of
the above study.

Setting
- 2 public hospitals: A tertiary hospital and a
General hospital
- Department of Rehabilitation Medicine,
University of Malaya Medical Centre (UMMC)
and Rehabilitation Department, Hospital Serdang
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Outpatient Phase III Cardiac Rehabilitation and the Training System
of the Masters of Cardiac Rehabilitation in Japan
MASAHIRO KOHZUKI,1 TAKAYUKI KAWAMURA,2 ATSUKO ISHIDA1
1
2

Department of Internal Medicine and Rehabilitation Science, Tohoku University Graduate School of Medicine;
Department of Health Service Management, Tohoku Fukushi University, Sendai, Japan

KOHZUKI ET AL.: Outpatient Phase III Cardiac Rehabilitation and the Training System of the Masters of
Cardiac Rehabilitation in Japan. Cardiac rehabilitation (CR) is an integral component of the continuum of care for
patients with cardiovascular diseases. The CR program usually consists of three stages: the acute stage (phase I),
subacute stage (stage II) and maintenance stage (phase III). Phase III CR is recognized as a community or homebased program committed to encourage exercise and a healthful lifestyle with the goal of minimizing the risk of
recurring cardiac problems (secondary prevention). The Japanese Association of Cardiac Rehabilitation (JACR)
established a certification program for the Master of Cardiac Rehabilitation (MCR) to improve quality of cardiac
rehabilitation services and to educate the professionals playing a pivotal role in a primary CVD prevention programs
in Japan. The number of certified MCR has increased to 1835 by 2008. JACR also established a non-profit organization
Japan Heart Club (JHC) in 2004 and started to publish learning materials for health promotion and prevention of
CVD. JHC also provides opportunities to participate in CR programs in the community by the activities of "MedEX
Club", a multidisciplinary facility provides MCR-supervised exercise sessions, education for patients, and training
classes for citizens and health professionals. There are seven MedEx Club branches and 11 classes are being offered
nationwide. The MedEx Club can offer convenient, affordable, safe and enjoyable phase III programs and, in the
near future, it may be recognized as. a standard model of phase III CR service in Japan. (J HK Coll Cardiol 2008;16
(Suppl 1):A23-A28)
Cardiac rehabilitation, master, phase III, Japan Heart Club, MedEX Club
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Cardiac Rehabilitation Program As a
Lifelong, Multidisciplinary Approach
Over the past two decades, risk factor
modification programs for cardiac patients, commonly
referred to as cardiac rehabilitation (CR), have evolved
into a comprehensive management strategy. The
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American Heart Association (AHA) and the American
Association of Cardiovascular and Pulmonary
Rehabilitation (AACVPR) define CR programs as,
"Coordinated, multifaceted interventions designed to
optimize a cardiac patient's physical, psychological, and
social functioning, in addition to stabilizing, slowing,
or even reversing the progression of the underlying
atherosclerotic processes, thereby reducing morbidity
and mortality".1
Core components for CR recommend a
multidisciplinary approach to CR consisting of trained
and competent staffs which include physician, cardiac
specialist nurse, physical therapist, dietician,
occupational therapist, administrator, social worker, and
so on.2 The team should also include, where appropriate,
pharmacist, physical activity/exercise specialist, and
psychologist. The core components of CR are (1)
lifestyle management: (physical activity, diet, weight
management, and smoking cessation; (2) education; (3)
risk factor management; (4) psychosocial counseling;
(5) cardio-protective drug therapy and implantable
devices; and (6) long-term management strategy. The
content of these components should be developed
collaboratively by the core CR team and should be
delivered by competent, appropriately skilled
professionals.
The CR program usually consists of three stages:
the acute stage (phase I), subacute stage (stage II) and
maintenance stage (phase III). Phase III CR is
recognized as a community or home-based program
committed to encourage exercise and a healthful
lifestyle with the goal of minimizing the risk of recurring
cardiac problems (secondary prevention). For the
patients' benefit, phase III CR programs should be
convenient, affordable, safe and enjoyable. The
European Society of Cardiology also recommends that
cardiac patients should be oriented to a long-term
maintenance regimen with the use of support systems
such as coronary clubs, gymnasiums or other facilities
to promote long-term prevention strategies in the
community.3 In Germany, a close network of currently
approximately 6600 heart groups has been established,4
the concept of cardiac reconditioning centers for the
prevention and rehabilitation of coronary patients has
been tremendously successful.5

A24

Japan Heart Club and the Certification
Program for the Masters of CR
With support of the Japanese Association of
Cardiac Rehabilitation (JACR), the Japan Heart Club
(JHC), a non-profit organization, was established in
2004. The missions of JHC are to (1) organize
scientific meetings and workshops for health
promotion and prevention of cardiovascular diseases
(CVD); (2) publish journals and learning materials
for health promotion and prevention of CVD, (3)
conduct research for health promotion and prevention
of CVD; (4) organize facilities and develop programs
for primary and secondary CVD prevention; (5) offer
education programs and certification for the Master
of Cardiac Rehabilitation (MCR), and other healthrelated professionals; (6) collaborate with national
and international research institutes.
Certification program for MCR started in 2000.
The objectives of the certification program are to
improve quality of cardiac rehabilitation services and
to educate the professionals playing a pivotal role in
a primary CVD prevention programs in Japan. The
JACR certifies those who understand the purpose of
CR and have knowledge, skills and abilities for
providing comprehensive CR program through a
comprehensive team approach. Referring to American
College of Sports Medicine certification objectives,6
the MCR certification examination is based upon the
knowledge, skills and abilities (KSA's) in each of the
11 categories below:
1.
2.
3.
4.
5.
6.
7.
8.
9.

Anatomy and Biomechanics (4 KSAs)
Exercise Physiology (8 KSAs)
Electrocardiology (7 KSAs)
Human behavior and psychology (6 KSAs)
Pathophysiology (13 KSAs)
Clinical diagnosis and treatment (7 KSAs)
Health appraisal and fitness testing (10 KSAs)
Cardiac rehabilitation (3 KSAs)
Secondary prevention and patient education for
CAD (11 KSAs)
10. Exercise programing (14 KSAs)
11. Safety, injury prevention and emergency care
(3 KSAs)
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Minimum requirements for candidates are as follows:
- Candidates must possess any of the following
certifications or degrees: physician, registered nurse,
physical therapist, occupational therapist, clinical
laboratory technician, medical engineer, clinical
psychologist, and/or exercise trainer.
- Have been a member of the JACR for more than 2
years.
- Have a minimum of 1 year of experience in a CR
program or equivalent, and submit 10 case reports
about the diagnosis, tests, treatment, and
rehabilitation for patients with CVD.
The number of certified MCR has increased to
1835 by 2008 (Figure 1). As shown in Figure 2, the
MCR attracts health-related professionals with various
backgrounds some of which include physical therapists
(39%), physicians (24%), nurses (18%), and clinical
labolatory technicians (13%).

Community-based Phase III CR and
Primary Prevention Programs in Japan
One of the missions for JHC is providing
opportunities to participate in a CR program in the
community. MedEX Club, a multidisciplinary facility
provides MCR-supervised exercise sessions, education
for patients, and training classes for citizens and health
professionals. There are seven MedEx Club branches
and 11 classes are being offered nationwide (Figure 3).
The purpose of the MedEx club is to promote regular
physical activity in CR patients and prevent cardiac
disease and the recurrence of coronary events. Exercise
training classes are held in various settings, some of
which include hospitals, community centers, fitness
facilities, and schools. The classes are typically held
once or twice a week under the supervision of the MCRs.
In the MedEx Club branch in Sendai, each session lasts
70 minutes and has a capacity of 12 people (Table 1).

Figure 1. The number of certified MCR from 2000-2008 (data from reference 7).
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Figure 2. The professional backgrounds of MCR (data from reference 7).

Figure 3. MedEx Club, the community-based CR programs in Japan (data from references 8 and 9).

A26

November 2008

J HK Coll Cardiol, Vol 16 (Suppl 1)

KOHZUKI ET AT.

Table 1. Current participants in MedEx Club at Sendai Branch
No Age Sex CVD
Type of
Coronary risk
Weight
procedure
factors
(kg)
1
76
F
AP
stent
DL
54
2
74
M
MI
stent
HT
63.5
3
56
M
MI
CABG
DM, HT
67
4
70
M
MI
Stent
HT
56
5
66
M
MI
stent
HT, DL
62
6
61
M
MI
stent
HT
65
7
78
M
MI
stent
IGT
53
8
64
M
DCM
HT, DM
66
9
61
F
Paf
ablation
Ob
82
10 74
M
DM, HT, DL, Ob
87
11 60
F
MI
stent
HT, DL
53
12 66
F
MI
CABG
DM, HT, DL, Ob
69

BMI
(kg/m2)
23.1
23.6
23.2
19.2
23.3
23.0
20.4
24.6
32.8
33.2
22.6
30.3

VO2@Peak
VO2@VT
(ml/kg/min) (ml/kg/min)
12.1
16.0
9.1
18.0
15.6
23.3
7.0
19.3
18.8
28.2
18.8
30.2
11.2
20.8
14.2
23.8
10.8
18.2
7.9
16.4
15.6
19.6
9.7
18.1

Abbreviations: AP: angina pectoris, MI: myocardial infarction, DCM: dilated cardiomyopathy, Paf: paroxysmal atrial fibrillation,
VT: ventilatory threshold, HT: hypertension, DL: dyslipidemia, DM: diabetes mellitus, IGT: impaired glucose tolerance,
Ob: obesity.

Prior to and post-exercise session, participants
measure their blood pressure and body weight and
fill in the self-health check sheet. The exercise session
starts with a 15 minute warm-up, either sitting or
standing, followed by 15 minutes of aerobic exercise
and 15 minutes of resistance training using elastic
bands or their own body weight. The intensity of
the aerobic exercise is determined by the
cardiopulmonary exercise test measured upon entry
to the club. Each session ends with cool down for 15
minutes which includes stretching of the major
muscle groups. In addition to weekly exercise
sessions, each patient keeps a log for blood pressure
and body weight in the morning and night as well as
step counts and exercise energy expenditure measured
by an accelerometer. The log is submitted to the MCR
program every 2 weeks. The MedEx club mainly
offers exercise-based CR program, but patients also
learn about physical activity, lifestyle modification,
psychological management from the MCRs and other
participants.
Cardiac rehabilitation is an integral component
of the continuum of care for patients with CVD, the
MedEx club can offer convenient, affordable, safe
and enjoyable phase III programs and, in the near

J HK Coll Cardiol, Vol 16 (Suppl 1)

future, it may be recognized as a standard model of
phase III CR service in Japan.
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Schedule of Cardiac Rehabilitation in Iran
FARZANEH TORKAN1 and LALEH HAKEMI2
From 1Physical Medicine & Rehabilitation Medicine Specialist, Milad Subspecialty Hospital; 2Internal Medicine
Specialist, NIOC Central Hospital, Iran
Cardiovascular disease especially coronary heart
disease is a major problem in many countries.
Cardiovascular diseases account for nearly 29% of all
cause mortality and 10% of disease load in 2001. Post
myocardial infarction survivors suffer a re-infarction 5
times the healthy population. Secondary prevention
protocols can help the patients to live healthier with
fewer morbidity and mortality. Cardiac rehabilitation
decreases coronary heart disease mortality for nearly 26%.
The old population is expanding in most countries,
including I.R. Iran, and 36.8% of Iranian elderly have
cardiac diseases.
There are some specialized cardiac rehabilitation
centers in large cities in Iran in which their program
consist of:
1. in- patient programs with an early assessment for risk
factor management and mobilization,
2. transition cares and discharge planning design for
daily activities like driving, lifting, sexual activity and
so on,
3. out-patient rehabilitation and secondary prevention,
the patients are assessed for risk factors and they will
be divided into different categories.
Necessary interventions for minimizing the
effects of risk factors explained to patients such as non
pharmacologic interventions or a healthier life style
(quitting tobacco use, healthier diet, regular physical
activity, weight management, stress reduction).
In this stage, the patients undergo medical
evaluation and exercise testing and based on the results,
exercise plan is prescribed and ECG monitoring and
medical supervision applied when indicated.
Appropriate equipment, staffing and safety
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measures were utilized appropriately by the
rehabilitation programs. In Iran, specialized physiatrists,
nurses, physiotherapists, nutritionists, psychologists
work as a group.
National health systems and Iranian health
ministry together with insurance companies have started
their supports of rehabilitation protocols, however they
are only for secondary prevention strategies (post
CABG, post angioplasty, post AMI,...).
Despite this, the current status in Iran is far from
optimum in terms of facilities, knowledge, attitude and
of course clinical practices.
Our future direction is making our efforts for
changing life style habits in the population for primary
prevention. On the other hand, we have to expand cardiac
rehabilitation centers and enhance education of the staff;
also we ought to try our best to get together the insurance
companies to suppor primary prevention protocols in
high risk individuals.
There is very limited researches in Iran. However,
there are important results in the organization of
secondary prevention strategies. The effectiveness of
secondary prevention measures, the costs of disease and
its consequences compared to the costs of prevention,
the KAP analysis on the target population can help a
fruitful organization.
In a study of 118 coronary artery disease patients
in Shahid Rajaee Hospital, after the monitoring period,
BMI, weight, waist circumference, and waist to hip ratio
decreased (p<0.001) however, these indices returned to
the pre rehabilitation period after 12 months (Masoumi
2005).
In another study of 8 weeks exercise rehabilitation
on 100 patients (Farahani 2003), 10% increase in METs
was observed compared to pre exercise situation
(p=0.001). A 6% decrease in resting heart rate and 18%
increase in maximal attainable heart rate were found.
There is a slight decrease in systolic blood pressure and
improvement in lipid profile.

November 2008

A29

Medicine and Spirituality: A New Task for Heart Friends Around the
World
FLAVIO BURGARELLA and SARAH BURGARELLA
From Heart Friends Around The World (HFATW), Italy

Spirituality is a complex and interdisciplinary
part of the human experience. It includes aspects both
philosophical and inherent to emotional behaviour.
Philosophical aspects include the search for the person's
sense of the purpose and truth of life, and for beliefs
and values in which he/she lives. Aspects of emotional
behaviour include a sense of hope, love and belonging,
of inner peace and consolation.
Many people reach their spiritual dimension
by religion, through a personal relationship with the
divine. Other people find this dimension through a
connection with the nature, the arts and the music,
or with values and moral principles, or also in the
search for scientific truth. Every religion tries to give
us a direction and assistance in our spiritual quest,
developing a specific set of beliefs, teachings and
practices. The relationship of the person with the
religious organization is very variable, it can be
extremely positive or negative.
The assessment of the spiritual dimension during
the medical examination is a way to start the practice
of incorporating spirituality into medical practice. The
doctor must first learn his/her spiritual values and what
he/she believes in, in order to give the necessary
attention, without prejudice, when he/she talks to the
patient about spiritual concerns. This is particularly true
when the thought of the patient is different than the
thought of the doctor.
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Establishing a positive relationship between
doctor and patient is crucial to discuss spiritual issues,
and allocating the appropriate time to the matter is very
important too. The evaluation of the spiritual resources
of the patient may be manifested in the anamnestic
debate and the initial conversation and may open the
way for more in-depth interviews. During this evaluation
of spirituality, issues like the fear of the unknown and
the search for hope are important items with which the
patient is compared to his/her spiritual dimension. With
specific questions, more information can be obtained
than by using only standardized tests for a formal
assessment of spirituality. The evaluation of spirituality
includes questions on issues that will be proposed during
the anamnesis in order to determine which factors might
play a spiritual role in the disease of the patient, as well
as in therapy and healing process.
There are many systems used to conduct a formal
assessment of spirituality. They have been especially
prepared for religious or as means of investigation; they
rarely have been used during a normal medical
examination. Doctors have to take into consideration
any factor that could affect the health of their patients,
maintaining balance and professional ethics.
Doctors can begin to incorporate spirituality into
medical practice in three ways: by studying the problem
scientifically, applying the techniques for the
assessment of spirituality, and by therapeutic
intervention. Scientific studies include the evaluation
of the connection between spirituality and health and
the planning of further studies to clarify its effects. It is
always important to keep the mind open to new ways of
learning, considering that there will be always things
that cannot be understood. Therapeutic interventions
include considerations on the spirituality of the patient
and recommendations on prevention, health education,
treatment and anything that might help the healing
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process. Although it is not easy to measure, the
physician's ability to provide the necessary compassion
and connection, so that the patient can feel the doctor
truly present and participating, is an important
therapeutic intervention.
Spirituality is an important and multidisciplinary
aspect of human experience that is difficult to
understand and to completely assess, using only the
scientific method. The doctor who begins to integrate
spirituality into medical practice should take into
consideration the principle of "primum non nocere"
and maintain absolute respect for the rights of the
patient, in his/her autonomy and freedom of thought
and belief. If practiced in a responsible manner,
Medicine can make a significant contribution to the
integration between Science and Spirituality.
Heart Friends Around The World is an
international movement, born on previous experiences
of the association, of which maintains the basic
structure, including the existing affiliated groups, aiming
to promote human health through a route that develops
in the body, mind and spirit.
Heart Friends Around The World is affiliated to
the International Federation of Cardiology, collaborates
with the World Health Organization, and in 1994 had
already laid the foundations of its existence by involving
in its programs physicians, cardiologists and patients
worldwide, predominantly coming from low- and
middle-income countries, to promote prevention and
rehabilitation of cardiovascular disease. The following
paragraphs illustrate the Heart Friends Around The
World Manifesto, whose vision is to promote the Good
by the promotion of health and whose mission is a global
health promotion, in its aspects of body, mind, spirit.
Heart Friends Around The World believes in the
importance of everyday life, in the relationship between
body and mind, in the development of interpersonal
relationships. It also considers the education of women
as a priority for her health and that of his family.
Heart Friends Around The World believes that
old age is an asset in the search for spiritual life, and
that young people are a resource of health and values,
although nowadays are mortified by excesses both in
consumerism and in deprivation.
Heart Friends Around The World believes that
the body needs a balanced diet in its supply of water,
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sugars, proteins and fats, recommending the
consumption of fruit and vegetables several times a day.
As the hunger must be fought, so the excessive
introduction of calories, leading to obesity, diabetes and
development of chronic non-communicable diseases,
must be avoided.
Heart Friends Around The World proposes the
practice of a regular physical activity, with a medium
muscle commitment. A slow and prolonged race practice
is a good basis for maintaining the health and the
associated state of mental and physical well-being.
Heart Friends Around The World believes that
the proper use of drugs can help to maintain the state of
health obtained by the treatment of the disease. It also
believes that the pharmacological correction of potential
risk factors is a practice to be fostered, according to the
results of updated scientific publications. It also
proposes to take action in order to produce new drugs
at low cost, so that they can be used even in developing
countries, protecting its right to health as an inalienable
well for the human being.
Heart Friends Around The World considers that,
in the relationship between doctor and patient, the
positive attitude is a vital component to get that
confidence, that mutual trust, which is so important for
the recovery of health status.
Heart Friends Around The World finds its essence
in the relationship between doctor and patient, striving
to have a consistently positive attitude towards the
patient and receiving in return what has been given in
the form of Good for its professional and spiritual
growth. The right man acts the Good for love of the
Good, lives in the Good, in an independent manner by
religion or no religion to which he belongs.
Heart Friends Around The World is in continuous
search for figures of mystical expression such as
religious, poets and philosophers who can indicate to
us the most appropriate spiritual journey, namely that
journey that opens us to a far greater reality and that
helps us to expand our conscience. These figures will
be proposed through their writings, so that everyone
can have the freedom to create their own spiritual way.
Heart Friends Around The World is confident in
the creativity of all the healthcare workers and citizens
who recognize the Manifesto, so that they can be are
carriers of dissemination of this thought.
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Ethnicity: The Other CV Risk Factor?
SANDEEP GUPTA
From Whipps Cross and St Bartholomews Hospitals, London, United Kingdom

People of south Asian background (namely
Indians, Pakistanis, Bangladeshis and Sri Lankans)
have a 40-50% greater mortality from coronary heart
disease (CHD) than those of White-Caucasian,
European origin. A statistic known for some 5
decades. Those of African-Caribbean and Chinese
descent have tended to have lower rates of CHD
mortality. Several lines of hypotheses attempt to
unravel 'genetic versus environment' factors to
explain the excess CHD risk amongst south Asians.
A predisposition to insulin resistance, at an early age,
with subsequent development of metabolic syndrome
and diabetes mellitus remains the strongest line of
evidence. Cigarette smoking, lack of physical activity
and dietary issues may then exacerbate the genetic
component.

T h e I N T E R H E A RT s t u d y r eve a l e d t h e
importance of the same traditional risk factors in all
populations and cultures. Perhaps the 'potency' of
individual risk factors may impact on differing ethnic
groups at different thresholds? For example, the
concept of lower waist circumference targets in those
of Chinese descent when diagnosing metabolic
syndrome.
A strategy of increased awareness, altering
the guidelines/targets to address the 'ethnicity' risk
factor... in addition to a more aggressive approach
on CV risk factor management remain the focus
of attention. Whether lowering the threshold to
treat lipids, blood pressure or blood sugar merits
further debate.
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Towards Person-related Cardiac Care: Weighing the Evidence on
Type D Personality
JOHAN DENOLLET
From CoRPS - Center of Research on Psychology in Somatic diseases, Tilburg University, The Netherlands

The distressed or Type D personality refers to
the combination of two personality traits, negative
affectivity and social inhibition. Cardiac patients with
this personality profile tend to experience negative
emotions, but are not likely to express themselves
towards other people. Type D personality can be easily
assessed with the use of the 14-item DS14 self-report
scale, and its prevalence ranges between 20%-35%.
Clinical evidence indicates that Type D personality is
an independent predictor of poor prognosis, including
cardiac death and (recurrent) myocardial infarction,
with the majority of odds ratios ranging between 2.5
and 6.8. Longitudinal research also indicates that Type
D personality is a major determinant of depression,
anxiety and poor perceived health status, with the
majority of odds ratios ranging between 2.6 and 6.0. In
addition, Type D personality has a modulating effect

on the outcome of invasive interventions such as
percutaneous coronary intervention, coronary bypass
surgery, implantable cardioverter defibrillator treatment,
and heart transplantation. Unlike depression, Type D is
not confounded by disease severity, and Type D
personality still predicted major adverse clinical events
and cortisol dysregulation after adjustment for
depressive symptoms. Apart from cortisol reactivity,
other biological (cardiovascular reactivity, immune
dysregulation) as well as behavioral (poor selfmanagement, reluctance to consult clinical staff,
unhealthy life style) mechanisms might mediate the
relationship between Type D personality and prognosis.
Overall, these finings indicate that the Type D construct
has substantial predictive power, is associated with
several pathways of disease, and may have important
incremental value in clinical research and practice.
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An Update on the Treatment of Stable Angina Pectoris
KATHY BERRA
From Stanford Prevention Research Center, Standfore University School of Medicine, California, USA

Chronic stable angina (CSA) is one of the most
common symptoms experienced by persons with
coronary heart disease. It is estimated that over 140
million persons worldwide suffer from symptoms of
angina. The incidence of angina increases with age
and results in diminished quality of life, loss of
productivity, and disability. Currently, in the US, one
in 10 people over the age of 65 have chronic stable
angina. By 2010, approximately 18 percent of the
US population will be over the age of 65 − this will
increase to 30 percent by 2025. These aging
demographics are similar worldwide. Thus, angina
will present as a chronic condition requiring
significant health care resources.
Although angina affects both men and women,
women have more symptoms of angina when compared
to men. Medical costs associated with chronic stable
angina exceed 15 billion dollars per year, with indirect
costs being likely as high.
Medical therapies for relief of anginal symptoms
date back to the 1880's when nitrates were first used.
Nitrates were followed nearly a century later with beta
blockers . Soon, coronary artery bypass surgery became
available and calcium channel blockers showed
promise. In the late 1970's, percutaneous coronary
interventions (PCI) became widely used to improve
A
Aspirin (anti-thrombotic) &
Antianginal therapies

B
Beta blockers &
Blood pressure

symptoms. More recently, a new medication, ranolazine
(Ranexa), a late sodium channel blocker, became
available for treatment of anginal symptoms in patients
who do not respond to traditional medical therapies.
Spinal cord stimulation, and enhanced external
counterpulsation (EECP) are non-pharmacologic and
non-surgical therapies also used to improves symptoms.
Spinal cord stimulation is generally reserved for patients
who have received maximal surgical and medical
therapy and have refractory angina. EECP uses a series
of cuffs wrapped around the legs that deliver compressed
air synchronized to the cardiac cycle. It has been shown
to be well tolerated, safe, and effective in reducing
anginal symptoms. More research needs to be done with
these therapies.
Treatment goals for patients with CSA should
include improving longevity as well as quality of life
(QOL). Strategies to improve longevity include reducing
disease progression, preventing new events, readmission
to the hospital, and reducing mortality. Treating anginal
symptoms includes therapies to diminish symptoms,
improve functional capacity, and improve quality of life
through emotional support and education.
The mnemonic A, B, C, D and E is often used as
a way to prompt the recollection of important therapies
for persons with chronic stable angina.
C
Cigarette smoking &
Cholesterol

D
Diet &
Diabetes

E
Education &
Exercise
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Education is a key component of care for patients
with chronic illness such as coronary artery disease. The
use of "integrative rehabilitation" for patients with
angina has been studied. Integrative rehabilitation
includes acupuncture, a self-care program, acupressure,
Chinese health philosophy, stress management, and
lifestyle adjustments. Integrated rehabilitation in
patients with severe angina has been shown to add
quality years to patient's lives and was cost effective.
Get Tough on Angina (GTOA) is a public health
initiative designed to increase quality of life (QOL) in
persons with angina and to increase the public's
awareness of chronic stable angina and its impact on
health and QOL. GTOA was developed by the
Preventive Cardiovascular Nurses Association. It
includes three main components:
 An educational brochure and handbook for patients
and families available in both English and Spanish;
 A slide and script set for a four-part educational
support group to be led by nurses or other health care
providers;
 A slide and script set for a one hour community
education forum. Both slide and script sets include
detailed information about the educational content,
class activities, and homework.
The GTOA program is available free of charge.
All of the products can be ordered by emailing the
Preventive Cardiovascular Nurses Association at www.
pcna.net.
Chronic stable angina is a common symptom that
is rising in incidence along with an aging population
and an improved ability to prevent death from coronary
atherosclerotic vascular disease. In spite of advanced
medical and interventional therapies, anginal symptoms
remain common and negatively affect quality of life

J HK Coll Cardiol, Vol 16 (Suppl 1)

for millions. Angina also contributes enormously to the
personal, societal, and financial burdens attributed to
poor health. Providing patients with medical, surgical
and educational/support will reduce both morbidity and
mortality and enhance Quality of Life.
* The Get Tough on Angina program was made possible
through an unrestricted educational grant from
Cardiovascular Therapeutics to the Preventive Cardiovascular
Nurses Association.
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Effect and Molecular Mechanism of Physiological Ischemia Training
of Skeletal Muscle on Angiogenesis at Remote Sites with Pathological
Ischemia in Rabbit Models of Coronary and Peripheral Artery Stenosis
JIANAN LI, MEI SHEN, JING GAO
From Nanjing Medical University, Nanjing, China

Background
This study was designed to test the hypothesis that
physiological ischemia exercise training of normal limb
can promote angiogenesis in pathological ischemic limb.

measured by microspheres technique. Collateralization
was evaluated by immunohistochemistry. VEGF mRNA
and protein detection were analyzed by western blot
and real time RT-PCR.

Results
Method
The New Zealand white rabbits had left femoral
artery ligated (FAL) and electrode implantation
performed on the right sciatic nerve. They were
randomly assigned to 4 groups. FAL-N was the group
without electrical stimulation (ES). FAL-HE had its
subjects with high intensity ES (2.5 mA, 40 Hz, 1 ms)
on the right hindlimb. FAL-LE had its subjects with
low intensity ES (0.3 mA, 40 Hz, 1 ms) on the right
hindlimb. BFAO-HE had its subjects with FAL on both
hindlimbs and high intensity ES (2.5 mA, 40Hz, 1 ms)
on the right hindlimb. The ES procedure was 5 minutes
stimulation followed by 5 minutes rest, repeated 8 times
daily for 4 weeks. Collateral circulation was grossly
examined by angiography, relative blood flow was

Collateral blood flow in all major muscles of the
left hind limb in the FAO-HE was the highest among
the 4 groups (P<0.01). Capillary supply (P<0.001),
expression of VEGF mRNA (P<0.001) and protein
(P<0.01) in gastrocnemius muscle remarkable increased
in FAO-HE, there was no statistically significant
difference among other groups.

Conclusion
Angiogenesis associated with up-regulation of
VEGF expression in the pathological ischemic limb may
be facilitated by the physiological ischemic exercise
training with normal limb for 4 weeks.
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Exercise Prescription in Cardiac Patients
FARZANEH TORKAN1 and LALEH HAKEMI2
From 1Physiatrist & Electro Diagnostic Specialist, Milad Subspecialty Hospital; 2Internal Medicine Specialist,
NIOC Central Hospital, Iran

Physical inactivity is an independent risk factor
for coronary heart disease. The optimal amount of
physical activity is controversial and is an area of
challenge. Physical activity also has an impact on
secondary prevention. Two meta analyses on RCTs
(O'Connor et al, Berlin et al) showed a 20% to 25%
reduction in mortality of post MI survivors with
regular physical activities. And a more recent study
(Jollife, 2001) showed a 31% reduction in mortality
with regular physical activity.
Also Weight surveillance is very important.
Those with BMI of 20-25 Kg/m2 are at lower risk for
coronary heart disease than those who are overweight
or obese (Arch Internal Medicine 2000). The
reduction in weight generally is achieved via
decreasing energy intake and increasing physical
activities (Douketis et al 1999). The primary goal is
a 10% weight reduction.
The exercise prescription can be divided in two
sets of programs, that is in patient and out patient
programs.

The exercise prescription depends on when or
whether a cardiac event has occurred before and also
depends on the exercise capacity of the patient and
should be individualized. A sub-maximal exercise
stress test my help exercise capacity out patiently.
Exercise tolerance test can help classifying the
individuals into categories for special needs on
medical supervisions or ECG monitoring during
exercise. Also, the contraindications and special
precautions have to be addressed in some conditions.
Some situations such as silent angina, congestive
heart failure, pacemakers and implantable cardiac
defibrillators, cardiac transplant are aspects of cardiac
patients that need special attention.
For each stage of prescription the FITT
(Frequency, Intensity, Time, and Type) should be
identified.
These special programming will be reviewed
in the presentation.
Appropriate equipment, staffing and safety
measures help minimize the rehabilitation programs.
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Electrical Stimulation of Skeletal Muscles in Patients with Heart
Failure: An Alternative to Aerobic Training?
MASAHIRO KOHZUKI,1 MAKOTO NAGASAKA,1 PETR DOBSAK2
1

Department of Internal Medicine and Rehabilitation Science, Tohoku University Graduate School of Medicine,
Sendai, Japan; 2Department of Functional Diagnostics and Rehabilitation, St. Anna's Faculty Hospital and Masaryk
University, Brno, Czech Republic
KOHZUKI ET AL.: Electrical Stimulation of Skeletal Muscles in Patients with Heart Failure: An Alternative to
Aerobic Training? The exercise training has been shown to improve the functional capacity, quality of life and also
the patterns of strength muscles in patients with chronic heart failure (CHF). Most of actual training types, however,
are based on the systemic exercises resulting in increased cardiac workload. This could lead to onset of life-threatening
side effects such as fatal dysrhythmias. Moreover, most of patients with CHF have low exercise tolerance and poor
motivation to exercise. Low-frequency electrical stimulation (ES) has been shown to increase oxidative capacity in
the skeletal muscle fibers, to enhance muscular regeneration and to prevent atrophy. We aimed to evaluate the
possible benefit of ES in patients with mild to severe CHF, and to compare the results with the conventional bicycle
training. In our data, 6 weeks ES (60 min/day) of quadriceps and calf muscles of both legs significantly improved
muscle strength and blood flow in patients with advanced CHF. Moreover, a similar improvement of exercise capacity
in patients with CHF can be achieved either by aerobic bicycle training or by local ES of the strength muscles of the
lower limbs in patients with mild to moderate CHF. Although the effectiveness of conventional exercise protocols in
cardiovascular rehabilitation is beyond doubt, the safety and easy application of ES could be of great benefit in the
rehabilitation of patients with CHF, especially those with a severe grade of the disease. Future studies should also
address the possibility of combining ES with some type of classical exercise training. (J HK Coll Cardiol 2008;16
(Suppl 1):A38-A42)
Electrical stimulation, exercise, heart failure, skeletal muscle
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Chronic Heart Failure and
Exercise Training

Electrical Stimulation: Animal Hindlimb
Ischaemia Model Study11

Dyspnea and premature fatigue of skeletal
muscles are common symptoms of reduced exercise
capacity in subjects with chronic heart failure (CHF).
CHF is a complex metabolic syndrome with impaired
left ventricular function and poor prognosis. 1 The
exercise training has been shown to improve the
functional capacity, quality of life and also the patterns
of strength muscles, and therefore should be considered
as an integral part of therapeutic standards in such
patients.2-5 Most of actual training types, however, are
based on the systemic exercises resulting in increased
cardiac workload.6-7 This could lead to onset of lifethreatening side effects such as fatal dysrhythmias, and
for this reason classical rehabilitation programs need
medical supervision and assistance. Other problems
related to the choice of adequate exercise therapy for
these patients are the grade of disease, low exercise
tolerance and poor motivation to exercise.
Low-frequency electrical stimulation (ES) of
strength muscles has been shown to increase oxidative
capacity in the skeletal muscle fibers, to enhance
muscular regeneration and to prevent atrophy.8 Nuhr
et al.9 reported that ES increased functional capacity
in patients with advanced CHF compared with
sedentary controls. Recently, results from the first
randomized trial comparing home-based ES and
classical exercise training have demonstrated that
both methods could significantly influence functional
capacity, muscle strength of patients with mild to
moderate CHF.10 However, chronic effects of ES on
systemic blood pressure, heart rate in mild to moderate
CHF, or chronic effects of ES on systemic blood
pressure, heart rate serum enzymes and functional
capacity in severe CHF have not been elucidated.
Regarding to the dramatic pathophysiologic changes
which deteriorate the organism in conditions of chronic
heart failure (including strength muscle mass) there is
enough reasons to take the profit from ES also in
conditions of CHF. We aimed to evaluate the possible
benefit of ES in patients with mild to severe CHF, and
to compare the results with the conventional bicycle
training.

ES in skeletal muscle at a level far below the
threshold of muscle contraction has been reported to
promote local angiogenesis in a hindlimb ischaemia
model of rats. We completely excised bilateral femoral
arteries of male Sprague-Dawley rats. After the
operation, electrodes were implanted onto the centre of
the fascia of the bilateral tibialis anterior (TA) muscles,
tunnelled subcutaneously and exteriorized at the level
of the scapulae. The right TA muscles of rats were
stimulated continuously at a stimulus frequency of
50 Hz, with a 0.1 V stimulus strength and no interval,
for 5 days. The left TA muscles served as controls. We
found that angiogenic factors, such as vascular
endotherial growth factor (VEGF), and hepatocyte
growth factor (HGF) were significantly increased by
ES in stimulated muscles compared with control rats.11
It is concluded that both VEGF and HGF may contribute
to the local angiogenesis produced by ES in a hindlimb
ischaemia model of rats.11

J HK Coll Cardiol, Vol 16 (Suppl 1)

Electrical Stimulation in Patients with
Severe CHF12
We evaluated 15 patients with advanced grade of
CHF (mean age 52±7 years; NYHA class III-IV; EF
19±3%) admitted at hospital for heart graft (Table 1).
ES was performed 60 min/day, 7 days a week for 5
consecutive weeks, using dual-channel battery-powered
stimulator.12 The stimulator delivered a biphasic current
of 10 Hz frequency. The electrical stimulated muscles
were quadriceps and calf muscles of both legs. Self-

Table 1. Characteristics of patients included in the
study12
Women/men
1/14
Age (years)
56.5±5.2
Heart failure aetiology
10/5
(ischaemic/nonischaemic)
NYHA class (III/IV)
4/11
Left-ventricular ejection fraction (%)
18.7± 3.3
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adhesive surface electrodes were positioned on the
thighs approx. 5 cm under inguinal fold and 3 cm over
the upper patella border; in the calf muscles the
electrodes position was the area approx. 2 cm under the
knee joint and just over the proximal end of Achilles
tendon. The current characteristics were set up as
follows: "on-off" mode stimulus (20s stimulation, 20s
rest), pulse width 200 msec, rise and fall time 1s, and
maximal stimulation amplitude 60 mA. The stimulation
was performed in supine position, at the same day period
and under supervision of medical staff. The first session
of stimulation was started with lower amplitudes
(around 30 mA). In the following days this value was
gradually increased (by 10-15 mA/day) until the final
value of 60 mA was achieved and well tolerated by the
patient (in 2-4 days).12
Effects of ES on the muscle strength and blood flow
in patients with advanced CHF were examined before and
after 6 weeks of 10 Hz ES of quadriceps and calf muscles
of both legs (1 h/day, 7 days/week). Dynamometry was
performed weekly to determine maximal muscle strength
(Fmax; N) and isokinetic peak torque (PTmax; Nm); blood
flow velocity (BFV) was registered before and after 6 weeks
of ES using pulsed-wave Doppler velocimetry of right
femoral artery. Six weeks of ES increased significantly
Fmax (p<0.001), and also PTmax (p<0.01). Mean BFV in
femoral artery increased after 6 weeks (p<0.05); BFV
values at rest before and after 6 weeks of ES did not differ
significantly.12
After 6 weeks of LFES, all patients had less
dyspnea and a marked decrease in subjective feelings
of fatigue during everyday activities, although this
change was not statistically significant. Similar results
were observed for NYHA classification: 4 patients
moved from NYHA IV to NYHA III after 6 weeks of
stimulation and the remainder were unchanged but not
(e.g., from NYHA III to NYHA IV).12
ES did not cause any significant changes of systolic
blood pressure and diastolic blood pressure, nor were
there significant changes in the recorded values of heart
rate. In order to evaluate the possible risk of damage to
muscle fiber by stimulation, the activity of both CK and
LDH was monitored at the beginning, after 1 week and
after 6 weeks of stimulation and only insignificant
increases after 1 week of stimulation was observed and
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after 6 weeks of stimulation, the serum levels of both
enzymes returned to baseline.12 It is concluded that ES
may improve the skeletal muscle strength and the blood
supply. Thus, this method could be recommended in the
treatment of patients with severe CHF.

Electrical Stimulation and Aerobic
Exercise Training in Patients with Mild
to Moderate CHF13
Thirty patients with stabilized form of CHF
(mean age 56±6 years, NYHA class II-III, mean EF 35
±5%) were randomly assigned to a rehabilitation
program using either electrical stimulation of skeletal
muscles or bicycle training (Table 2).13 Patients in the
first group had 8 weeks of home-based ES applied
simultaneously to the quadriceps and calf muscles of
both legs (1 h/day for 7 days/week); patients in the
second group underwent 8 weeks of 40 min aerobic
exercise (3 times a week; 5 min warm-up without
workload, 30 min of training alternating 1 min of work 2 min of relaxation, and 5 min of cool down without
workload), The realization of the exercise training was
strongly individual, performed at the level of anaerobic
threshold determined by spiroergometry, and under
supervision of medical staff (doctor, physiotherapist and
nurse).
After the 8-week period significant increases in
several functional parameters were observed in both
groups: maximal VO2 uptake (ES group: p<0.05;
bicycle group: p<0.01), maximal workload (ES group:
p<0.05; bicycle group: p<0.01), distance walked in 6
minutes (ES group: p<0.05; bicycle group: p<0.05), and
exercise duration (ES group: p<0.05; bicycle group:

Table 2. Characteristics of patients included in the
study13
Women/men
7/23
Age (years)
56.3±6.0
Heart failure aetiology
24/6
(ischaemic/nonischaemic)
NYHA class (II/III)
22/8
Left-ventricular ejection fraction (%)
34.7±5.0
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p<0.05) (Figure 1). The QoL score assessed using
t h e M i n n e s o t a L iv i n g w i t h H e a r t F a i l u r e .
Questionnaire was significantly improved in the
bicycle group (from 41.4±5.3 to 27.3±6.3; p<0.03),
whereas there was only a slight improvement in the
ES group (from 39.6±2.9 to 31.4±4.8; NS). The
present results demonstrated the good tolerance and
significant improvement of functional capacity after
8 weeks of ES. The increases in VO2peak, Wpeak,
and distance walked in 6 minutes, and also the
exercise duration after 8 weeks of LFES were very
similar to the increases in these parameters in the
bicycle group. Other parameters (HRpeak, VO2AT
and QoL) significantly increased in the bicycle group
but not in the LFES group (only slight improvement
was observed). Despite the differences between the

2 methods (myostimulation activity is local, whereas
bicycle exercise training challenges the entire body),
LFES could be regarded as an acceptable analogue
of endurance training which can improve the
physiological condition of CHF patients in a period
of several weeks, and can be easily performed at home
without medical supervision.13

Future Perspectives of Electrical
Stimulation in Patients with CHF
Electrical stimulation of skeletal muscles in
humans has been shown to be a useful therapeutic tool
in neurology,14 postoperative treatment, and in cases of
long-term immobilization.15 In a recent study, LFES was

Figure 1. Results of peak oxygen uptake, peak workload, 6 minutes walking test, and exercise duration in both groups at
baseline and after 8 weeks of the given type of rehabilitation.13
J HK Coll Cardiol, Vol 16 (Suppl 1)
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reported to improve the functional capacity in
claudicants. 16 Hamada, et al. 17 observed enhanced
energy consumption, carbohydrate oxidation, and whole
body glucose uptake after low-frequency electrical
stimulation of the lower limbs, a finding that suggests
the possibility of therapeutic application of LFES for
diabetic subjects. However, the number of studies
concerning the effects of LFES in cardiovascular
rehabilitation is still very low. The effectiveness of
conventional exercise training in cardiovascular
rehabilitation has been sufficiently proven,18 and LFES
is not likely to replace it. But the safety and ease of
application could be especially beneficial in patients
with advanced CHF (III-IV).
ES should be considered as a valuable alternative
to classical exercise training in patients with CHF.
Recently, results from the first randomized trial
comparing home-based ES and classical exercise
training have demonstrated that both methods could
significantly influence functional capacity, muscle
strength of patients with CHF.10 Similar results were
shown by Nuhr et al in a group of patients with advanced
CHF, and an increase of slow myosin heavy chain
isoforms at the expense of the fast ones and increased
intensity of oxidative enzymatic activity were also found
after LFES.9
Although the effectiveness of conventional
exercise protocols in cardiovascular rehabilitation is
beyond doubt, the safety and easy application of ES
could be of great benefit in the rehabilitation of patients
with CHF, especially those with a severe grade of the
disease.
The effectiveness of conventional exercise
protocols in cardiovascular rehabilitation is beyond
doubt and the patients with mild heart failure would
adopt exercise. But the patients with a severe grade of
CHF who can not exercise would adopt ES for the safety
and easy application. There are scarcely limitations
except the allergies of the electrode. Further
investigations should yield more detailed data, including
information about possible interactions between the
central and peripheral cardiovascular mechanisms
during muscle stimulation. Future studies should also
address the possibility of combining LFES with some
type of classical exercise training.
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Exercise and Hypertension
CHUL KIM
Rehabilitation Medicine, Sanggye Paik Hospital, Inje University Medical College, Korea
KIM: Exercise and Hypertension. Even mild-to-moderate hypertension significantly increases the risk of left
ventricular hypertrophy, renal disease, and stroke. Antihypertensive drugs are effective to lower blood pressure and
decrease the risk of the target organ damage, but adverse side effects and cost have led to a search for nonpharmacological interventions. The USA Joint National Committee Guidelines on hypertension report strongly
recommended lifestyle modification to prevent hypertension as definitive therapy for some and as adjunctive therapy
for all hypertensive patients. Lack of physical fitness increases the risk of hypertension and is a strong predictor of
cardiovascular mortality independent of blood pressure and other risk factors. Contrarily, physical activity can
prevent hypertension and decrease systolic and diastolic blood pressure. The type of exercise should be primarily
endurance physical activity (walking, jogging, or bicycling) regular basis supplemented by resistance exercise. The
blood pressure is reduced early after the initiation of dynamic exercise training and no further reduction occurs after
3 months but disappears abruptly with detraining. Some antihypertensive drugs such as diuretics and beta blockers
can interfere with exercise performance but alpha blockers, calcium channel blockers, and angiotensin converting
enzyme inhibitors do not interfere with exercise performance and are well tolerated by active hypertensive individuals.
If hypertension is poorly controlled, heavy physical exercise as well as maximal exercise testing should be discouraged
or postponed until appropriate drug treatment has been instituted and blood pressure lowered. (J HK Coll Cardiol
2008;16(Suppl):A43-A47)
Exercise, hypertension, physical activity
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Introduction
Physically inactive individuals have a 1.5 greater
relative risk of developing hypertension than those with
high levels of activity. A review of cross-sectional
studies in children as well as longitudinal dynamic
training studies in young adults below the age of 30
indicate that blood pressure (BP) is inversely related to
leisure time physical activity.1 Adults up to 40 years
old who engaged in regular physical activity had a 30%
lower risk of developing hypertension than sedentary
individuals.2 Regular physical activity has a protective
effect against cardiovascular disease and all cause
mortality. 3 Contrarily, physical inactivity is an
independent risk factor for hypertension and coronary
artery disease, regardless of age, body mass index, and
fasting plasma insulin levels.4

Dynamic Exercise and the BP Response
I. Acute Dynamic (Aerobic) Exercise and the
BP Response
BP rises during dynamic exercise and the rate of
rise is related intensity and level of training. Systolic BP
starts to rise at the beginning of exercise, continues rising
in a linear relationship with higher workload, and reaches
the peak at the end of the exercise or maximal workload.
The exercise induced increase of systolic BP in borderline
or definite hypertensive persons is roughly parallel to the
changes in normotensive persons. However, the maximal
BP at peak exercise in hypertensive subjects is higher than
normotensive subjects due to the higher starting BP in both
treadmill or bicycle exercise. These differences in BP
between normotensive and hypertensive subjects are related
to systemic vascular resistance rather than cardiac output.
The increase in systolic BP of 50 to 70 mmHg at peak
exercise shows no significant difference between treadmill
and bicycle exercise whereas change of diastolic BP during
exercise is different between those two exercise modes.
Diastolic BP does not change or slightly decreases during
treadmill exercise, but it tends to slightly increase during
bicycle exercise. This is related to greater resistance to the
exercising skeletal muscle than running.
An excessive or an exaggerated increase in BP
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during exercise testing may be a marker of future sustained
hypertension.5 The cause of this abnormal response may
be due to a failure to reduce total peripheral resistance
adequately during exercise as a result of initial structural
vascular change. Several studies showed that an
exaggerated response to exercise (systolic BP > 210 mmHg
in men and >190 mmHg in women) increased the risk of
hypertension 1.5-to fourfold.6 Subjects with exaggerated
exercise blood pressure have a higher mean 24-h BP than
subjects with normal exercise BP. An exaggerated exercise
BP can be hazardous in the hypertensive subject who wants
to continue strenuous exercise, since the repetitive BP peaks
triggered by physical activity may impact chronic endorgan damage or cardiovascular events.

II. Training Effect of Dynamic Exercise on
Hypertension
The reports from several meta-analysis studies
(including total 155 studies) demonstrate that aerobic
exercise training reduces resting systolic and diastolic
pressure to 10 mmHg in mild to moderate essential
hypertension.7 Age and gender seem to be not a limiting
factor. Endurance training can lower BP also in patients
taking antihypertensive drugs and may eliminate or
reduce the need for medications.8 Although the BP
reduction from exercise training is small, it may have
significant effects to reduce the incidence of stroke and
coronary heart diseases. Aerobic exercise can decrease
the BP response to stressful conditions, blunt daytime
BP peaks, reduce variability, and contribute subsequent
target organ damage such as reduction of left ventricular
wall mass.9
Exercise capacity is 30% reduced in hypertensive
subjects compared to age-matched controls. But
physical exercise training can increase maximal oxygen
consumption and maximal BP. Unlike the resting BP,
the maximal BP during exercise is not reduced, but in
fact is increased parallel to exercise tolerance and higher
fitness levels. In sedentary hypertensive subjects, an
increased total peripheral resistance is the most likely
mechanism for the rise in BP with exercise. Whereas,
the higher maximal BP after training in hypertensive
subjects is probably due to an increase in cardiac output
and improved ventricular function.10 High fitness groups
shows lower systolic and diastolic pressure and slower
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increase rate of the systolic pressure than sedentary
group.11

Static Exercise and the BP Response
Acute static exercise increases both systolic and
diastolic BP in either normotensive or hypertensive
subjects by reflex increases in cardiac output with
minimal or no change in vascular resistance. 12
According to the weightlifting subjects study by
MacDougall et al,13 the greatest peak pressure occurred
during the double-leg press where the mean value for
the group was 320/250 mmHg. Peak pressure with the
single-arm curl exercise reached a mean group value of
255/190 mmHg. The magnitude of the BP rise is
proportional to the intensity of muscle contraction, the
size of muscle mass used in contraction, and the duration
of exercise.14 During heavy weightlifting with a Valsalva
maneuver, the BP response is extremely exaggerated
but may be dramatically reduced with an open glottis
or slow exhalation during exercise. Narloch and
Brandstater demonstrated that the mean BP at 100%
maximum double-leg press exercise with Valsalva was
311/284 mmHg compared to that of slow exhalation
when the mean BP was 198/175 mmHg. 15 So this
breathing technique may help to prevent cardiovascular
complications in hypertensive patients.
Several preliminary studies showed that
supervised static exercise program, particularly circuit
training, have acceptable hemodynamic responses and
safe clinical limits and can reduce BP in hypertensive
patients despite the inherent potential to acutely elevate
BP. However, an abrupt elevation of BP induced by
weightlifting increases myocardial oxygen demand,
which may impact myocardial ischemia. So, heavy
resistance training requiring high voluntary effort is
generally not recommended in hypertensive patients and
even moderate weight training should be delayed until
resting BP is under control.

Prescription of Exercise Training to Patients
All controlled hypertensive patients should
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participate in exercise training. It can be used with other
non-pharmacologic interventions and without
medication in uncomplicated mild-to-moderate
hypertensive patients. The patients with BP higher than
180/105 and patients with cardiovascular complications
such as target organ damage, diabetes, or elderly should
start exercise training only after BP is controlled by
antihypertensive drugs. Obese patients need aggressive
weight reduction combined with a walking program
prior to more intense exercise training.
Initially, pre-training assessment is necessary to
evaluate exercise risk stratification. The history
including family history and physical examination on
cardiovascular disease or conditions that might limit
exercise capability should be taken. A resting ECG is
recommended for all hypertensive patients and
echocardiogram in selected patients. Although the
American College of Sports Medicine does not
recommend exercise test as a screening test to identify
high risk subject for developing hypertension as a result
of an exaggerated exercise BP response, it can provide
information for risk stratification. A graded exercise test
is often recommended for adults over the age of 40 who
plan to begin an exercise training program and should
be performed in moderate to severe hypertensive
patients with evidence of left ventricular hypertrophy
from an ECG or in diabetic hypertensive patients
because of high incidence of silent myocardial
infarction.
The BP response to dynamic exercise varies from
sport to sport. Walking, running, cycling, or T'ai chi do
not cause a sustained increase in BP and possibly are
the most suitable endurance exercises for hypertensive
patients. Swimming can be an alternative exercise in
patients with obesity, exercise induced asthma, or
orthopedic problems but showed higher BP levels than
running at comparable heart rates with smaller
cardiopulmonary effects. Vigorous sprints, rowing,
downhill skiing, and mountain sports are unsuitable for
hypertensive patients.
Although there are no specific guidelines in
exercise management of hypertension regarding
intensity and frequency, low-to-moderate intensity
endurance exercise training is recommended in general
rather than high intensity in lowering BP in hypertensive
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patients. Based on a consensus statement by the World
Hypertension League, hypertensive patients should
exercise at an intensity of 50 to 85% maximal oxygen
consumption or 50 to 70% of maximal heart rate for 20
to 60 min, 3 to 5 days per week. The lower intensity
requires longer duration.
In most studies, BP is reduced early (3 weeks to
3 months) after the initiation of moderate intensity
dynamic exercise in both normotensive and hypertensive
subjects, and no further reductions occurs after 3
months.16 The BP lowering effect of exercise training
is evident only as long as a regular endurance exercise
training program is maintained17 and BP rises gradually
toward the baseline for 1 to 2 weeks after cessation of
exercise. So, the maintenance of regular exercise is
necessary and must be encouraged.

Antihypertensive Drugs for
Active Hypertensive Patients
The choice of medication should be
individualized and based on hypertension in association
with other diseases. There are no absolute
contraindications to use any drug classes in active
hypertensive patients although certain classes of drugs
are preferred, or are better tolerated.
Diuretics are effective to fall BP during exercise
by decreasing peripheral resistance and plasma volume.18
The most trouble but manageable problem with diuretics
for active persons is hypokalemia. Exercise with
hypokalemia may interrupt skeletal muscle blood flow
resulting in rhabdomyolysis and acute renal failure. To
ensure against potassium loss, patients taking diuretics
such as thiazide should receive potassium supplements.
Diuretics and nonselective beta blockers can increase
triglycerides and VLDL cholesterol by 10 to 30% and
reduce HDL cholesterol by 6 to 25%.
Beta-adrenergic blocking agents especially
nonselective beta blocker such as propranolol blunt
exercise mediated increases in heart rate and cardiac
output and may reduce exercise performance, and is
greater with chronic administration than with acute
dosing.19 However, in case of ischemic heart disease,
beta blockers can be used without having a negative
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effect on exercise capacity. 20 In patients with
bronchospasm as a component of chronic obstructive
lung disease, any beta blockers should be avoided.
Alpha-adrenergic blocking agents doxazosin,
prazosin, and terazosin do not suppress cardiac output
or exercise capacity and are excellent choices for use in
active hypertensive patients. Calcium channel blockers
verapamil, diltiazem, and nifedipine reduce systolic and
diastolic BP during exercise possibly through reduction
in systemic vascular resistance. So, calcium channel
blockers are beneficial for patients who are not good
candidates for beta blockers.

Conclusion
Antihypertensive drugs are effective to lower BP
and decrease the risk of the target organ damage, but
adverse side effects and cost have led to a search for
non-pharmacological interventions in mild to moderate
hypertension. Dynamic exercise or aerobic training such
as walking, running, or bicycling exercise is the choice
exercise for hypertensive patients. Low-to-moderate
intensity exercise appears to lower systolic and diastolic
blood pressure with an average of reduction of 10
mmHg. The blood pressure is reduced early after the
initiation of dynamic exercise training and no further
reductions occurs after 3 months but disappears abruptly
with detraining.
Some antihypertensive drugs such as diuretics
and beta blockers can interfere with exercise
performance but alpha blockers, calcium channel
blockers, and ACE-I do not interfere with exercise
performance and are well tolerated by active
hypertensive individuals. If hypertension is poorly
controlled, heavy physical exercise as well as maximal
exercise testing should be discouraged or postponed
until appropriate drug treatment has been instituted and
blood pressure lowered.
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Cardiovascular disease is the leading cause of
death in developed and developing countries. In Asia,
heart attacks and stroke are major causes of morbidity
a n d m o r t a l i t y. T h e r i s k f a c t o r s l e a d i n g t o
cardiovascular disease are well known. 1 Of these,
smoking, blood pressure and cholesterol are the
major modifiable risk factors. In highly developed
countries such as the United States, we and others
have shown that the prevalence of these risk factors
is declining. 2 This is not the case in developing
countries.
Cardiovascular diseases form a continuum,3 in
which cardiovascular risk factors lead to
atherosclerosis, which is not clinically overt at first,
but in middle age, may manifest itself as ischaemic
heart disease, cerebrovascular and peripheral
vascular disease. In old age, accumulated injuries to
the myocardium lead to chronic heart failure whereas
in the brain, vascular disease is an important cause
of senile dementia. The question then arises − can
we intervene earlier in the cardiovascular continuum?
Data from the Hong Kong Cardiovascular Risk
Factor Prevalence Study showed that hypertension
and diabetes are sequelae of obesity.4,5 They support
the usefulness of the concept of the metabolic
syndrome. 6-8 Central obesity leads to elevated
triglycerides and reduced high density lipoprotein
cholesterol. Raised blood pressure and raised blood
glucose follow later.9,10 This provides a window of
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opportunity to prevent cardiovascular disease by
preventing the development of the leading risk
factors. Numerous studies have shown that lifestyle
measures to reduce central obesity will reduce blood
pressure and the development of diabetes.11-13
As a result of economical development,
physical activity is declining in Asia.14,15 HDL does
not decrease with age in American women but it does
so in Hong Kong Chinese women.16 At the same time,
a diet that traditionally provides abundant calories
for farming and manual labour may be inappropriate
for a sedentary lifestyle.17-19 This may explain the high
incidence of diabetes among Asians.
For those who already have cardiovascular
disease, medications to modify blood pressure,
cholesterol and platelet function have been shown
in large clinical trials and meta-analyses to
have favourable effects on outcome. 20-23 The
INTERHEART study has eloquently shown that 90%
of heart attacks can be explained by nine risk factors,
the majority of which are related to lifestyle and can
be modified by changes in lifestyle.24 It is high time
we put this knowledge into action.
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Hypertension is one of the leading causes of
cardiovascular disease worldwide. More than 1.5
billion individuals will suffer hypertension by the
year 2025. This condition will account for up to 50%
of heart disease risk and 75% of stroke risk. 1
Moreover, hypertension presently accounts for direct
global health costs estimated to be more than 400
billion dollars. 2 High blood pressure defined as
systolic pressure >140 and diastolic pressure >90
mmHg is a significant problem in both the United
States and China. Over 73 million Americans or one
in three adults have hypertension. 3 In a national
household survey conducted in China in 2002 the
prevalence of hypertension in those 18 years and older
was found to be 19%. This figure translates into more
than 160 million hypertensive individuals. 4 The
growing rate of obesity and high intake of sodium in
the diet both in the United States and China are likely
reasons for the increase in hypertension rates.
Hypertension prevention and treatment
includes both lifestyle interventions of weight loss,
sodium restriction, adoption of the DASH diet,
exercise and alcohol restriction. Studies such as the
DASH and PREMIER trials suggest that weight loss
and dietary changes can significantly lower systolic
and diastolic blood pressure and should be more
readily adopted in community settings.5,6 Increasing
fruit and vegetable intake and decreasing saturated
fats as well as improving exercise have the potential
to not only effect hypertension but the associated
CVD risk factors of dyslipidemia and diabetes.
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Contemporary meta-analysis comparing various
antihypertensive medications used in blood pressure
trials of 168,593 individuals suggests that the majority
of reduction in CVD endpoints is due to the lowering
of blood pressure rather than the choice of agent used
to manage hypertension.7 The majority of these trials
resulted in the lowering of blood pressure to
approximately 135/75 mmHg. 7 Ensuring patient
adherence to antihypertensive regimens is important to
increasing better overall hypertension control. Data
suggests that at least 50% of patients taking antihypertensive regimens may discontinue therapies by one
year.8 Efforts must also be instituted to focus on the
patient's acceptance of the medication regimen, how
well it is executed and whether persistence continues
beyond one year.
Home blood pressure monitoring (HBPM) has
served as an effective method for improving the
diagnosis of white coat and masked hypertension, and
to improve medication adherence and control. Many
organizations within the United States, Europe and Asia
recommend the use of home blood pressure monitoring
in the majority of individuals with hypertension.
Ensuring the appropriate blood pressure technique,
frequency and scheduling of measurement, and
evaluating the need for ambulatory versus HBPM helps
clinicians obtain important information to guide
decisions about management.9 Moreover, HBPM offers
the physiologic feedback needed for patients to observe
their blood pressure values. This is especially important
due to hypertension being an asymptomatic condition.
Managing resistant hypertension is also critical
to better blood pressure control. Data from ALLHAT
indicates that 27% of individuals were on three or more
medications with blood pressures still not at goal.10
Predictors of resistant hypertension from ALLHAT
include older age, higher baseline systolic blood
pressures, left ventricular hypertrophy, obesity, chronic
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kidney disease ( CR>1.5 mg.dL), diabetes, living in the
southeast part of the U.S., African-Americans, and
women.10 The causes of resistant hypertension include
pseudoresistance, white coat effect, lifestyle factors,
drug-related causes and secondary causes. A treatment
algorithm should be followed to better manage this
condition.10
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How to Achieve Regression of Atherosclerosis
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Hong Kong
TOMLINSON ET AL.: How to Achieve Regression of Atherosclerosis. Coronary artery disease and stroke are the
leading causes of death in most developed countries and the prevalence of these diseases is increasing rapidly in
developing countries. Atherosclerosis is a dynamic process that in most patients shows a gradual progression with
episodes of more rapid deterioration usually related to thrombotic episodes. Many of the early trials of lipid lowering
agents showed only very small degrees of angiographic regression despite impressive reductions in cardiovascular
events. The development of noninvasive imaging techniques to study atherosclerotic changes in the arterial wall,
such as computed tomographic imaging of coronary calcium, intravascular ultrasound of the coronary arteries,
multidetector computed tomographic angiography, B mode ultrasound of the carotid arteries, and magnetic resonance
imaging of the carotid arteries has facilitated studies of lesion progression and provided evidence that aggressive
pharmacological interventions, particularly those of lipid-altering therapies, can reduce the rate of progression or
in some cases actually produce regression of atheromatous lesions. A multimodality approach to the management of
all the risk factors in patients with coronary artery disease is likely to produce the best results, but the evidence for
lowering low-density lipoprotein cholesterol with intensive statin therapy is currently the most convincing. The lipid
responses to statins vary widely between individuals because of a combination of phenotypic and genotypic factors,
which are also likely to affect outcomes measured by the various imaging techniques as well as cardiovascular
events, so there may be considerable scope for the individualization of treatments to achieve greater benefits when
more pharmacogenetic data are available. (J HK Coll Cardiol 2008;16(Suppl 1):A52-A61)
Atherosclerosis, coronary artery disease, imaging techniques, individualized therapy, statins
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Introduction
It has only been in recent years that regression of
atheromatous plaques in humans has been considered a
real possibility. Earlier concepts of the pathology of
advanced atheromatous lesions in humans and in animal
models considered that they contain components that
might not regress, such as necrosis, calcification and
fibrosis. Many of the early trials of lipid lowering agents
showed only very small degrees of angiographic
regression, despite large reductions in clinical events
giving rise to the so-called 'angiographic paradox' but
meta-analysis of trials of statin therapy showed that the
LDL-cholesterol level on therapy and the percentage
reduction in LDL-cholesterol both were good predictors
of angiographic benefit.1 The notion that lipid-rich,
vulnerable plaques have a central role in acute coronary
syndromes and the predominant benefit derived from
statins in reduction of cardiovascular events was through
stabilisation of lipid-laden plaques, rather than
regression of atherosclerosis was also developed.2 This
was shown in human carotid plaques removed during
carotid endarterectomy where 3 months of pravastatin
treatment had a plaque-stabilising effect decreasing
lipids, lipid oxidation, and inflammation, and increasing
collagen content compared to no lipid-lowering therapy.3
The increasing evidence from several large
clinical outcome trials has clearly shown that aggressive
LDL-cholesterol reduction with statins reduces hard end
points of cardiovascular events.4 The development of
new imaging techniques has also been able to show that
aggressive lipid lowering slows the progression of
atherosclerosis. Arterial lumen size may not be a very
accurate measure of atheromatous plaque and lesion
remodeling may confound the effects of therapeutic
interventions. Autopsy studies had shown that
atherosclerotic human coronary arteries enlarged in
relation to plaque area and the cross-sectional area of
the lumen was preserved until the lesion occupied at
least 40% of the internal elastic lamina area. 5
Furthermore, vulnerable plaques may be relatively small
but may easily rupture and result in acute thrombotic
events of unstable angina, acute myocardial infarction,
and sudden cardiac death. 6 The development of
noninvasive imaging techniques to study atherosclerotic
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changes in the arterial wall, such as computed
tomographic (CT) imaging of coronary calcium,
intravascular ultrasound (IVUS), multidetector CT
angiography, B mode ultrasound of the carotid arteries,
and MRI of the carotid arteries has facilitated studies
of lesion progression and provided extremely useful
information for clinical trials.7, 8

Screening Guidelines
Some of these noninvasive imaging techniques
have been included in guidelines for screening
asymptomatic individuals who are considered high risk
by the traditional risk factor-based approach. The
Screening for Heart Attack Prevention and Education
(SHAPE) Task Force proposed the First SHAPE
Guideline to detect and treat individuals with subclinical
atherosclerosis using 2 noninvasive imaging techniques:
coronary artery calcium scoring using computed
tomography and carotid intima media thickness and
plaque using B-mode ultrasonography.9 The National
Cholesterol Education Program and the American Heart
Association also suggested that noninvasive screening
tests may be an option for advanced risk assessment in
appropriately selected individuals, specifically in those
who are at intermediate or indeterminate risk.10, 11

Electron-Beam Tomography of
Coronary Artery Calcium
A retrospective study showed that aggressive
LDL-cholesterol lowering with statins correlated
significantly with reduction in coronary calcium-volume
score by electron-beam CT, indicating that even
coronary artery calcifications can shrink with
appropriate treatment. 12 In the BELLES (Beyond
Endorsed Lipid Lowering with EBT Scanning) study
in 615 hypercholesterolaemic postmenopausal women
randomized to intensive (atorvastatin 80 mg/day) and
moderate (pravastatin 40 mg/day) lipid-lowering
therapy using sequential electron-beam tomography
(EBT) scanning to quantify changes in coronary artery
calcium (CAC) as a measure of atherosclerosis burden
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only 475 completed the study and despite greater
reductions in LDL-cholesterol in the intensive statin
therapy it did not result in less progression of coronary
calcification over 1 year.13

Coronary Artery Intravascular Ultrasound
The IVUS technique allows tomographic
assessment of lumen area, plaque size, distribution, and
composition and it was recognized that it was likely to
be particularly useful in atherosclerosis regressionprogression trials with lipid lowering or other therapies
which might reduce atheroma burden.14, 15 Serial changes
in plaque progression and lumen reduction as assessed
with IVUS were compared with 3 established risk scores
for primary prevention, PROCAM, SCORE, and
Framingham, in 56 patients with established
atherosclerosis and there was a positive linear
relationship between the estimated risk of clinical events

derived from all 3 established risk-score algorithms and
the extent of plaque progression measured by serial
IVUS.16 The main lipid-modifying studies using IVUS
are summarised in Table 1.
The first large study to use this technique to
examine the changes in coronary atheroma with statin
t r e a t m e n t s wa s t h e R E V E R S A L ( R ever s i n g
Atherosclerosis with Aggressive Lipid Lowering) study,17
which was only able to demonstrate a lack of
progression of coronary atheroma with high-dose (80
mg) atorvastatin, which reduced LDL-cholesterol to a
mean of 79 mg/dL compared to a level of 110 mg/dL
with pravastatin 40 mg. In the pravastatin treated group
there was progression of coronary atherosclerosis
(change in atheroma volume compared with baseline
2.7%; 95% confidence interval [CI], 0.2% to 4.7%;
p =0.001). Analysis of the groups receiving atorvastatin
and pravastatin combined, indicated that a reduction in
LDL-cholesterol >50% was needed to obtain regression
of coronary atheroma volume and changes in CRP also

Table 1. Summary of intravascular ultrasound trials in patients with coronary disease receiving lipid-altering treatment
Variables
Study medications
Duration of study, month
Age, y
Male,%
Body mass index, kg/m2
Mean baseline levels
Total cholesterol, mg/dL
LDL-cholesterol, mg/dL
Triglyceride, mg/dL*
HDL-cholesterol, mg/dL
Percent atheroma volume, %
Total atheroma volume, mm3
Mean change from baseline
Total cholesterol, %
LDL-cholesterol, %
Triglyceride, %*
HDL-cholesterol, %
Percent atheroma volume, %
Total atheroma volume, mm3

REVERSAL17
(n=502)
Atorvastatin 80 mg vs.
Pravastatin 40 mg
18
55.8 vs. 56.6
71 vs. 73
30.5 vs. 30.5

ASTEROID21
(n=349)
Rosuvastatin 40 mg
24
58.5
70.2
29.1

ILLUSTRATE25
(n=910)
Atorvastatin vs.
Atorvastatin + torcetrapib
24
57 vs. 56.9
70.5 vs. 70.4
30.3 vs. 30.6

231.8 vs. 232.6
150.2 vs. 150.2
197.2 vs. 197.7
42.3 vs. 42.9
38.4 vs. 39.5
184.4 vs.194.5

204
130.4
135
43.1
39.6
212.2

157.5 vs. 157.7
84.3 vs. 83.1
123.9 vs. 122.0
45.2 vs. 46.0
37.1 vs. 37.0
198.7 vs. 196.1

-34.1 vs. -18.4†
-6.3 vs. -25.2†
-20.0 vs. -6.8†
2.9 vs. 5.6
0.5 vs. 1.9†
-0.4 vs. 5.1‡

-33.8
-53.2
-14.5
14.7
-0.98
-14.7

1.9 vs. 7.2†
6.6 vs. -13.3†
-8.2 vs. -14.3†
-2.2 vs. 58.6†
0.19 vs. 0.12
-6.3 vs. -9.4‡

ACTIVATE28
(n=408)
Pactimibe 100 mg vs.
placebo**
18
58.8 vs. 59.6
65.8 vs. 71.6
30.9 vs. 31.0
173.4 vs. 171.5
96.0 vs. 94.8
144 vs. 150
44.6 vs. 42.4‡
39.8 vs. 39.3
198.1 vs. 196.5
NA
NA
NA
NA
0.69 vs. 0.59
-1.3 vs. -5.6‡

*Data was presented as median except for REVERSAL trial; **212 (79.1) and 204 (76.7) patients in placebo group and pactimibe group
using statins respectively; †: p<0.001 between 2 treatment groups ; ‡: p<0.05 between 2 groups; NA: data not available
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predicted regression in REVERSAL.17 In the clinical
study of the same dosing strategy after acute coronary
syndromes, the PROVE IT-TIMI 22 (Pravastatin or
Atorvastatin Evaluation and Infection Therapy:
Thrombolysis in Myocardial Infarction 22) trial, there
was a marked reduction in adverse cardiovascular events
with atorvastatin compared to pravastatin with a 16%
(95% CI; 5 to 26%; p=0.005) reduction in the hazard
ratio in favor of atorvastatin, supporting the theory of
stabilisation of lipid-laden plaques without major
regression of atherosclerosis with intensive statin
therapy.18
More recently in the ASTEROID (A Study To
Evaluate the Effect of Rosuvastatin on Intravascular
Ultrasound-Derived Coronary Atheroma Burden) trial
of 2 years treatment with rosuvastatin 40 mg daily, mean
LDL-cholesterol levels decreased by 53% (from 130
to 61 mg/dL) and mean high-density lipoprotein (HDL)
cholesterol levels increased by 15% (from 43 to 49 mg/
dL) and there was a decrease in mean percent atheroma
volume (from 39.6% to 38.6%) and mean atheroma
volume in the most diseased 10-mm subsegment (from
65 to 59 mm 3). 19 A post-hoc analysis of data from
REVERSAL, ASTEROID and 2 other IVUS studies
showed in univariate analysis that mean levels and
treatment-mediated changes in LDL-cholesterol, total
cholesterol, non-HDL cholesterol, apolipoprotein B, and
ratio of apolipoprotein B to apolipoprotein A-I were
significantly correlated with the rate of atherosclerotic
progression, whereas treatment-mediated changes in
HDL-cholesterol were inversely correlated with
atheroma progression.20 Mean levels of LDL-cholesterol
and increases in HDL-cholesterol remained independent
predictors of atheroma regression in multivariate
analysis. Substantial atheroma regression was seen in
patients with on treatment levels of LDL-cholesterol
less than the mean (87.5 mg/dL) and increases of HDLcholesterol greater than the mean (7.5%).
Quantitative coronary angiography in the patients
in the ASTEROID trial also showed evidence of lesion
regression by decreasing percent diameter stenosis and
improving minimum lumen diameter. 21 It was
concluded that aggressive lowering of LDL-cholesterol
and a moderate increase in HDL-cholesterol with
rosuvastatin 40 mg resulted in regression of coronary
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atherosclerosis. The ASTEROID trial did not have any
control group and the ongoing SATURN (Study of
Coronary Atheroma by Intravascular Ultrasound: Effect
of Rosuvastatin versus Atorvastatin) study will remedy
this by comparing the effects of rosuvastatin 40 mg or
atorvastatin 80 mg treatment for 2 years on
atherosclerotic disease as measured by IVUS in patients
with coronary disease undergoing angiography.22
The importance of increases in plasma HDLcholesterol has been shown in some animal models of
atherosclerosis in which infusion of native HDLcholesterol or lipid-free apolipoprotein A-1 (apo A-1)
reduced plaque size.23 Furthermore, weekly infusions
of the recombinant mutant apolipoprotein apo A-1
Milano for 5 weeks resulted in modest plaque regression
determined by IVUS in patients after an acute coronary
event.24 The approach to increase HDL-cholesterol was
pursued in the ILLUSTRATE trial with torcetrapib, an
inhibitor of cholesteryl ester transfer protein (CETP)
and in the IVUS study in patients with coronary disease,
compared with atorvastatin monotherapy, torcetrapibatorvastatin combination therapy resulted in an
approximate 61% relative increase in HDL-cholesterol
and a 20% relative decrease in LDL-cholesterol, but
there was no significant difference in the change in
atheroma volume for the most diseased vessel segment
between the two treatment groups.25 This lack of benefit
seems to be associated with an increase in systolic blood
pressure of 4.6 mmHg and an increase in circulating
aldosterone which could have negated the beneficial
effects on lipids. Likewise, the clinical trial to investigate
whether torcetrapib might reduce major cardiovascular
events in patients at high cardiovascular risk
(ILLUMINATE) was terminated prematurely because
of an increased risk of death and cardiac events in
patients receiving torcetrapib.26
Another negative IVUS study was the ACTIVATE
(Acyl-CoA: Cholesterol Acyltransferase Intravascular
Atherosclerosis Treatment Evaluation) Study with the
ACAT inhibitor pactimibe, which has beneficial effects
on foam cell formation and other antiatherosclerotic
effects in animal models.27 Pactimibe (100 mg per day)
in addition to usual care for secondary prevention,
including statins, if indicated, did not improve the
primary efficacy variable (percent atheroma volume)
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and adversely affected two major secondary IVUS
efficacy measures and it was concluded that this
treatment may actually promote atherogenesis in
humans.28

Carotid Intima-Media Thickness
Carotid intima-media thickness (CIMT) is related
to most of the conventional cardiovascular risk factors.
In subjects in the Atherosclerosis Risk in Communities
(ARIC) study and a group of patients with coronary
heart disease (CHD), carotid thickness showed
approximately linear positive associations with fasting
plasma LDL-cholesterol and apolipoprotein B (apoB)
and negative associations with HDL-cholesterol and
apoA-I levels.29 CIMT was shown to predict not only
stroke but also CHD events in studies such as the
Rotterdam study, 30 the Cholesterol Lowering
Atherosclerosis Study,31 and the Cardiovascular Health
Study.32 In the follow up from the ARIC study, greater
CIMT was associated with increased risk of CHD and
future ischaemic stroke incidence.33, 34
A number of studies have shown that the
progression in CIMT can be influenced by modification
of the cardiovascular risk factors. The main lipidmodifying studies using CIMT endpoints are
summarised in Table 2. In the ASAP (aggressive versus
conventional lipid lowering on atherosclerosis
progression in familial hypercholesterolaemia) study,
aggressive LDL-cholesterol reduction with atorvastatin
80 mg resulted in a decrease in CIMT of -0.031 mm
(95% CI; -0.007 to -0.055; p=0.0017), whereas with
conventional LDL-cholesterol lowering with
simvastatin 40 mg it increased by 0.036 mm (95% CI;
0.014-0.058; p=0.0005).35 In the ARBITER (Arterial
Biology for the Investigation of the Treatment Effects
of Reducing Cholesterol) trial comparing the effects of
atorvastatin 80 mg daily and pravastatin 40 mg daily
on CIMT in patients that met National Cholesterol
Education Program (NCEP) II criteria for lipid-lowering
therapy, atorvastatin induced progressive CIMT
regression over 12 months (change in CIMT, -0.034±
0.021 mm), whereas CIMT was stable in the pravastatin
group (change of 0.025±0.017 mm; p=0.03).36 A further
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study in patients with CHD and low levels of HDLcholesterol (ARBITER 2) compared the addition of
placebo or extended-release niacin to statin therapy.
HDL-cholesterol increased by a mean of 21% in the
niacin group and mean CIMT increased significantly
in the placebo group (0.044±0.100 mm; p<0.001) and
was unchanged in the niacin group (0.014±0.104 mm;
p=0.23), but the overall difference in CIMT progression
between the niacin and placebo groups was not
statistically significant at 1 year (p=0.08). 37 Some
participants from the ARBITER 2 study were enrolled
in ARBITER 3 and took extended-release niacin 1000
mg daily for another 12 months.38 The changes in CIMT
suggested regression in atherosclerosis occurred over
24 months related to increases in HDL-cholesterol.
The study with torcetrapib on CIMT in patients
with heterozygous familial hypercholesterolemia
(RADIANCE 1 study) showed that the use of torcetrapib
with atorvastatin, as compared with atorvastatin alone,
produced a large increase in HDL-cholesterol levels and
substantial decreases in LDL-cholesterol and
triglyceride levels but failed to reduce progression of
atherosclerosis, as assessed by a combined measure of
CIMT, and was associated with progression of disease
in the common carotid segment.39 Similar findings were
reported in another study comparing the combination
of torcetrapib with atorvastatin to atorvastatin alone in
patients with mixed dyslipidaemia (RADIANCE 2
study).40 This lack of benefit of torcetrapib on CIMT
appears to related to the increases in blood pressure and
aldosterone as in the other studies with torcetrapib.
In the METEOR (Measuring Effects on IntimaMedia Thickness: an Evaluation of Rosuvastatin) study
in 984 middle-aged asymptomatic subjects with low
CHD risk (Framingham risk score <10%), modest
CIMT thickening (1.2 to <3.5 mm), and elevated
LDL-cholesterol (mean, 154 mg/dL), rosuvastatin 40
mg daily resulted in statistically significant reductions
in the rate of progression of maximum CIMT over 2
years vs. placebo.41 The change in maximum CIMT for
the 12 carotid sites was -0.0014 mm/year (95%
CI; -0.0041 to 0.0014) for the rosuvastatin group vs.
0.0131 mm/year (95% CI; 0.0087 to 0.0174) for the
placebo group (p<0.001). In another small trial, the
ACADIM (the Asymptomatic Carotid Atherosclerotic
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Table 2. Summary of Carotid Intima-Media Thickness trials in patients with lipid-modifying treatments
ASAP35
(n=325)
FH

ARBITER36
(n=161)
Patients eligible
for lipid
lowering therapy

Atorvastatin 80 mg
vs. simvastatin 40 mg
24
48
NA
26

Atorvastatin 80 mg
vs. pravastatin 40 mg
12
58 vs. 61
68.4 vs. 74.4
NA

Variables
Subjects

Study medications

Duration of study, month
Age, y
Male,%
Body mass index, kg/m2
Mean baseline levels
Total cholesterol, mg/dL
386 vs. 397
LDL-cholesterol, mg/dL
309 vs. 322
Triglyceride, mg/dL
166 vs. 164
HDL-cholesterol, mg/dL
46 vs. 45
Carotid intima-media thickness, mm
0.93 vs. 0.92
Mean change from baseline
Total cholesterol, %
-41.8 vs. -33.6†
LDL-cholesterol, %
50.5 vs. -41.2†
Triglyceride, %
-29.2 vs. -17.7†
HDL-cholesterol, %
13.2 vs. 13.4
Carotid intima-media thickness, mm -0.031 vs. 0.036†
Variables
Subjects
Study medications

NA
-48.5 vs. -27.2†
NA
NA
-0.034 vs. 0.025‡

RADIANCE 139
(n=850)
FH
Atorvastatin vs.
Atorvastatin + torcetrapib
60 mg
24
45.2 vs. 46.8
51.1 vs. 47.6
26.7 vs. 26.7

Duration of study, month
Age, y
Male,%
Body mass index, kg/m2
Mean baseline levels
Total cholesterol, mg/dL
LDL-cholesterol, mg/dL
Triglyceride, mg/dL
HDL-cholesterol, mg/dL
Carotid intima-media thickness, mm
Mean change from baseline
Total cholesterol, %
LDL-cholesterol, %
Triglyceride, %
HDL-cholesterol, %
Carotid intima-media thickness, mm
†

229 vs. 234
148 vs. 155
203 vs. 211
49 vs. 49
0.625 vs. 0.615

ARBITER 237
METEOR42
(n=167)
(n=984)
CHD patients on
Individuals with
background
moderately elevated
statin therapy
cholesterol and low risk
of cardiovascular disease
Niacin 1000 mg
Rosuvastatin 40 mg
vs. placebo
vs. placebo
12
24
67 vs. 68
57 vs. 57
89.7 vs. 92.5
60 vs. 59
NA
27.1 vs. 27.5
154 vs. 161
87 vs. 91
154 vs. 172
39 vs. 40
0.893 vs. 0.868

229 vs. 230
155 vs. 154
126 vs. 134
50 vs. 49
0.76 vs. 0.76

NA
NA
NA
+21% vs. no change
0.014 vs. 0.044

RADIANCE 240
(N=752)
Mixed dyslipidaemia
Atorvastatin + placebo vs.
Atorvastatin + torcetrapib
60 mg
24
56.5 vs. 57.9
65 vs. 63
30.0 vs. 30.0

-33.7 vs. 0.3†
-48.8 vs. -0.3†
-15.7 vs. 10.1†
8.0 vs. 2.8†
0.0004 vs. 0.088†

ENHANCE43
(n=720)
FH
Simvastatin 80 mg + placebo vs.
Simrvastatin + ezetimibe
10 mg
24
45.7 vs. 46.1
49.3 vs. 53.5
26.7 vs. 27.4‡

213.5 vs. 213.0
138.9 vs. 138.4
97.4 vs. 97.4*
51.8 vs. 52.9
0.72 vs. 0.71

184 vs. 185
101 vs. 101
166 vs. 167
48 vs. 48
0.83 vs. 0.83

400.0 vs. 400.0
317.8 vs. 319.0
160 vs. 157*
47.4 vs. 46.7
0.65 vs. 0.67

5.1 vs. 3.8
6.3 vs. -14.4†
2.1 vs. -7.7†*
2.5 vs. 54.4†
-0.0014 vs. 0.038
(per year)†

2.3 vs. 5.9†
4.4 vs. -13.3†
1.5 vs. -12.6†
-1.8 vs. 61.6†
0.008 vs. 0.0013
(per year)†

-31.9 vs. -45.3†
-39.1 vs. -55.6†
-23.2 vs. -29.8†*
7.8 vs. 10.2
0.0024 vs. 0.0019

: p<0.01 between 2 groups; ‡: p<0.05 between 2 groups; *Data was presented as Median; NA: data not available
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Disease in Manfredonia) Study, treatment with
rosuvastatin (10 mg/day) for only 16 weeks in 66
subjects with hypercholesterolemia and carotid
atherosclerosis at baseline significantly reduced the
CIMT of both common carotid arteries as well as
improving lipid and lipoprotein levels.42
Thus, aggressive reduction of LDL-cholesterol
with statins appears effective in reducing CIMT over a
relatively short period of time. However, in the
E N H A N C E ( E z e t i m i b e a n d S i m va s t a t i n i n
Hypercholesterolemia Enhances Atherosclerosis
Regression) study in 720 patients with familial
hypercholesterolemia treated with 80 mg of simvastatin
either with placebo or with 10 mg of ezetimibe for 24
months, there was no significant difference in changes
in CIMT between the two treatments despite additional
reductions with the combination treatment of 16.5%,
6.6% and 25.7% for LDL-cholesterol, triglycerides and
C-reactive protein, respectively.43 Whilst at first sight
this may not appear to support the concept that lower
levels of LDL-cholesterol will result in greater benefits,
it should be noted that the patients in this study had
smaller baseline values for CIMT than in most previous
studies and they had been treated aggressively with
statins for some years previously and many of them had
taken part in the earlier aggressive versus conventional
lipid lowering on atherosclerosis progression in familial
hypercholesterolaemia (ASAP).35

High-Resolution Magnetic
Resonance Imaging
The role of magnetic resonance imaging (MRI)
for detection and monitoring of the development and
progression of atherothrombosis responsible for
ischemic events has been reviewed recently. 7,44 It
appears particularly useful to characterize carotid
atherosclerotic plaque and identify vulnerable lesions.45
In hypercholesterolemic patients with moderate carotid
stenosis, noninvasive MRI was able to determine the
distribution of lesions and lesion types reproducibly and
showed a wide range of lesion types, including advanced
lesions.46
The ORION (Outcome of Rosuvastatin
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treatment on carotid artery atheroma: a magnetic
resonance Imaging ObservatioN) trial used highresolution magnetic resonance imaging (MRI) to
evaluate the effect of low-dose (5 mg) and high-dose
(40/80 mg) rosuvastatin for 2 years on carotid artery
atherosclerosis in 43 patients with fasting LDLcholesterol >100 and <250 mg/dL and 16% to 79%
carotid stenosis by duplex ultrasound. 47 LDLcholesterol was significantly reduced by 59.9±3.3%
in the high-dose group and by 38.2±2.4% in the lowdose group (both p<0.001) and HDL-cholesterol
increased by 10.1±2.0% in the high-dose group
(p<0.001) with no significant change from baseline
in the low-dose group (2.2±3.2%; p=0.05). At 24
months, the overall plaque burden remained
unchanged for both dosage groups, but in all patients
with a lipid-rich necrotic core (LRNC) at baseline,
the mean proportion of the vessel wall composed of
LRNC (%LRNC) decreased by 41.4% (p=0.005).

Statin Pharmacogenetics
It is worth noting that the clinical efficacy,
in terms of LDL-cholesterol lowering, and the
safety of statin treatment varies considerably from
person to person because of a combination of
phenotypic and genotypic factors. 48-50 These
factors are also likely to effect outcomes measured
by the various imaging techniques as well as
cardiovascular events so there may be considerable
scope for the individualization of treatments when
more pharmacogenetic and pharmacogenomic data
are available to predict these responses. A recent
study using the genome-wide scan for genetic
markers of simvastatin-related myopathy found
that a common variant in the hepatocyte uptake
transporter organic anion-transporting polypeptide
1B1 (OATP1B1), encoded by the gene SLCO1B1, was
associated with increased risk of myopathy, and this
polymorphisms may be useful in the future for the
choice of drug and dosage to achieve maximum efficacy
and safety.51 Rosuvastatin shows increased systemic
exposure in Asians compared with Caucasians and
regulatory authorities including the FDA have
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recommended starting with lower doses (5 mg) in
'Asian' patients.52 The OATP1B1 uptake transporter
does influence hepatic uptake of rosuvastatin but
the higher systemic exposure did not appear to be
related to the common polymorphisms and
haplotypes in SLCO1B1 in a study examining the
ethnic differences in disposition of rosuvastatin
in Singapore. 53 In that study there was considerable
overlap in the measures of rosuvastatin systemic
exposure between different ethnic groups so a
number of other genotypic or phenotypic factors
are likely to be involved in determining efficacy
and safety.
In the DISCOVERY Asia study conducted at 70
centers in China, Hong Kong, Korea, Malaysia, Taiwan,
and Thailand,54 the starting dose of 10 mg rosuvastatin
produced no adverse effects and the reduction in LDLcholesterol was similar to that seen in other studies with
rosuvastatin 10 mg mainly in Caucasians reviewed by
Schuster55 or in the STELLAR trial.56

Conclusions
The development of these new imaging
technologies has allowed the visualisation of arterial
wall thicknesses, areas, and volumes and plaque
composition and burden and enables the early detection
of atherosclerosis, refinement of risk assessments, and
monitoring of atherosclerosis progression/regression. A
multimodality approach to the management of lipid risk
factors in patients with coronary artery disease is likely
to produce the best results, but the evidence for potent
statins is still the most compelling at present. The results
of several ongoing trials should help to clarify whether
combinations of pharmacologic agents may be even
more efficacious in the long-term management of
patients at risk for atherosclerosis events. A
pharmacogenetic approach may eventually allow the
individualisation of treatments for even greater benefits.
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Update in Medical Treatment
YAT-YIN LAM
From Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong

Majority of patients referred for cardiac
rehabilitation have severe coronary artery diseases (e.g.
post myocardial infarction, percutaneous coronary
intervention or coronary artery bypass grafting).

Medications prescribed during cardiac rehabilitation for
these patients include specific therapies and drugs to
modify cardiovascular risk factors. The following table
summarizes the commonly used drugs:

Specific treatment for coronary artery diseases
Anti-platelets
Aspirin, Clopidogrel
Symptoms control

Nitrates (po, sublingual, patch)

Anti-heart failure medications

Beta-blockers (Metoprolol XL, Bisoprolol, Carvedilol)
ACEI (Captopril, Ramipril) or ARB (Valsartan)
Aldosterone antagonists (Eplerenone)

Drugs for secondary prevention
Risk factors
Medications
Smoking
Varenicline tartrate
Buproprion SR
Transdermal nicotine patch
Hypertension
Various anti-hypertensives
Dyslipidaemia

Obesity

Diabetes Mellitus
Depression

Statins
Fibrates
Bile acid sequestrants
Nicotinic acid
Ezetimibe
Sibutramine
Orlistat
Rimonabant
Various oral hypoglycaemics
Insulin
Anti-depressants

Target
Smoking cessation

BP <140/90 mmHg or <130/80 mmHg if DM
or renal impairment
LDL-C <2.6 mmol/L (if TG ≥2.3 mmol/L,
non–HDL-C <3.4 mmol/L),
<1.8 mmol/L in very high risk patients

BMI 18.5 to 24.9kg/m2
Waist circumference:
Male <40 inches
Female <30 inches
HbA1c<7%
Stable mood
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Update in Interventional Treatment and Rehabilitation
ALBERT WAI-SUEN LEUNG
From Specialist in Cardiology, Hong Kong

The progress of cardiology intervention has been
rapid and spectacular in the past twenty to thirty years.
The term 'intervention' is aimed to describe an invasive
treatment modality as separated from non-invasive
treatment method, which usually means drug treatment.
Initially, invasive treatment means surgery, which
involves making open wounds to work out a treatment.
Nowadays, this term is singled out to describe invasive
treatment that involves no or very small surgical wounds.
Common examples are making access to central
vascular structures such as the heart through the use of
peripheral arteries or veins. A better term for this
approach is 'endovascular intervention'. Intervention can
now be broadened to include treatment modules that
can facilitate rehabilitation. A good example is the use
of cardiac re-synchronization therapy to treat and to
rehabilitate patients with certain types of congestive
heart failure.
The most popular endovascular intervention
nowadays is coronary revascularization, which means
repairing a diseased (usually narrowed) coronary artery.
It was first named percutaneous transluminal balloon
angioplasty (PTCA), by using an inflatable (and
deflatable) balloon device to expand the coronary lumen.
The first human case was performed in 1977. After 3
decades, in the year 2007, we have seen exponential
increase in the worldwide use of percutaneous coronary
intervention (PCI), a broader term that includes all kinds
of endovascular devices that can be used to modify the
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lumen size of coronary artery. It is estimated that just
in the USA, 1,000,000 PCI procedures were performed
annually.
Steady improvements in the equipment used for
PCI have been and will certainly be on-going.
Reductions in device profile, improvements in catheter
flexibility and introduction of stents have extended the
scope and breadth of clinical practice. The type of
lesions amenable to PCI has become progressively more
complex, and the outcomes have progressively
improved. Special attention has to be drawn to the use
of drug-eluting stents (DES) which had developed in
the early 2000s. Randomized trials and registries have
demonstrated the benefit of DES in patients with focal
de-novo lesions as well as in patients with long and
small vessels, chronic total occlusions, bypass graft
diseases, in-stent restenosis, and in patients with STEMI.
Other currently available devices are rotational
atherectomy, thrombectomy and aspiration devices, and
embolic protection devices. Technical improvements
worth mentioning comprise the use of intra-vascular
ultrasound (enable operators to visualize directly the
artery lumen and artery wall characteristics), the access
through radial artery (smaller wound and better
haemostasis as compared to femoral approach), and the
designs of vascular closure devices for femoral
approach. Finally, the adjunctive drug therapies have
added values in the outcome of PCI. Examples are dual
oral anti-platelet therapies (aspirin plus clopidogrel) and
intravenous glycoprotein 2b3a inhibitors.
Endovascular interventions have already been
successfully applied in other fields of cardiology.
Percutaneous mitral valvuloplasty was first performed
in 1984 as an alternative to surgical mitral valve
commissurotomy in patients with rheumatic mitral
stenosis. The most commonly used approach now is to
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perform a transseptal puncture to gain assess to the left
atrium, followed by a pressure-distensible dumbbellshaped balloon dilatation of the stenotic mitral valve.
Other valvular interventions include percutaneous mitral
valve repair, aortic valvuloplasty, and percutaneous
aortc valve replacement.
Another kind of endovascular interventions is
aimed for non-coronary obstructive vascular disease.
This category consists of atherosclerotic disease of the
abdominal aorta and the arteries below (renal,
mesenteric, aortoiliac and femoropopliteal), or disease
of the supraaortic extracranial arteries (subclavian,
vertebral, common carotid and internal carotid), or even
the disease of intracranial arteries (e.g. proximal mid
cerebral). The most common technology involved is still
endovascular ballooning and stenting. Newer techniques
have been used in some particular areas, such as cryoballoon for femoropopliteal disease. Sometimes
atherosclerotic disease of the abdominal aorta will
present in the form of aneurysm rather than obstruction,
then endovascular deployment of aortic stent graft can
be considered.
Endovascular interventions have also been
practiced in certain kinds of congenital heart diseases
and congenital vascular diseases. The procedures can
be performed in neonatal, childhood, adolescent or adult
stage, depending on the symptom manifestation and
urgency of intervention. An example of intervention in
adulthood is alcohol ablation in the treatment of
hypertrophic obstructive cardiomyopathy (HOCM), in
which the septal branches of coronary artery that supply
the hypertrophic septal muscles are ablated with alcohol
(to make a confined myocardial infarction of the septal
muscles). Another example is the closing of atrial septal
defect or patent ductus arteriosus with endovascular
occlusive devices. Embolization of cerebral artery
aneurysm by embolization coils is a method to prevent
or to treat rupture aneurysm.
The practice of non-drug therapy for cardiac
arrhythmias has created a different category of
intervention, another name for it being electrotherapy.
It involves a totally different concept by aiming to stop
the generation and propagation of abnormal electrical
impulse in the heart, or to trigger an impulse when
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necessary. It can be subdivided into 2 parts, catheter
ablation therapy and implantable device therapy.
The purpose of catheter ablation is to destroy
myocardial tissue by delivering electrical energy
through electrodes on a catheter placed next to an
area of the myocardium integrally related to the onset
or maintenance of the arrhythmia. The first catheter
ablation procedures were performed using directcurrent shocks, but this energy source has been
supplanted by radiofrequency (RF) energy, hence the
term radiofrequency ablation (RFA). Usually the
target tissue has been identified by a preceding
procedure called electro-physiology stimulation
(EPS), which involves the placement of several
diagnostic electrode catheters in strategic positions
inside the heart (such as right atrium, right ventricle,
next to His bundle, and coronary sinus) and
programmed stimulation of the heart through
different electrodes to trigger the suspected
arrhythmia. The target tissue can usually be the slow
pathway in AV node, an accessory pathway or the
right ventricular outflow tract. The ablation is claimed
successful when the initially triggered arrhythmia is
not reproduced by subsequent programmed
stimulation. Advances in this field include the use of
newer energy source such as cryothermal energy,
specially designed ablation catheters, and new
mapping techniques such as electroanatomical
mapping. The ablation therapy for atrial fibrillation
is gaining popularity as well.
The advances in implantable devices are
rapidly growing. The first kind of implantable device
is permanent pacemaker, designed to treat bradyarrhythmia, such as AV block or sick sinus syndrome.
It consists of an impulse generator box usually
inserted subcutaneously in the infra-clavicular region.
One or 2 pacing leads (single or dual chamber type)
are placed transvenously into the right ventricle apex
and/or right atrial appendage, and then connected to
the generator. Impulse is generated whenever a delay
in atrial and/or ventricular rhythm is detected.
Advances in pacemaker technology have been
tremendous. The leads, the generator, the pacing
mode, the pacing algorithm and the site of pacing
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have all been modified according to the need, the
safety and the comfort of patients. The most important
advance, however, is the incorporation of antitachycardia and defibrillation function in the
implantable device, hence the name implantable
cardioverter-defibrillator (ICD). ICD is now indicated
in patients with ventricular tachycardia and ventricular
fibrillation, or to prevent sudden cardiac death in severe
heart disease cases.
The ever growing complexity of implantable
devices has allowed more disease entities to be
treated. The concept of cardiac resynchronization
therapy (CRT) is another product. It is designed to
treat patients with refractory heart failure as a result
of severe structural heart disease that is not amenable
to other modes of treatment. It is especially suitable
for patients with dys-synchronized left and right heart
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contraction, reflected by the presence of left or right
bundle branch block. Usually a third pacing lead is
inserted via the coronary sinus into a cardiac vein in
order to trigger the left ventricle. Thus, synchronized
a t r i o - ve n t r i c u l a r a n d ve n t ri c u l o - ve n t r i c u l a r
contraction can be maintained. Better designs in leads
and anchoring methods are now available, and new
indications are forthcoming. The combination of CRT
and ICD has created the device known as CRT-D.
New advance in intervention techniques and
creation of new concepts is a non-stop process. The yield
of today is the effort of the past, not to mention the
compulsory elimination of those outdated. Be it cardiac
or non-cardiac, catheter-based or device-based, new toys
are bound to come and replace the old. It is our role to
keep abreast of the updated knowledge in order to make
our patients benefit.

November 2008

A65

Update in the Rehabilitation of Heart Failure
KEI-PUI LEUNG
From Department of Medicine & Rehabilitation, Tung Wah Eastern Hospital, Hong Kong

Heart failure is the final path of various heart
diseases. The cardinal symptoms are exercise
intolerance, breathlessness and fatigue. Preventive
measures that stop heart failure development along
its track are most important. Rehabilitation in heart
failure patients includes the following components:
i) maintain a normal salt and fluid status and remove
the multiple adverse effects of organ congestion,
ii) maximize anti-heart failure medications to slow

down or to reverse the cardiac remodeling process,
iii) empower patients with knowledge and skills for
self management, and iv) improve functional capacity
and quality of life through exercise training. Exercise
training can improve the morphological and
biochemical changes in skeletal muscles related to
chronic heart failure. Other beneficial effects include
autonomic adaptation, decrease in inflammatory
markers, and possibly, central adaptation.
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Healthful Eating for a Healthy Heart
SELINA KHOR
From State Registered Dietitan, United Kingdom; Accredited Dietitian, Hong Kong Dietitians' Association,
Hong Kong

The main aim of the workshop is to translate
the updated evidence-based dietetic message into
down-to-earth information according to clients'
ability to comprehend and accept; most of all to enjoy
foods as healthy persons. The workshop conducted
in Cantonese, will be started off with a brief
presentation of the latest dietary guidelines for
dyslipidaemia and "healthful eating for a healthy

heart". It will be followed by group discussion on
the application of the guidelines such as healthy food
choices, shopping tips, menu planning, cooking and
eating out tips etc. Other aspects such as the common
food beliefs and food fads will also be discussed. At
the end of the workshop, the audiences are expected
to be able to adopt a healthful diet suitable for
dyslipidaemia and "healthy heart".
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Nourish Your Heart: Say Goodbye to Stress
CELIA HOI-YAN CHAN, CECILIA LAI-WAN CHAN, ANDY HAU-YAN HO
From Centre on Behavioral Health, The University of Hong Kong, Hong Kong

In Hong Kong, the health care system is mainly
organized under a Western medicine framework, yet the
concepts of Chinese medicine are widely held in
people's health belief systems. In view of the advantages
of the health concepts derived from Western medicine
and traditional Chinese beliefs on health among Hong
Kong Chinese, Chan and colleagues 1 developed a
cultural relevant model, the eastern Body-Mind-Spirit
(BMS) model, for understanding health and illness.
Integrating the fundamental concepts of traditional
Chinese medicine and eastern philosophical concepts
of Buddhism and Taoism, the BMS model promotes
the idea of holistic health by emphasizing the
interconnectedness and balance between the body, mind,
and spirit: "Body" refers to the individual's physical
health. "Mind" means one's mental health and
psychological wellbeing within the individual as well
as in the context of society. "Spirit" is the meaning of
life and a peace of mind. Within the BMS model, disease
is considered a disturbance of the equilibrium between
the body, the mind and the spirit; therefore, treatment
should lie on restoring and maintaining a balance rather
than being allopathic. Systemic thinking and prevention
are thus fundamental.
Intervention programs derived from the BMS
model are constituted of five primary principles: (1)
Normalization of traumatic experience; (2) Letting go
of the need for absolute attachments, and acceptance of
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the unpredictability of life; (3) Forgiveness and selflove as the keys to joy and peace of mind; (4) Expression
of emotions; and (5) Reinforcement and stabilization
of long-term efforts to change through social support
and commitment to help others. Eastern health practices
that involve both physical movements and meditation
at the same time, such as acupressure and Tai Chi
exercise, are often employed techniques. With these
techniques being integrated with Western group
psychotherapeutic techniques including emotional
expression and enhancement of social support, BMS
intervention aims to foster a sense of control and
independence, and to promote a positive and
empowering spirit among clients.1,2 The BMS model
has been applied to divorced women,2 infertile couples
undergoing in-vitro fertilization,3 and most extensively,
cancer patients.4 Efficacy of the BMS intervention has
been established.1,3
This workshop will focus on a holistic approach
of chronic illness management. Holistic health involved
the interconnection of body, mind and spirit. Based on
the concepts of Traditional Chinese Medicine and
Chinese philosophies, the model adopts an integrated
and reflective approach that postulates physical,
psychosocial and spiritual well-being as an integrated
whole. Bridging together Eastern and Western health
philosophies and practices in developing a holistic and
culturally sensitive Body-Mind-Spirit model for pain
management as well as the intervention for patients with
heart diseases. The aim of the workshop is to facilitate
the self-awareness on the association between the body
and the mind, as well as learning techniques in
relaxation, with the ultimate aim of achieving a
harmonious dynamic equilibrium within the person and
between the person and the environment.
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Behavioral Skills Training
NANCY HOUSTON MILLER
From Stanford Cardiac Rehabilitation Program, Stanford University School of Medicine, USA

Introduction
Patients' adherence with many lifestyle changes
and medications hovers at only 50% per year. 1,2
Improving patient-provider communication and
education and behavioral skills enhances patient
adherence. Moreover, multi-component strategies
appear to be more effective than single interventions in
helping individuals change behavior. While
maintenance of behavior change is difficult, it is
encouraging that more than two-thirds of the U.S.
population is attempting to make lifestyle changes such
as limiting salt, fat, and cholesterol and getting regular
exercise.3
Meta-analysis of controlled trials of cardiac
education show the success of interventions related
to diet, exercise, smoking, blood pressure, medication
adherence and stress. The most successful programs
incorporated close to 10 hours of contact time
extending over 10 or more visits. More than 50% of
successful programs used at least two interventions,
including self-monitoring and some form of social
support. More than 75% of the successful trials
included behavioral skills rather than an exclusive
focus on imparting knowledge.4
Various theories and models of health behavior
change underlie cardiovascular risk reduction. These
include social learning theory5 the most widely used
theory known to help individuals change health
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behaviors; the trans-theoretical model (stages of change)
to assess readiness;6 relapse prevention training for the
addictive behaviors of smoking, alcohol and obesity;7
and motivational interviewing that enables the counselor
to be guided on appropriate communication skills.8
However, these theories explain only about 30% of the
variance in predicting change in patient’s behavior.9
Two additional factors are key: the elements of applied
behavioral therapy and the continuous quality
improvement process.
For many years behavioral scientists have used a
combination of 11 strategies to support the change
process. These strategies include setting positive
expectations about results, precisely defining behaviors,
setting realistic goals, using contracts or written
agreements, training around relapse prevention to help
individuals with lapses in behaviors, modeling the
desired behavior, feedback about progress, problemsolving, finding cues and prompts for helping to
remember medications, self-monitoring, rewards, and
encouraging social support. 9 The choice of these
elements varies from one behavior to another. For
example, cues and prompts are most important for
enhancing medication-taking behavior as the most
common reason for non-adherence is due to patients
forgetting their medicines. Relapse prevention is the
most critical element of behavioral therapy for smokers
who lapse and smoke a cigarette or entirely relapse in
the early days following a quit attempt. For weight
control the self-monitoring of foods and weight are
especially salient. Social support from a buddy in a
weight loss program or from a family member or friend
provides additional benefit. Problem-solving and selfmonitoring are applicable to most behaviors and should
be applied in the early stages of helping individuals to
adopt lifestyle changes. A combination of two or more
of these elements fosters success in the adoption and
maintenance phases of health behavior change.4
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Continuous quality improvement (CQI) fosters
health behavior change. Why is this so important?
Adherence is increased when health care professionals
provide feedback to patients on progress toward their
goals. An evidence-based practice incorporating
adherence monitoring at every visit, and flagging of the
electronic medical record, enhances clinician's
capability to facilitate the change process. The CQI
process is facilitated by multi-disciplinary teams with
champions, provider training, feedback offered to staff,
and guidelines and protocols.10 Quality improvement
programs such as the American Heart Association's Get
with the Guidelines 11 utilize a continuous quality
improvement process to ensure that patients receive the
appropriate lifestyle interventions and medications prior
to hospital discharge.

Skills for the Individual Practitioner
Helping individuals change their behavior
requires health care professionals to become
communicators, educators and coaches - not just one
but all three. These important skills of communication,
education, and coaching are more fully described below.

Communication
Four communication skills, active listening,
warmth and empathy, open-ended questions, and
interactive communication provide the basis of
motivational interviewing and a patient-centered
approach. These four skills facilitate data gathering
(through active listening and open-ended questioning),
relationship-building (through warmth and empathy)
and partnering (interactive communication).
On average, physicians redirect a discussion as
soon as 23 seconds into the patient's opening statement
of concerns within an office visit. Once redirected,
patients rarely come back to important information that
remains uncovered.12 In a study of active listening where
patients were not interrupted, patients took an average
of 92 seconds to express their concerns at the beginning
of a visit.13 Active listening involves (1) refraining from
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asking questions immediately while individuals are
sharing concerns or information, (2) responding by
checking your understanding of what is being said by
patients and (3) being attentive to patients' verbal and
non-verbal behavior. According to the World Health
Organization, warmth and empathy from health care
professionals are central determinants of patients'
adherence.14 Warmth and empathy convey concern and
interest, ease anxiety and build trust and satisfaction.
These skills are conveyed through asking patients to
share their concerns about changing health behaviors,
acknowledging emotions and providing non-verbal cues.
Suggestions for undertaking these skills and those noted
below are shown in Table 1.
Open-ended questioning facilitates
communication about adherence to medications and
other lifestyle behaviors. This is especially important
when patients' physicians spend on average 3.94 minutes
(20-25% of office visit time) discussing medications,
asking on average 9 yes/no questions.15 The use of yes/
no questions is especially ineffective for low-literate
patients. They nod "yes" even when they don't
understand. In contrast, two key words that facilitate
change are "what" and "how." As shown below, openended questions that can help to detect and prevent
medication problems and improve adherence include
the following:
"What types of problems have you had with your
medicines?"
"How do you remember to take your medicines?"
"Many people forget to take their medicines at one
time or another. How many times have you missed
a dose of your medicine (s) over the past week?"
The fourth communication skill, interactive
communication, involves improving your understanding
of what a patient is saying. More than half of the
American adult population has difficulty in
understanding health care instructions.16 All too often
individuals leave an office setting or hospital with an
inadequate understanding of their diagnoses and
treatments. Misunderstandings are also compounded by
health care professional's use of unfamiliar medical
terms, and the social, cultural and educational
differences between patients and providers. As shown
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Table 1. Examples of communications skills for health behavior change
ACTIVE LISTENING
MD:
Hello, Mr. Jones. It's been two months since your surgery. How are things going?
Mr. J: Pretty well, Except that I feel tired a lot . This has occurred since I've gone back to work. (Goal: Encourage pt to
continue rather than address first concern.)
MD:
Go on
Mr. J.: In the evening I fall asleep in front of the television right after dinner. I don't feel I have the energy I did before
surgery. And, I'm not exercising like you told me.
MD:
(Nods silently) (Goal: Affirm with nod; use silence to elicit more information)
MD:
I see. (pause) What else. (Goal: Continue to affirm and prompt more)
Mr. J: I think I may be getting depressed again.
WARMTH AND EMPATHY
RN:
You'll be going home from the hospital tomorrow. How are you feeling about that? (Goal: Draw out emotions)
Mrs. J.: Well, I'm really not sure how I'm going to manage. I'm pretty overwhelmed and nervous that I'll start smoking again.
RN:
Yes, I understand that you have a lot to remember and to do. What's your greatest concern about slipping and having
a cigarette? (Goal: Acknowledge the emotion and ask pt to elaborate.)
Mrs. J.: You know I'm going to go home with my son and I don't want to be a burden on him. He also smokes and I really
worry that I will pick up one of his cigarettes.
RN:
It sounds like you have some anxiety here. I have spoken to your son as well about making sure that he supports you
in your effort to quit smoking by not leaving cigarettes around or smoking in front of you. He seems very
supportive. Is this helpful to you? (Goal: Offer reassurance and problem-solving to ease fears.)
OPEN-ENDED QUESTIONS
Q: Tell me what you are doing to help you lose weight?
A: I've been biking 3 times per week and eating more fish than beef
Q: What do you think is preventing you from exercising regularly?
A: I really get bored easily and can't find the time to walk.
Q: I understand. What exercise do you think you might enjoy?
A: Well, I used to ride my stationary bike all the time and think that might be better for me.
INTERACTIVE COMMUNICATION
1. Ask pts to repeat by important information and instructions in their own words:
MD: Mr. Jones, can you tell me in your own words why it is important to control your high blood pressure.
Pt.: Well, I understand that if my blood pressure is not controlled I can get heart disease or have a stroke.
MD: That's correct. And we also talked about the fact that high blood pressure can cause kidney disease and damage to
your eyes.
2. Ensure you summarize at the end of a visit to improve patient recall
MD: So you don't have problems undertaking an exercise program can you tell me in your own words what you need to do
to carry out your exercise sessions? Or
MD: To make sure my explanation was correct, can you tell me what you should do to safely undertake your exercise
sessions?
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in Table 1, interactive communication involves checking
a patients' understanding of information and providing
clarification or reinforcement as needed. Two skills
contribute to interactive communication including the
repeat back/clarify/repeat back method to check
understanding, and asking a patient to summarize the
discussion at the end of a visit to check the patients
understanding.

Education
Sydney J. Harris once said, "The whole purpose
of education is to turn mirrors into windows."
Physicians, nurses, cardiac rehabilitation specialists,
nutritionists and other allied health individuals need to
be educators. Patients' ratings of how well their
physicians provided information about their illness and
treatment were very important as predictors of the
success in diabetes self-management. 17 Effective
messages around health behavior change can often be
provided in 1-3 minutes. The impact of these messages
is enhanced by limiting content to one or two key facts,
tailoring the message for a given patient, and being clear
and directive. An example of such a message around
smoking is provided in Table 2. Educating also involves
capitalizing on teachable moments such as at the end
of an office visit in which new information was
conveyed, when a lifestyle change is recommended, or
when starting a new therapy or treatment. Finally,
education around health behavior change includes
ensuring that all members of the office staff provide

up-to-date educational information for family members
and friends, use visual aides in exam rooms, write down
important instructions, and cover walls with posters and
materials that promote healthy practices.

Coaching
Fewer than 25% of American adults eat the
recommended servings of fruits and vegetable; only
31% engage in regular physical activity; 21% smoke
cigarettes, and 65% are overweight or obese. 18
Coaching is an interactive process that involves give
and take between the healthcare professional (coach)
and the patient. As shown in Figure 1 the Stanford
Cardiac Rehabilitation Program developed programs
to assist individuals to change behavior and have
identified three steps in the coaching process. The first
step involves a brief, personalized message involving
persuasion, one of the elements of building selfefficacy, an important component of social learning
theory. 5 Examples of critical statements to help
individuals are shown in Table 3. Part of the process
of step one also includes assessment of patients'
readiness or willingness to change. Research indicates
that using a simple yes/no question can accomplish
this task which is also to encourage patients to think
and talk about behavior change.9 The transtheoretical
model or what is known as stages of change may also
facilitate the steps of assessing readiness.6
Step 2 in the process of coaching involves setting
incremental goals and assessing patients' confidence to

Table 2. Education around smoking cessation
A 1-3 minute message
Giving up cigarettes is the single most important thing you can do for your health. (clear and directive)
Smoking decreases the amount of oxygen that is carried in the blood to your heart and other parts of your body.
(key information)
Your chest discomfort (angina) is caused by a lack of blood flow to your heart muscle. Continuing to smoke is likely
to cause you more chest discomfort. (tailored to the pt.)
I would like to help you remain off cigarettes for good. Are you willing to attempt to quit smoking now? (supportive)

J HK Coll Cardiol, Vol 16 (Suppl 1)
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Figure 1.

Table 3. Critical opening statements
Losing 10 pounds over the next 3 months will help to lower your cholesterol and blood pressure and will better
control your blood sugar. This weight loss may also lessen your need for medication.
Walking at least 15 minutes every day at a moderate pace can reduce your risk of heart disease by as much as 3040%.
Limiting your daily alcohol to one glass of wine will help to lower your blood pressure and make it easier for you to
lose weight. Wine has over 100 calories per glass.
Keeping your portion sizes to the size of your fist is one way to help you control how much you eat. You can look at
your plate to see if you have the right portion sizes.

make a change. Goals must be specific, measurable and
within a time-frame. Examples of measureable goals
include "Can you…
"Walk at least 10 minutes on level ground at 2 miles
per hour every day for the next seven days."
"Eat at least 3 different fruits and 3 different
vegetables every day this week."

0
Not at all
Confident
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1

2

3

4

Assessing patient's confidence to achieve these
goals is accomplished by using a self-efficacy scale
measured on a scale of 0-100 or 0 to 10 as shown below.
Responses of 70 or greater on a scale of 0-100 or 0-7
(scale 0-7) indicate a good chance of success in
undertaking the behavior. Ratings invite exploration if
lower. It is useful to explore barriers by asking the
question: "Why is your confidence a 3 instead of a 5?"

5
Somewhat
Confident
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As people adopt new behaviors one of the most
important keys in helping them achieve their goals is to
ask them to self-monitor their behaviors. Selfmonitoring tools include diaries, logs, calendars, placed
in plain view such as on a refrigerator, next to the bed,
or on a kitchen table.9 Daily self-monitoring is useful
during the first three months of adopting new behaviors.
During maintenance the frequency may be reduced to
weekly for a period of 3-6 months. Self-monitoring
should be reinstituted if individuals lapse into old
behaviors.
Step 3 in the process of coaching for health
behavior change involves follow-up by telephone, mail
or through visits. This gives individuals the impetus and
motivation to continue change. Goals for patients should
be recorded, patients asked about their progress, and a
problem-solving approach reinstituted when goals are
unmet. Unmet goals may require assisting patients to
develop new goals.
As shown in Figure 1, at any step in the process
of change, patients may need to deal with barriers. This
involves a problem-solving approach. Coaching
questions to uncover barriers when patients are reluctant
to change include queries such as:
"What's standing in your way" or "Your confidence
seems low. Can you tell me why?"
Three of the most common barriers include
misinformation or lack of information, previous
experiences that have been negative for patients, and
lack of support. Providing key educational messages to
individuals needing more information, supporting
individuals to move beyond negative experiences, and
helping them to find support resources in the health care
system, within their community or existing circle of
family and friends all promote success. A problemsolving approach is important in addressing when
difficulties of health behavior change occur. Key steps
in this process include: identifying the problem and
possible reasons for it, selecting the main reason and
listing solutions, weighing the pro's and con's of each
solution and selecting one or two solutions to try,
attempting the solution, and repeating the solution if
the initial solution is not successful.

J HK Coll Cardiol, Vol 16 (Suppl 1)

In summary, helping individuals to change their
behaviors requires that health care professionals
improve their skills in communicating, educating and
coaching. These lessons will not only help us to help
our patients but may better serve our skills in facilitating
the change process.
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Updates on Smoking Cessation
RONALD LAM and CINDY LAI
From Department of Health, Hong Kong

Context

Results

Smoking is associated with an increased risk
of total and cause-specific death, and ample
evidence is available which showed quitting
smoking could reduce such risk at any age.
Cardiologists are encouraged to provide smoking
cessation treatment or suitable referrals for
smoking clients.

Physician advice, however brief, is effective
in motivating patients to quit. The 4 "A"s (ask,
advise, assess, assist and arrange) model are suitable
for use at outpatient setting. Management strategies
comprise addiction therapy, cognitive behavioral
intervention, pharmacological treatment and relapse
prevention. In addition to nicotine replacement
therapy, other first line medications include
benzodiazepine and varenicline, and combination
therapies produce better abstinence than single
therapy.

Objective
To provide an overview of updates in treatment
strategies for smokers.

Methods
Drawing references from evidence-based
practices of Mayo Clinic Nicotine Dependence
Centre, and Clinical Practice Guidelines: Treating
Tobacco Use and Dependence 2008 update from the
USA Department of Health and Human Services, the
key management strategies for treating tobacco
dependence are reviewed.

There is also a dose-response effect between
intensity of intervention and abstinence rates. If very
limited time is available, cardiologists can adopt an
"Elicit-Provide-Elicit" model to help current smokers
to quit.

Conclusions
Smoking is now treated as a disease entity, and
no longer a mere personal habit. All healthcare
professionals therefore have the ethical and moral
responsibility to document smoking history and make
appropriate interventions or timely referrals.
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Motivational Interviewing and Smoking Cessation: What Is It and Is
It Effective?
DOUGLAS TAT-CHAU LAI
From Department of Health, Hong Kong

Background
Motivational Interviewing is a relatively new
counseling technique commonly used in the field of
addiction treatment like smoking cessation. It is also
recommended by international smoking cessation
guidelines for poorly motivated smokers.

interviewing (different aspects of the counseling e.g. the
use of decision balance technique, problem feedback,
or just "general spirit" etc.), the total duration of
treatment, the nature of follow-up support, the use of
supplementary technique (e.g. the use of self help
booklet, computer program) and whether the treatment
provider were administering the treatment as directed
(e.g. was there supervision of the counseling process,
videotaping or guided by a manual).

Objectives
To study the efficacy of Motivational Interviewing
on Smoking Cessation and to identify potential effect
modifiers.

Methods
A comprehensive literature search was done on
studies about the use of "motivational interviewing" on
"smoking cessation". This study was limited to
randomized controlled trial and those trials with explicit
reference to the counseling method "motivational
interviewing" as innovated by Miller & Rollnick. The
following indicators were noted: credentials of the
treatment providers, the specific training procedures (for
performing motivational interviewing e.g. focused
workshops), the exact nature of motivational

Address for reprints: Dr. Douglas Tat-Chau Lai
Chai Wan Families Clinic, 1/F Main Block, Pamela Youde
Nethersole Eastern Hospital, Chai Wan, Hong Kong
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Results
Preliminary analysis indicates that the
motivational interviewing is efficacious for smoking
cessation with pooled odds ratio 1.5 (95% CI 1.32-1.7).
The duration of the study period (6, 12 months or longer
abstinence), the duration of the counseling sessions and
the number of follow-up sessions are potential effect
modifiers. However, the trainings that were given to the
treatment provider were not mentioned in about half of
the studies. Methods to ensure fidelity of counseling
were either not described or inadequately described in
most papers.

Conclusions
Motivational interviewing seems to be a
promising technique for smoking cessation. The
potential effect modifiers identified may help to guide
the formulation of an effective counseling program. But
as there were large variations in the integrity of the
interventions used, the results should be interpreted with
caution.
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The Influence of Nutrition on Cardiovascular Health
VANESSA LAI-FAN AU
From Department of Dietetics, Alice Ho Mui Ling Nethersole Hospital, Hong Kong

Cardiovascular disease remains the leading
cause of mortality in industrialized countries and is
rapidly becoming a primary cause of death
worldwide. Therefore, identification of the nutritional
factors that most effectively decrease cardiovascular
disease's risk is essential. The relationship between
diet and cardiovascular disease has been studied
intensively for nearly a century. The following dietary
strategies have been proven to be effective in
preventing cardiovascular disease. (1) Balance calorie
intake and physical activity to achieve and maintain
healthy body weight. (2) Consume diets rich in fruits,
vegetables and whole grains. (3) Substitute
polyunsaturated fat and monounsaturated fat for
saturated fat and trans fat. (4) Increase consumption
of Omega-3 fatty acids from fish, fish oil supplement

or plant source. (5) Include adequate dietary fiber,
especially soluble fiber. (6) Minimize the intake of
beverages and foods with added sugar. (7) Choose
and prepare foods with little or no salt. (8) Consumes
alcohol in moderation. (9) Phytostanols, nuts and
soys are suggested to be included as part of a
cardioprotective diet. Also, other functional
ingredients/nutrients with possible effect on
cardiovascular disease risk are antioxidants,
prebiotics, dairy bioactives, Folate, B vitamins,
vitamin D, vitamin K2. Studies have suggested that
nutrition play an important role on the prevention
of cardiovascular disease. The presentation will
discuss the dietary factors effect on cardiovascular
health and how to apply these recommendations
to practice.
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Facilitating Self-management Behaviors in Cardiac Patients
PETER POON
From Hong Kong Society for Rehabilitation, Hong Kong; and Stanford Patient Education and Research Center, USA

With the ageing of our population and the
increased rates of chronic conditions such as Cardiac
Conditions, our Health Services have a growing need
to better manage chronic disease. Effective support for
self-management is an important component of such
change.

Aims of the Workshop
To introduce to the health care professionals with
the knowledge, skills in applying self-management
strategies in care of cardiac patients.

Objectives of the Workshop
By the end of the workshop, the participants will
be able to:
1. Identify the key principles and strategies in
facilitating patient's self-managing health behaviour
2. Identify the core self-management skills in the patient
educational and rehabilitation programs.
3. Acquire the steps in conducting an important self
management strategy − Action Planning and Problem
Solving.

Program Approach and Format
Content
1. Key health theories in relating to self-management
and behavioural change
2. Self-management support provided by the health care
professionals
3. Acquiring some of the practical skills in facilitating
self-managing health behavior

It consists of presentation, interactive and
participatory discussion, demonstration and practice.

Address for reprints: Mr. Peter Poon
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Exercise in Practice for Cardiac Patients
MANDY SHUN-YAN LEUNG
From Department of Physiotherapy, Tung Wah Hospital, Hong Kong; Certified Clinical Exercise Specialist, American
College of Sports Medicine, USA

Cardiac Rehabilitation is imperative for cardiac
patients. It aims at improving cardiovascular and
respiratory function;1,2 returning to premorbid functional
status and activity level; developing a safe and effective
home ex program and developing a long-term exercise
habit; and educating for secondary prevention.1 There
are 4 phases in a comprehensive cardiac rehabilitation,2,3
i.e. Phase I: In-patient physical training; Phase II:
Supervised institutional physical training with education
following hospital discharge; and Phase III & Phase IV:
Exercise in community without ECG monitoring or
under supervision.
Before exercise training starts, physical
assessments should be proceeded for exercise
prescription. 2 These include current exercise habit;
physical status; cardiorespiratory endurance (exercise
testing, 6-minute walk test2-4); body composition (fat
& fat-free tissue, height, weight, Body Mass Index,
Waist-Hip Ratio); muscular strength, endurance and
flexibility.2,3
Patient's maximum cardiorespiratory endurance
(maximum aerobic capacity) is measured in terms of
Maximum Oxygen Uptake (VO2max):-3
VO2max = Maximum cardiac output (L/min) x
Arterial-venous O2 difference (mL O2/L)
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It reflects the ability of the heart to deliver O2
to the working muscles and the muscle's ability to
generate energy with O 2. The change of VO 2max is
related to mode, frequency, duration, intensity and
progression of the exercise training.3
Each exercise session should include 10
minute warm up, 20-30 minutes endurance training
(3-5 days per week), 10-15 repetitions x 1 set x
8-10 exercises for resistance training (2-3 days per
week), and 10 minutes cool down. 2-5 The training
effect depends on the overloading and specificity
principles. 3,6-9 For the intensity of exercise, ACSM
recommends 40%/50% to 85% VO 2 Reserve or
Heart Rate Reserve. The common method for
intensity calculation is the Karvonen Method
(Heart Rate Reserve Method):- 3
Training Heart Rate = {(Maximum Heart Rate Resting Heart Rate) x 40-85% of Training zone}
+ Resting Heart Rate

Monitoring during Phase II cardiac exercise
training should contain ECG monitoring (for initial
session or high risk patient), Blood Pressure, Heart Rate,
Rate of Perceived Exertion (RPE), and Oxygen
concentration (SaO2) (if indicated).3
The art of exercise prescription is the successful
integration of exercise science with behavioral
techniques that results in long-term program compliance
and attainment of the individual's training goals.
Maintaining exercise compliance after Phase II cardiac
rehabilitation is challenging. It can be improved by
setting individual short- and long-term, realistic and
measurable goals; improving confidence level, signing
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contract; giving feedback; revising training plan;
recording diary; seeking social support system; and
regular follow up.3

5.
6.
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Return to Work after Acute Myocardial Infarction
TONY KA-KEUNG WONG
From Occupational Therapy Department, Tung Wah Hospital, Hong Kong

Cardiovascular diseases represent the second
leading cause of death in Hong Kong. According to the
recent statistic published in Statistical Report Hospital
Authority 2006/2007 of Hong Kong,1 5619 deaths (15%
of all deaths) in 2006 were accounted for cardiovascular
disease.
Ischaemic heart disease, being the major
component of cardiovascular disease, is therefore an
important cause of both mortality and morbidity. The
objective of cardiac rehabilitation is to restore an optimal
physical, mental and social condition in patients with
ischaemic heart disease; allowing them to resume an
active role in the community as soon as possible after
the heart attack. The cardiac rehabilitation program is a
multidisciplinary practice involving not only the patient
and the physician but also the patient's relatives, the
occupational therapist, physiotherapist, nursing
specialist, dietician, and clinical psychologist.
The incidence of myocardial infarction rises with
increasing age but the age of onset is in turn decreasing.
The onset of myocardial infarction even happened as
young as at early 30. These patients are at working age
and most of them are expected to return to work.2 Thus,
to assist the patient to return work is one of the important
goals of cardiac rehabilitation and also the responsibility
of occupational therapist.3
During the process of recovery from a heart attack,
the occupational therapist provides unique intervention to
both the physical and psychological dysfunctions of the
patients. In order to facilitate the patients return to work,
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work evaluation and training are offered. The process starts
in the in-patient phase. Early intervention will anticipate,
identify and modify barriers to return to work and alleviate
the anxiety of patients.4 The return to work process usually
includes clinical evaluation, work evaluation, work
simplification & modification, simulated work training and
vocational counseling.

Clinical Evaluation
For cardiac patients, cardiac function is the
primary consideration. They include the disease nature,
functional capacity, exercise testing result (MET),
ejection fraction and the existing cardiac related sign &
symptom. In general, the objective data of exercise
testing result gives a guideline in advising patients to
safe activity level and daily engagement.

Work Evaluation
Work evaluation includes the identification of
various demands of a specific job. The barriers that exist
and the potential hazards at the workplace are explored
before resumption of work. Job analysis provides stepby-step breakdown of job task to find out critical job
demands. 5 In addition, the information of working
environment, and related work stress allow us to give
more appropriate recommendation to our patients in
return to work.

Work Simplification & Modification
In order to decrease cardiac workload and energy
consumption, several methods are employed in activity
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modification. For instance, avoiding extreme hot and
cold environment, and increasing awareness to the
ventilation in working environment. Optimal
structuring of the daily schedule can eliminate the
emotional stress due to time pressure. The use of
pacing control and frequent rest increase the activity
tolerance throughout work process. 6 Besides, work
simplification will also be used to educate patients
in analyzing new tasks so as accomplish the work
tasks in a more efficient way.

to work, financial situation, work stress and future career
planning. Therefore, counseling to patients' value,
satisfaction, expectation must be included in a
comprehensive rehabilitation program.
Return to work is an important marker of the
success of cardiac rehabilitation. It enables patient to
maintain economic independence. 9 Therefore, a
comprehensive cardiac rehabilitation program should
include the above components in order to help patients
to resume a productive life roles, hence improve their
quality of life.

Simulated Work Training
References
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patient's work demands.

Vocational Counseling
Psychological and social factors play an
important role to work resumption. 8 Thus patients'
perception on return to work is a crucial factor of a
successful intervention. In addition to patient's physical
state, we also have to focus on the motivation to return
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Driver Assessment for Cardiac Patients
JOCELYN AU
From Rehabaid Centre, Hong Kong

A comprehensive evaluation is required to
determine the ability to drive for patients with
cardiac problems. It involves off-road assessment
which includes evaluation of different components
involved in driving, i.e. visual, physical, cognitive
deficits as well as reaction time. It then follows
with an on-road assessment which actually
involves the patients to drive a vehicle in different
traffic situations to determine their safety and

competency on the road. Most cardiac patients may
not exhibit major physical disabilities which may
interfere with safe driving, but the concern is whether
they are medically fit to drive. A set of guidelines,
which is referenced from similar guidelines adopted
in various overseas countries, has been formulated
to enable medical practitioners to determine such
medical fitness, both for driving private cars and
commercial vehicles.
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